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The term ‘Access Arrangements’ can be defined as “guidelines, best practices, opinions, policies, 
agreements, etc. containing rules on access to and use of HBM and data collections stored within 
biobanks’. 
The term ‘Basic data’ is defined as ‘data that has not been subjected to analysis or any other 
processing, except for the purpose of storing the data or providing it to an applicant’.  
The term ‘Basic HBMs’ can be defined as ‘HBMs that have not been subjected to processing or any 
other manipulation, except for the purpose of storing the HBM or providing it to an applicant’. ‘ 
The term ‘Biobank’ refers to ‘a structure that obtains, processes, stores and provides human bodily 
material and possible also associated data and this (only) for scientific research purposes, excluding 
research that implies medical applications to humans” (art. 2, 27° of the Belgian Act on HBM of 19 
December 2008).  
The term ‘Biobank Network’ refers to ‘a group of institutions who freely assume the commitment to 
collaborate in the domain of biobanking and who (often) share the same procedures and quality 
policies, and who are (or might be) helped by a central hub for coordination in terms of service’ (1).  
The term ‘Biobank Initiatives’ covers biobanks, biobank networks as well as organizations.  
The term ‘Custodianships’ can be defined as the ‘caretaking responsibility for HBM and data that 
starts at the planning of a biobank initiative, prior to the collection, and continues through research use 
to final dissemination of research results’ (a slight adapted version of the definition used by R. Yassin 
et al. (2) and the National Cancer Institute (3)). 
The term ‘Epidemiology” could be described as “the study of the incidence, extent and causes of 
occurrences of disease epidemics. Such a study can lead to mitigation of the effects of future 
outbreaks of a disease, as well as the prediction of its likely extent.”  
The term ‘Organizations’ refers to ‘organizations and associations not directly involved in the 
management of a biobank or biobank network, but active in the development of guidelines, policies or 
best practices pertaining to access to HBMs or data or both’.  
The term ‘Ownerships’ can be defined as ‘The ultimate and exclusive right conferred by a lawful claim 
or title, and subject to certain restrictions to enjoy, occupy, possess, rent, sell, use, give away, or even 
destroy an item of property’1. 
The term ‘Residual HBM’ or ‘Leftover HBM’ refers to “the part of HBM that was removed for 
diagnostic purposes or treatment of the donor and that – after a sufficient and relevant part has been 
stored to conduct, refine or complete the diagnosis or treatment of the donor on the basis of new 
scientific data – has become redundant for such purposes and therefore could be destroyed” (art.2, 
33° of the Belgian Act on HBM). 
                                                       
1 http://www.businessdictionary.com/definition/ownership.html 
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The term ‘Personal Data’ refers to “any information relating to a person that can be identified, directly 
or indirectly, in particular by reference to an identification number or to one or more factors specific to 
his physical, physiological, mental, economic, cultural, or social identity” (art. 1, § 1 Belgian Privacy 
Act). 
The term ‘Personalised medicine’ refers to a medical model using molecular profiling for tailoring the 
right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to 
disease and/or to deliver timely and targeted prevention (Horizon 2020) 
The term ‘Researcher’ refers both to researchers from the academic sector (e.g., university or 
research institutes), the public sector (e.g., public institutions conducting research such as ministries, 
government agencies and public hospitals) and the private sector (e.g., private institutions, such as 
industrial or commercial businesses)(4).  
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1 General introduction 
1.1 Importance of biobanking for biomedical research 
Already in 2009, Time Magazine listed biobanking as one of the Top 10 ideas that change the 
world right now(5). The European Commission recognized the sound governance of biobanks as 
one of the most important challenges for the European innovation system (6). The European 
Strategy Forum on Research Infrastructures (ESFRI) identified biobanks as one of the main 
priority research infrastructures for the European Research Area (ERA) for the next 10 to 20 
years(7,8). The ‘Biobanking and Biomolecular resources Research Infrastructure’ (BBMRI) was 
one of the first projects under the European Research Infrastructure Preparatory Phase of the 
ESFRI (9,10). 
Millions of human biological material (HBM) and associated data are collected each year for a 
variety of purposes. These purposes include, for instance, basic research studies, clinical trials 
and epidemiological studies(11,12).  
Art. 2, 27° of 19 December 2008 of the Belgian Act on HBM defines a biobank as: “‘a structure 
that obtains, processes, stores and provides human bodily material and possible also associated 
data and this (only) for scientific research purposes, excluding research that implies medical 
applications to humans.” The collection and storage of HBM in so-called ‘biobanks’ is not a new 
phenomenon. It has been done for more than 100 years in different ways and for different 
purposes(13). The rise of new scientific disciplines, such as genomics, proteomics and 
bioinformatics, has considerably increased the demand for the systematic collection of large 
amounts of high quality HBM and data (9,10), and new sequencing technologies. The use and 
access to HBMs and data stored in biobanks, has therefore become a crucial component in many 
biomedical research projects (14–17).  
Collections of HBM and data vary in scope, form and scale, according to the type of HBM and 
data that is collected and the different purposes for which they are used (18). The scale ranges 
from small collections in hospital or university departments to the storage of large amounts of 
HBM in specifically designed and well-equipped facilities (13,19). 
Different aspects determine the value of a biobank. The quality of the samples and associated 
data and the ability to link the samples with donor information are two of these factors(20).  
In the realm of translational research, biobanks will take a central place in the R&D process of 
medicines. Biobanks can provide a crucial platform for international and interdisciplinary 
cooperation and act “as key drivers for next generation biomarker (diagnostics) research and drug 
discovery”(21). Good functioning models for access to HBM and data are crucial. 
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The legal framework that determines access to biobanks often remains unclear. The absence of a 
defined set of applicable rules creates legal uncertainty for biobanks and applicants. The PhD 
project investigated the hopes and concerns of the different stakeholders – focusing on custodians 
of biobanks and applicants – in biobanking. It mapped and characterised the (existing) 
heterogeneous legal framework applicable to biobanks and formulated recommendations for the 
development of a transparent, feasible and encouraging legal framework suitable for access to 
biobanks. 
1.2 Different types of human biological material and associated data collected 
1.2.1 Different types of HBM 
Many different types of HBM are collected and stored in biobanks and used in biomedical research2. 
Biobanks collect solid human tissue, such as skin, brain, bone or tumour-related tissue. Another type 
of HBM and data stored in biobanks are human liquids, such as blood, urine, saliva and cerebrospinal 
fluids. Some biobanks also collect and store isolated human genetic material, such as DNA, RNA and 
specific types of genetic information contained in blood, tissues, serum, plasma, cells and cell lines. A 
fourth type of HBM is isolated cells, such as stem cells, T and B lymphocyte cells and liver cells.  
A distinction is often made between common and rare HBM. Common HBM, such as blood, is 
collected and stored on a regular basis and is therefore available in large amounts. Rare HBM, such 
as brain tissue or HBM relating to a rare pathology is only available in limited amounts. That is why 
some argue that access to and use of rare HBM should be handled with more caution(22). 
1.2.2 Degree of identification of HBM 
The degree of identification of HBM stored in a biobank may vary.  
The first option is that the origin of the HBM cannot be traced back to the original donor. In this case 
the HBM is stored alone or in combination with limited associated data, such as age, sex and 
pathology. It does not allow, with reasonable efforts, the identification of the patient(23). Since the 
HBM cannot be traced back, there is no possibility to obtain additional information about the patient 
that donated the HBM. This is called anonymous or anonymised HBM.  
The second option is that the origin of the HBM can be traced back to the donor on the basis of a 
code. Only the person that holds the identification code, can link the donated HBM to the identity and 
the personal information of the donor. The identification code is not accessible to researchers that use 
the HBM. This is called coded HBM.   
The last option is that the researcher has direct access to the code that allows the identification of the 
donor of HBM used in a research project. This is called identifiable HBM(19,24). 
                                                       
2 The distinction between the different types of HBM is not absolute, since some HBM can be considered as being 
several types of HBM. For instance, blood is a liquid tissue that contains cells, that contains DNA. We merely 
wanted to highlight that biobanks collect and store many different types of HBM.  
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1.2.3 Different types of data associated with HBM 
The value of HBM for medical and scientific research depends to a large extent on the availability of 
sufficient personal information about the donor and his pathology. This personal information may 
include demographic information – such as age and gender – as well as information about lifestyle, 
environmental factors, family history, the medical history of the patient from whom HBM was collected, 
medical interventions (including medicine), follow-up data (such as course of disease) (9,20,25).   
1.3 Different reasons to use human biological material and associated data for research 
purposes 
HBM and associated data can be used for diagnostic, therapeutic of research purposes. This PhD 
focuses on the use of HBM and data for research purposes.  
HBM and associated data are particularly important for translational research. Translational research 
can be considered as the essential link between basic and clinical research. It focuses on the use of 
data from pre-clinical studies in clinical research. This type of research tries to translate promising 
findings in the laboratory to an application for the patients. The development of personalized 
treatments or medicine is an example of such translational research.  
Biobanks can provide access to HBM and data for research aiming to identify new biomarkers. In 
doing so, they can play a crucial role in translational research. Biomarkers are specific cells, 
molecules, genes, gene products, enzymes or hormones that can be measured in an objective and 
quantitative manner. They can be used as an indicator of normal biological processes and 
pathological processes. Biomarkers provide support for the prediction, prevention, diagnosis and 
treatment of many existing diseases (26–29).  
HBM and data stored in a biobank can contribute to research on the identification of new molecular 
targets for drugs (26–28). They are also used to confirm results in humans clinical applications that 
were successfully tested in animal models(9,25). Well-characterized HBM are particularly interesting 
for research into new drug targets, since they mimic more accurately what happens in the human 
body.  
HBM can also be used to test a new drug before going into a clinical trial. This makes it possible to 
obtain more information about the human pathology. It can accelerate drug development, since it 
allows focusing more in the development and testing of a new drug. This should lead to less negative 
results in later phases of drug development (9).  
New techniques have made it possible to study in more detail the genetic material, DNA, RNA and 
proteins extracted from HBM such as tissues, cells and blood. This allows research on factors that 
may impact disease processes. Researchers try to better understand diseases by examining HBM of 
people both with and without the same disease. They compare their findings with genetic mutations as 
a result of environment and lifestyle of the patient (9). 
Combining HBM with "up to date" associated data from the donors is crucial to increase the chances 
of success of the research and to obtain significant results (9,25).  
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HBM and associated data are also very often used for cohort-based research or epidemiological 
research. Such research is conducted on a sample of the population of a particular country or part of a 
country. The participants of such research are randomly enrolled via population registries(30). After 
enrolment, HBM – such as blood or isolated DNA – and associated data are collected from the 
participants(9). Additional data is obtained via health questionnaires, physical measurements, 
psychological tests, etc. During the course of the study the participants are re-contacted on a regular 
basis – for instance every five years – to obtain follow-up HBM and data. This makes it possible to 
study a wide range of different health risks over a longer period of time(31).  
Epidemiological research is primarily devoted to the interaction between “the genetic background, 
lifestyle, environmental and others determinants that may influence the incidence, development and 
treatment response for various diseases” (31). Since patients are followed during a longer period of 
time, one can assess the exposures to those determinants prior to the development of a disease(32).  
Epidemiological research does not focus on the diagnosis and treatment of a particular 
disease(27,28). Examples of large-scale epidemiological studies are the UK Biobank, the HUNT study 
in Norway, the LifeGene Study in Sweden and the LifeLines study in the Netherlands(32). 
1.4 Biobanks 
Although collections of HBM and data have existed for more than a century, the term ‘biobank’ is still 
relatively new. The term appeared for the first time in scientific literature in 1996, but it only became 
commonly used after 2000. The term ‘biobank’ is used to refer to various types of collections of HBM 
and data that are stored for different purposes(33,34). Some alternative terminology that are still used 
– mostly outside Europe – are ‘biological specimen banks’, ‘bioresources’, ‘biological resources’ and 
‘biorepositories’.   
1.4.1 Legal definition of a biobank 
In order to acquire a deeper understanding of the term ‘biobank’, we looked into different definitions in 
international normative documents and legislation of a number of European countries3. The definition 
of a biobank in principle has an influence on the determination of the applicable rules. However, some 
postulate that the applicable legislation should be determined on the basis of the different activities 
pursued rather than on the definition of a ‘biobank’ as such(35). 
1.4.1.1 Overview of different definitions 
The international organization ‘Public Population Project in Genomics and Society’ (P³G) defines 
biobanks as “an organized collection of human biological material and associated information stored 
for one or more research purposes(4).”  
                                                       
3 The overview was created on the basis of definitions enlisted on the website of the EU funded research project 
PRIVILEGED (http://www.privileged.group.shef.ac.uk/projstages/stage1/introduction/biobank-defs/) and an 
overview of the Nordic Committee on Bioethics(38) and supplemented and updated with additional definitions in 
national legislations.   
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The Organization for Economic Co-operation and Development (OECD) defines ‘human biobanks and 
genetic research databases’ (HBGRD) as “structured resources that can be used for the purpose of 
genetic research and which include: (a) human biological materials and/or information generated from 
the analysis of the same; and (b) extensive associated information(36).” This definition is limited to 
collections of HBM and data that can be used for genetic research purposes.  
A paper describing the preparatory work to develop BBMRI-ERIC4 defines a ‘biobank’ as “large 
collections of well-documented, up-to-date epidemiological, clinical and biological information and 
accompanying material from large numbers of patients and healthy persons (10).”  
The statutes of the BBMRI-ERIC defines ‘Biobanks (and Biomolecular Resources Centres)’ as 
“collections, repositories and distribution centres of all types of human biological samples, such as 
blood, tissues, cells or DNA and/or related data such as associated clinical and research data, as well 
as biomolecular resources, including model- and micro-organisms that might contribute to the 
understanding of the physiology and diseases of humans (37).” This definition applies to all kind of 
collections of HBM and associated data, irrespective of whether such collections are used for research 
purpose or for therapeutic of diagnostic purposes. The definition furthermore includes biomolecular 
resources such as model- and microorganisms. 
Article 2, 27° of the Belgian Act of 19 December 2008 on HBM5 – as modified by an Act of 15 March 
2013 containing diverse health provisions – defines a ‘biobank’ as a “structures that obtains, 
processes, stores and provides human bodily material and possible also associated data and this 
(only) for scientific research purposes, excluding research that implies medical applications to 
humans6.” The Belgian Act of 19 December 2008 defines 3 additional types of infrastructures that 
collect HBM and data for therapeutic use of HBM and data. These are the bank for human bodily 
material, the intermediate structure for human bodily material and the production establishment. 
Distinct legal rules are applicable to the four different types of infrastructures.  
The Report no. 1414/20027 of the Danish ‘Biobanking Working Group’ defined a biobank as “a 
structured collection of human biological material available according to specific criteria and where the 
information contained in the samples can be traced to identifiable persons” (38). A collection is not 
considered as a biobank when samples in the collection cannot be traced directly or indirectly – for 
example via an encryption key – back to identifiable persons (39). 
  
                                                       
4 The Biobanking and Biomolecular resources Research Infrastructure-European Research infrastructure 
consortium 
5 The Belgian Act of 19 December 2008 on the procurement and use of human bodily material 
6 Free translation of future article 2, 27°: “de structuur die, met het oog op wetenschappelijk onderzoek met 
uitsluiting van onderzoek met geneeskundige toepassing op de mens, menselijk lichaamsmateriaal verkrijgt, in 
voorkomend geval bewerkt, bewaart en ter beschikking stelt, evenals desgevallend de daaraan gekoppelde 
gegevens die betrekking hebben op het menselijk lichaamsmateriaal en de donor”; 
7 The “Report on biobanks – proposal for a legal regulation of biobanks within the health field” (Report no. 
1414/2002) 
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The Norwegian legislation distinguishes between treatment and diagnostic biobanks, on the one 
hand, and research biobanks, on the other hand. A ‘treatment or diagnostic biobank’ is defined as “a 
collection of HBM contributed for the purpose of medical examination, diagnosis and treatment.” A 
‘research biobank’ is defined as a “collection of HBM that is used or is to be used for research 
purposes.” The Norwegian legislation does not seem to refer explicitly to the collection of associated 
data in combination with the HBM(38).   
The Portuguese legislation8 defines a ‘biobank’ in quite an elaborate manner as “any depository of 
biological samples and related derivatives, with or without a pre-defined period of storage, based on 
prospective collection or made up of previously collected material, obtained for health care purposes, 
public health monitoring programs, or for research, and that includes identified, identifiable, 
anonymized or anonymous samples.” The definition includes many different types of biobanks.  
The Swedish Act on Biobanks (SF 2002:297) defines a ‘biobank’ as “biological material from one or 
several human beings collected and stored indefinitely or for a specified time and whose origin can be 
traced to the human or humans from whom it originates9.”  
In 2004, the opinion on ‘Biobanks for Research’ of the German National Ethics Council defined 
‘biobanks’ as “collections of samples of human bodily substances that are or can be associated with 
personal data and information on their donors.” With bodily substances is meant, amongst others, 
cells, tissue, blood, or DNA as the physical medium of genetic information. The definition refers to the 
twofold character of biobanks, as collections of both samples and data.  
The Estonian Human Genes Research Act of 2000 defines ‘gene banks’ as “a database established 
and maintained by the chief processor consisting of tissue samples, descriptions of DNA, descriptions 
of state of health, genealogies, genetic data and data enabling the identification of gene donors.”  
The Icelandic Act on Biobanks No. 110/2000 defines a ‘biobank’ as “a collection of biological 
samples, which are permanently preserved.” Collections of HBM stored for less than 5 years are not 
considered biobanks10. The Icelandic legislation furthermore makes a distinction between research 
biobanks, that preserve research samples, or clinical biobanks, that preserve clinical samples(38).  
Report n° 7711 of the French National Consultative Ethics Committee on Health and Life Sciences 
remarks that ‘the word biobank today seems to allude to some form of deposit of property with a 
market value.’ The report instead uses the term ‘biolibraries’ as “an assembly of biological materials 
potentially vectors of genetic information (i.e. possessing cells or directly extracted genetic material). 
Files, possibly computerised, are associated to this assembly of biological material, and are composed 
of the data, which is essential for it to be exploited (origin of donors, genealogy, clinical and biological 
data). Samples may have been provided by healthy volunteers or the sick for clinical purposes, 
                                                       
8 Law no. 12/2005, 26th of January, article 19, no 1 
9 http://www.biobanks.se/biobank.htm 
10 http://www.privileged.group.shef.ac.uk/projstages/stage1/introduction/biobank-defs/ 
11 Report n° 077 of the French National Consultative Ethics Committee on Health and Life Sciences, entitled 
“Ethical issues raised by collections of biological material and associated information data: “biobanks”, 
“biolibraries”” of 20 March 2003 
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research projects, or judicial activities. To the above must now be added embryonic samples for the 
creation of stem cell banks.” This definition of ‘biolibraries’ includes many different types of collections 
of HBM and data and explicitly refers to the potential use of HBM and data for judicial activities. 
1.4.1.2 Comparison of different definitions 
The comparison of the different legal definitions of biobanks reveals that some differences in the 
wording of the term “biobank” could stem from different views on the concept of biobanks. A little more 
than half of the definitions limits the scope of biobanks to collections used for research purposes. The 
other half of the definitions includes the use of HBM and data for therapeutic and diagnostic purposes. 
The definitions of a biobank in Sweden, Estonia and Denmark explicitly provide that it only relates to 
identifiable HBM, while the legal definition of biobanks in Portugal and Belgium relates both to 
identifiable and non-identifiable HBM. The Icelandic definition only considers a collection of HBM (and 
data) as a biobank, when the HBM and data has been collected for a certain period of time (more than 
5 years).   
Other differences in wording seem to be merely different (practical) interpretations of the same 
concept of biobanks. The majority of the definitions stipulates that biobanks are collections that consist 
both of HBM and data, while a few definitions only (explicitly) refer to HBM and not to data. The 
majority of the definitions specify that biobanks concern collections of biological material of human 
origin, while some definitions do not clearly specify the type of biological material. The definition 
contained in the statutes of the BBMRI-ERIC also makes reference to biomolecular resources. In this 
PhD we use the legal definition of a biobank as provided in the Belgian Act on HBM. 
1.4.2 Different types of biobanks 
The concept of biobanks represents a large variety of collections of HBM and data stored and used for 
different purposes. An important distinction between different types of biobanks is based on their 
function or activity: (1) population-based prospective biobanks and (2) disease-oriented biobanks. The 
distinction between those types of biobanks is, however, not absolute, since one could use other 
criteria to distinguish different types of biobanks. 
1.4.2.1 Population-based (prospective) biobanks 
The Recommendation Rec (2006)4 of the Council of Europe defines a “population biobank” as a 
collection of HBM that: (i) has a population basis; (ii) is established, or has been converted, to supply 
biological materials or data derived therefrom for multiple future research projects; (iii) contains 
biological materials and associated personal data, which may include or be linked to genealogical, 
medical and lifestyle data and which may be regularly updated; (iv) receives and supplies materials in 
an organised manner” (40).  
A population-based biobank (prospectively) stores large amounts of HBM (and data) of well-defined 
phenotypes over a long period of time. It is used to identify and characterize the health status of large 
groups of individuals (3). HBM (and data) stored in such population-based biobanks is often collected 
from health volunteers rather than from patients. Such biobank is not necessarily located in a hospital 
(4). Examples of population-based biobanks are, the UK Biobank, the Norwegian Mother and Child 
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Cohort Study and the Hunt Study in Norway, CARTaGENE in Canada, the Estonian Biobank, the 
LifeLines Cohort & Biobank initiative in the Netherlands, Genome Database of Latvian Population and 
LifeGene in Sweden (41).  
Population-based biobanks can be further divided into three subtypes(9). A first subtype is a biobank 
consisting of a longitudinal collection of HBM and data obtained from a general population. The HBM 
and data was collected from individuals that were selected by means of random sampling. The type of 
HBM that is collected most often in this context is blood and isolated DNA. Usually HBM and 
associated data is collected at the beginning of a study. The collection is then completed and updated 
at specific times during the follow-up of the study. This approach has several advantages. Since one 
starts from a general population, one can study the natural frequency of the occurrence of a disease. 
Special attention is given to genetic variations and environmental risks. A second advantage is the 
ability to study the biomarkers that can predict the onset of a particular disease in a healthy individual. 
A disadvantage of this method is the long duration required to set up such kind of study. A sufficient 
number of individuals have to be affected by a particular disease before one can study the disease. A 
genome scan, required to investigate genetic polymorphism associated with a particular disease, for 
example, necessitates DNA of at least 10,000 individuals. This clearly shows how international 
cooperation that combines the stored HBM and data of different biobanks is important to accelerate 
such research (9,25,31). 
An example of the first subtype is the UK Biobank12 that aims to collect HBM and data of more than 
500.000 donors. The donors are selected to represent the ethnic diversity within the United Kingdom. 
They are recruited between the age of 40 and 69 years in order to make sure that the group of donors 
represent most of the different disease phenotypes(42,43). The aim of the UK Biobank is to study the 
influence of inherited genetic variations, environmental factors and the life style of the donors on the 
risk of developing particular diseases, such as cancer, heart disease, stroke, diabetes, arthritis, 
osteoporosis, eye disease, depression, and certain forms of dementia(31). 
A second subtype comprises biobanks that are focused on a specific isolated population. Such 
biobanks are for instance used to study specific ethnic groups for which one has sufficient information 
regarding the family history over several generations(9). 
A third subtype is biobanks based on HBM and data of twins (so-called “twin registry biobanks”). Such 
collections of HBM allow twofold research. It allows to study the genetic variations in twins in the same 
environment (e.g. dizygotic twins) or, alternatively, the environmental effects of twins with an identical 
genetic background (e.g. monozygotic twins) (9). Examples of such twin banks are the Swedish, the 
Danish and the Netherlands Twin Registry and the European project GenomEUtwin.    
  
                                                       
12 http://www.ukbiobank.ac.uk/ 
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1.4.2.2 Disease-oriented, clinical or hospital-integrated biobank 
A disease-oriented biobank, also called a clinical or hospital-integrated biobank (3), contains HBM in 
relation to specific pathological conditions. The HBM is collected from individuals in the framework of 
medical diagnosis or treatment. An important example of such disease-oriented biobanks are tumour 
biobanks(44). In this case HBM and data are usually collected from patients. This type of biobank is 
therefore typically integrated into a hospital (4). The types of HBM stored in this type of biobank are 
tissues, isolated cells, blood, urine or saliva. The HBM (and data) in this type of biobank can be used 
to study the different stages and the treatment of a particular disease at the molecular level. One can 
identify biomarkers that can be used for the prediction, diagnosis, and response to the treatment of a 
particular disease. In addition, the identification of novel pathways involved in a particular disease can 
lead to the discovery of new molecular targets. These molecular targets may, in turn, result in the 
development of more specific medicines. This type of biobank is used for at least two types of studies 
(9,25,31). 
Case control studies are a first type of studies that use HBM and data from disease-oriented biobanks. 
In this case HBM and data are stored both from both healthy and diseased individuals. The 
comparison of HBM and data from both groups can provide insight in certain disease profiles and 
mutant genes. It can furthermore be used to study the interaction between genetic and environmental 
factors(31). The HBM of the control group may be obtained from the collection of a population-based 
biobank (9,25,31). 
Prospective studies are another type of studies that use HBM and data from disease-oriented 
biobanks. HBM and associated data is collected to study the interaction between genetic factors and 
the response to treatments(31). Most biobanks contain in addition to the affected tissue also 
unaffected tissue from the same patient. This allows a direct comparison of changes at the genetic 
level (9,25,31). 
An example of a disease-specific biobank is the Spanish HIV HGM Biobank. This biobank was created 
in 2004 to collect and provide access to distinct HBM from HIV/AIDS Patients. The HIV HGM Biobank 
receives HBM (and data) from 37 hospitals in Spain and organizes those HBM in 7 cohorts of HIV-
patients according to specific criteria: (i) Cohort of Adults; (ii) Cohort of Long-Term-Non-Progressors; 
(iii) Cohort of Rapid Progressors; (iv) Cohort of Acute Infection; (v) Cohort of Lymphocyte-Non-
regenerators; (vi) Cohort of HIV-infected patients with liver organ transplant and (vii) cohort of 
paediatric HIV-infection. The different cohorts of HBM and data are accessible – free of charge – for 
national and international research projects13. 
                                                       
13 http://www.esbb.org/biobanks-featured.html 
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1.5 Biobank networks 
1.5.1 Concept of biobank networks 
Access to large amounts of HBM and data is crucial for many biomedical research projects. That is 
why several initiatives have been taken to develop biobank networks to share and combine different 
collections of HBM and data. The concept of a ‘biobank network’ can be defined as ‘a group of 
institutions who freely assume the commitment to collaborate in the domain of biobanking and who 
(often) share the same procedures and quality policies, and who are (or might be) helped by a central 
hub for coordination in terms of service’ (1).  
1.5.2 Classification of biobank networks 
Biobank networks are developed for various purposes. These could be the development of standard 
operation procedures (SOPs) in relation to the governance of biobanks and the quality of HBM and 
associated data, the collection and sharing of HBM and data or the creation of common research 
infrastructures(26,45).  
Shickle, Griffin and El-Arifi distinguish seven different types of biobank networks. Quite a lot of the 
existing networks are a mixture of these seven different types(45).  
The primary purpose of a storage network is to provide common storage facilities. This enables the 
participating biobanks to reduce their costs. The savings generated by such a network could be 
invested in technology to increase the quality of the HBM. Every participating biobank is given a 
certain storage capacity within the common facilities. The individual biobanks remain the custodians of 
their HBM and data. They maintain the right to control how to provide access to their collection. An 
example of such a network is the "Singapore Tissue Network"(45). 
Bring-and-share storage networks could be considered a subtype of the storage networks. 
Participating biobanks that make their HBM and data available to other participants pay a lower fee 
compared to those participants that only use storage facilities. Participants can request that their HBM 
and data will only be available to other researchers after completion of their own research project. In 
this case they may have to pay an additional fee for such “preferential access.” An example of such a 
network is the Istituto Nazionale per la Ricerca sul Cancro, Biological Bank and Cell Factory in 
Italy(45).  
A third type of biobank network is the catalogue network. This type of network consists of a central 
database where researchers can search whether the participating biobanks provide access to 
particular HBM and data for use in their research project. The HBM and the data are stored at the 
facilities of the participating biobanks. The biobank network only provides access to a minimum 
dataset to search the different collections. This type of network is particularly useful when a researcher 
wants to have access to rare HBM and an individual biobank cannot provide sufficient amounts of 
such HBM. Examples of such type of network are the Belgian Virtual Tumourbank (BVT) and the 
OECI-TuBaFrost consortium (45).      
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Partnership networks are based on a formal partnership agreement between the different participating 
biobanks. This agreement may contain rules on how to collaborate. It could develop common rules on 
the storage and processing of HBM and data as well as rules and procedures that apply when 
researchers want to access the collection of HBM and data. The partnership aims to share knowledge 
between the different partners. The collections of HBM and data of the different partners can either be 
stored at one central location or can remain at the facilities of the different partners. Usually the 
partnership will create a central hub to manage the coordination and the administration of the network. 
A common catalogue allows researchers to search the collection of HBM and data. The partnership 
network could hold custodianship and therefore decide on access to HBM and data collected in the 
framework of the network. The partners could maintain the right to decide on access to HBM and data 
that was collected prior or outside the network. The partners need to agree on what will happen with 
the collection of HBM and data in case the network would dissolve. An example of a partnership 
network is the “Victorian Cancer Biobank” in Australia(45).  
A contribution network could be described as a collaboration between a biobank and clinicians or 
researchers. Clinicians and researchers provide the biobank with valuable or rare HBM and data that 
they collected in the framework of their clinical or research facilities. The biobank will usually store and 
govern the collection of HBM and data at a central facility. Custodianship over the collection HBM and 
data will be exercised by the biobank. It will also be the biobank that decides on access to the 
collection for research purposes. Professional organizations or associations of clinicians and 
researchers that are active in a particular disease domain may set up such contribution networks. An 
example of such a contribution network is the "Paediatric Tumour bank" in Australia (45). One could 
argue that another example would be the initiatives taken by some hospitals to store and manage 
HBM and data collected in their different departments, in a central facility. We see examples of this in 
Belgium and other countries  
A sixth type of network is called expertise networks. This type of network focuses on the sharing of 
expertise and does not involve the exchange of HBM and data. Quite a lot of those initiatives are 
active in matters concerning ethical, legal and societal issues (also called ELSI issue) in relation to 
biobanks. Some of those initiatives aim to encourage the harmonization of SOPs or access rules and 
procedures. Examples of such networks are the ‘Public Population Project in Genomics and Society’ 
(P3G), the International Society for Biological and Environmental Repositories (ISBER), the European, 
Middle Eastern & African Society for Biopreservation and Biobanking and the National Swedish 
Biobanking Programme (45). 
Networks of population cohorts are the final type of networks mentioned by Shickle, Griffin and El-
Arifi(45). The participating biobanks of such network are prospective or retrospective population 
cohorts. Such cohorts comprise of HBM of adults or children in a particular population or a part of such 
population. The creation of networks between population cohorts can enlarge the possibilities to study 
common causes of morbidity or mortality. The collaboration between population cohorts is particularly 
important in relation to rare disease. In this case the different participating cohorts might only dispose 
of a limited number of HBM affected by such rare disease. Only a limited number of networks of 
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population cohorts exist(45). One could consider the ‘European Prospective Investigation into Cancer 
and Nutrition (EPIC) study’ as a network of population cohorts14. EPIC is a “multi-centre prospective 
cohort study designed to investigate the relation between diet, nutritional and metabolic 
characteristics, various lifestyle factors and the risk of cancer and other chronic diseases”(46). EPIC 
recruited more than 500.000 donors across 10 European countries and is one of the largest cohort 
studies in the world. EPIC consists of several national or regional cohorts, such as EPIC-Denmark and 
EPIC-Germany.  
1.5.3 Examples of biobank networks in Europe, the Benelux and Scandinavia 
We hereunder to provide examples in the Benelux, Scandinavia and Europe of some of the different 
types of biobank networks mentioned above. Some or all of the networks described hereunder, could 
be considered a mixture of different types. 
The ‘Karolinska Institutet Biobank’ in Stockholm (Sweden) could be considered a combination of a 
storage network and a network of cohorts. The Karolinska Institutet Biobank manages many different 
types of collections of HBM and data. Some collections are stored and managed at the request of 
researchers or health care authorities. The Karolinska Institutet Biobank however also manages HBM 
and data collected in the framework of large population-based cohorts – such as TwinGene cohort15, 
the ‘60-year old cohort’16 and the LifeGene17 cohort – and in the framework of disease based studies. 
The Karolinska Institute biobank offers different types of services to the principal investigators that 
store their HBM and data in the biobank Such services cover (i) advice on the planning and the ethical 
and legal compliance of a study; (ii) the registration, processing, storage and withdrawal of samples; 
and (iii) DNA extraction(47). 
The Belgian Virtual Tumourbank18 (the ‘BVT’) is an example of a disease-specific, catalogue network. 
The Belgian Virtual Tumourbank was official created in 2008 as a result of the Initiative 27 of the 
Belgian National Cancer Plan. The general aim of this initiative was the promotion of translational 
cancer research and the collaboration between cancer researchers in Belgium. The BVT consists of 
11 hospitals, among which the major Belgian university hospitals. A Royal Decree of 20 September 
2009 indicates the conditions that a hospital has to meet to receive financing for its participation in the 
BVT. The tumour samples and associated data are stored and managed by the biobanks participating 
in the BVT. The Belgian Cancer Registry coordinates the activities of the BVT. It created – in 
collaboration with the different biobanks – a central database with minimum datasets on the available 
residual human tumour samples. A coded version of the central database is accessible to research 
groups, which allows them to search for HBM and data that could be interesting for their research 
projects. When a researcher wants to use particular HBM and data in his research project, he has to 
submit an access request to the local biobanks that store and manage the HBM and data (48). 
                                                       
14 http://epic.iarc.fr/about/cohortdescription.php 
15 http://ki.se/en/meb/twingene-and-genomeeutwin 
16 http://ki.se/en/imm/the-60-year-old-cohort 
17 http://lifegene.ki.se/ 
18 http://www.kankerregister.org/tumourbank.aspx?url=BVT_home 
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Another biobank network initiative in Belgium is the creation of a Flemish Biobank by the Centre for 
Medical Innovation (CMI). The CMI was officially founded in December 2009 at the initiative of the 
Flemish Government, the Flemish Ministry of Economy and Scientific Affairs, the 5 Flemish University 
Medical Centres and representatives from the Health Care Industry. The first project of CMI was the 
creation and coordination of a Flemish biobank. This will be a virtual biobank (network), which focuses 
on specific diseases fields. CMI developed harmonized quality criteria for HBM and accompanying 
clinical data sets. It emitted a report, entitled the ‘Ethical and Legal Framework applicable to 
Biobanks.” CMI furthermore aims to create a central IT backbone that should result in a database that 
would allow translational research projects between different universities and/or industry19. The 
different participating hospitals maintain the custodianship of their collections of HBM and data. In the 
future the Flemish Biobank initiative aims to establish collections of HBM and data “in disease 
domains in which the Flemish knowledge institutes and Flemish industry has a strong position.” Pilot 
biobanks will be set-up in the 5 disease domains: (i) sudden cardiac death; (ii) diabetes; (iii) 
inflammatory bowel disease; (iv) rheumatic arthritis and (v) diabetes(49). 
Another initiative that could – to a certain extent – be considered a catalogue network is the Danish 
National Biobank initiative. The initiative created an online registry that enables researchers to access 
the combined data of all Danish biobanks that participate in the initiative. In the future the Danish 
National Biobank Registry wants to provide an overview and access to more than 15 million HBM – 
relating to different diseases – in existing and future collections. When a researcher has found the 
HBM and data that he wants to use in a research project, he should contact the Coordinating Centre 
that will assist him in obtaining access to the HBM and data20.  
The OECI-TuBaFrost consortium is a European virtual biobank network (or catalogue network) that 
brings together biobanks specialized in cancer. The consortium initial started as a research project 
funded by the 5th Framework Programme of the European Union. Later the project resulted in the 
creation of a consortium between the different participating biobanks. From 2006 until 2010 the 
TuBaFrost Consortium was integrated into the Organisation of European Cancer Institutes (OECI) 
Pathobiology working group. This working group supports the European virtual biobank infrastructure 
in the management of the exchange platform OECI-TubaFrost. The further development of OECI-
Tuba Frost has been possible through support from the EurocanPlatform project. The OECI-
TuBaFrost exchange platform contains a central database application. This application allows to 
search which HBM and data are available in the collections of the different participating biobanks. The 
platform supports the exchange of HBM and data within a project consortium. Access to such HBM 
and data is limited to the members of the consortium, while the database is accessible to all OECI 
members(50,51).   
  
                                                       
19 http://cmi-vzw.be/history.htm 
20 http://www.biobankdenmark.dk/About%20the%20Biobank.aspx 
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The Parelsnoer Institute in the Netherlands could be considered a diseased-focused, partnership 
network. This initiative is a collaboration between all eight Dutch university hospitals. Its aim is to 
create a national research infrastructure for clinical epidemiology(31). The Parelsnoer Institute 
consisted in 2007 of eight cohorts. They each focus on one syndrome, also called pearls. These 
different syndromes are: inflammatory bowel disease, rheumatoid arthritis, stroke, hereditary colon 
cancer, leukaemia, neurodegenerative diseases, kidney failure and diabetes. Those eight syndromes 
were chosen due to their importance for the Dutch health care system. In the course of the project 
new cohorts have been added in relation to the following syndromes: CONCOR (congenital heart 
defects), endocrine tumours, ischemic heart disease and pancreas(52). One expects to accelerate 
research by focusing on the collection of HBM and data and research projects concerning a limited 
number of syndromes(53). The cohorts provide access both to HBM and data collected in a 
prospective manner(54).   
An example of an international expertise network is the Public Population Project in Genomics and 
Society (P³G). P³G is a not-for-profit consortium. It provides the international research community with 
online access to expertise, tools and services in relation to ethical, legal, social, epidemiological and 
technical issues with respect to (population-based) biobanks. P³G also manages an online catalogue 
with information on large-population based biobanks. Finally P³G participates in the development of 
the BRIF (Bioresource Research Impact Factor)21.  
The ‘Biobanking and Biomolecular resources Research Infrastructure’ (BBMRI) was initiated in 2008 
under the European Research Infrastructure Preparatory Phase of the ESFRI roadmap. It was funded 
by the European Union (9,10). The preparatory phase of BBMRI lasted for three years and came to its 
end in January 2011. On 3 December 2013, BBMRI was officially awarded the Community legal 
framework for a European Research Infrastructure (ERIC). BBMRI-ERIC22 is established as a pan-
European (distributed) research infrastructure and network. It consists of existing and de novo 
population-based and disease-oriented biobanks, as well as biomolecular resources. The aim of 
BBMRI-ERIC is to facilitate access to the different biobanks and biomolecular resources and to 
support high quality biomolecular and medical research (37). That is why BBMRI-ERIC wants to act as 
an “umbrella network” that contributes to the development of common standards and a clear ethical 
and legal framework(9,10). A general inventory of the different participating biobanks and biomolecular 
resources is currently being created as well as common access requirements (9,10). The structure of 
the BBMRI network is represented as a “disturbed hub and spoke scheme” (see Figure 1). In this 
scheme, the various biobanks, biomolecular resources and specialized technology centres are 
connected via their specific hub.  
                                                       
21 http://p3g.org/about-p3g/glance 
22 The Biobanking and Biomolecular resources Research Infrastructure-European Research infrastructure 
consortium 
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Figure 1: Distributed hub and spoke structure of BBMRI 
Each participating country has its own national hub or node. This hub coordinates the national 
biobanks, biomolecular resources and technology centres and links its activities with the pan-
European activities of BBMRI-ERIC. National hubs have been created or are being created in Austria, 
Belgium, Czech Republic, Estonia, Finland, France, Germany Greece, Italy, Malta, the Netherlands 
and Sweden. Norway, Poland, Switzerland, Turkey and IARC23/WHO are observers to BBMRI-ERIC. 
Sweden, Norway, Denmark, Finland, Iceland, the Faroe Islands and Estonia have created BBMRI 
Nordic. BBMRI Nordic is a network comprising national infrastructures of those Nordic countries 
engaged in facilitating biobanks activities. The BBMRI-ERIC consortium today consists of more than 
59 members and 225 partners from more than 30 European countries. The headquarters of BBMR-
ERIC are established in Graz in Austria. The headquarters coordinates the interaction between 
different national hubs. It created a virtual search platform that provides access to research resources, 
facilities and expertise, available in the different participating countries24. 
  
                                                       
23 The International Agency for Research on Cancer http://www.iarc.fr/ 
24 http://bbmri-eric.eu/2 
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1.6 Legal framework applicable to ‘access to biobanks’ 
Different legal instruments determine the legal framework applicable to access to biobanks.  
The PhD project will study both binding legal instruments – such as international treaties or national 
legislation – and non-binding normative instruments or soft law that apply to access to biobanks. The 
PhD project will also study access arrangements and ‘key access conditions’. 
The most important binding legal instruments (or sources of law) at the international level are 
international conventions or treaties concluded between two or more countries. Other sources of law 
are international customs, general principles of law and judicial decisions of international courts(55).  
Binding legal instruments at the level of the European level are the Treaty on the European Union and 
the Treaty on the Functioning of the European Union. These Treaties contain the basic provisions on 
the European Union’s objectives and organizations. The main secondary sources of law at the level of 
the European Union are regulations and directives.  
The most important binding legal instruments at the national level are laws enacted by the national 
parliament. Other binding legal instruments at the national level are executive decrees – such as 
Royal and Ministerial Decrees – that implement national laws.  
Additional sources of law are non-binding normative instruments or soft law. The Oxford Dictionary of 
Law defines soft law as “guidelines of behaviour, such as those provided by treaties not yet in force, 
resolutions of the United Nations, or international conferences, that are not binding in themselves, but 
are more than mere statements of political aspiration.” Two important examples of such soft law are 
the Recommendation (2006)4 of the Council of Europe or the Helsinki Declaration. 
Another non-binding sources of law are access arrangements. Access arrangements can be defined 
as “guidelines, best practices, opinions, policies, agreements, etc. containing rules on access to and 
use of HBM and data collections stored within biobanks’.  
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2 Scope 
The project covers the various aspects of the legal framework applicable to ‘access to biobanks’ (see 
Figure 2).  
We define ‘access to biobanks’ for the purpose of this PhD project as ‘the relationship between the 
custodian of a biobank and a researcher who applies for access to HBM and data stored in a biobank 
(i.e. an applicant)’. 
We decided to focus on ‘access to biobanks’, since few research projects had studied this topic when 
this PhD project was initiated. We decided not to study the – without any doubt – important 
relationship between the custodian of a biobank and the donor/patient, since many previous research 
projects focused on the role, the participation and the expectations of the ‘donor’(56–62). That is also 
why we did not focus on the topics of biobank governance, consent and return of incidental findings 
(23,63–70).  
 
Figure 2 Graphical representation of scope of PhD 
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2.1 Objectives and research questions 
In an interdisciplinary context, the general objective of the project is to contribute to the creation of a 
clear and smooth legal framework – i.e. legislation, non-binding normative instruments and access 
arrangements – applicable to access to and use of HBM and data stored in biobanks.  
The specific objectives of the project are: 
• to assess to which extent access arrangements contain information on 21 identified ‘key 
access conditions’ (Chapter 1) 
• to assess the variation in how access arrangements apply those key access conditions to 
elucidate potential for harmonization (Chapter 2); 
• to investigate how access arrangements are applied in practice (Chapter 2); 
• to study the rights and obligations of custodians and applicants and - to a limited extent 
donors – as stipulated in the legal framework applicable to access to biobanks (Chapter 3); 
• to study the relationship between IPRs and biobanking and the sharing of research results 
(Chapter 4) 
Finally, Part 4 of the PhD formulates concluding findings and recommendations on a transparent, 
feasible and encouraging legal framework applicable to biobanks. 
The research questions of the project are:  
• Which legal framework determines the relationship between a biobank and a researcher 
applying for access to HBM and data stored in a biobank? (Chapters 1, 3 and 4) 
• Does the existing legal framework correspond to the needs of biobanks and other 
stakeholders? (Chapters 2 and 4) 
• To which extent is additional legislation or soft law required for the creation of a feasible and 
encouraging legal framework for biobanks? (Discussion and recommendation) 
The research questions apply in a transversal and horizontal way to the different chapters of the PhD 
project. The different research questions are studied in several chapters across the thesis and 
answered in the discussion and recommendation chapter. 
2.2 Methods 
Theoretical (legal) and empirical (qualitative) research methods were designed and used to perform 
the studies, including literature (scientific and legal) reviews, interviews and in-depth document 
analyses. The specific methodology used in each study is described in the different chapters. We 
nevertheless wanted to explain the general methodological choices made in the development and the 
conduct of the PhD project. 
The legal framework applicable to ‘access to biobanks’ is still a relatively new field. It is therefore no 
surprise that there is no overall consensus or general theory to delineate the legal framework that 
applies to ‘access to biobanks’. There are furthermore no ‘general accepted’ key conditions or 
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benchmark criteria to be taken into account when evaluating the legal framework applicable to ‘access 
to biobanks’. Due to the novelty of this field, we were not able to apply a specific, existing theoretical 
perspective as benchmark for our study25. We attempted to apply the ‘social constructivist theory’26 of 
ownership to develop the empirical study described in Chapter 2. According to this theory, “ownership 
is the result of a series of social choices and events that could well have been different.” This theory 
does not aim to answer the absolute question whether a particular stakeholder – such as the 
custodian, the applicant or donor – can be the ‘owner’ of HBM. Instead, the theory considers it more 
useful to see ownership as bundles of rights and obligations of different stakeholders in relation to a 
particular object. Such rights could include for instance the right to decide on the use of HBM, the right 
to transfer HBM, but also the obligation to protect the interests of the donors. Chapter 2 studied the 
different perspectives of stakeholders in relation to these (bundles of) rights and obligations. Since the 
theory of ‘social constructivism’ focuses on ‘ownership’, it did not allow us to provide a complete 
answer to the research question ‘which rights and obligations are held by stakeholders in relation to 
HBM and data?’ It appeared not possible to define the complete bundle of rights and obligations of the 
stakeholders. 
Although we did not apply a particular theoretical perspective, we did make a number of 
methodological choices in how to study the legal framework to access to biobanks.  
First, we decided to study the legal framework from a continental (or civil) law perspective, rather than 
a ‘common law perspective’. This is due to the fact that the majority of the countries within the 
European Union apply a ‘continental law perspective’ and the PhD candidate was trained in a country 
with a continental law tradition, in particular Belgium. The main source of law in a ‘continental law’ 
approach is legislation enacted by the legislator (the national parliament); the judicial courts are only 
expected to apply the law. In a common law system the decisions of judicial courts are considered 
much more as an important source of law. The ‘common law’ system is applied amongst others in the 
United Kingdom, the US and Australia(71). The fact that we applied a ‘continental law’ approach 
implies that the recommendations of the PhD project might be mainly useful to study the legal 
framework applicable to access to biobanks in ‘continental law’ countries and less in ‘common law’ 
countries.   
Second we decided to apply a ‘legal positivistic’ approach rather then a ‘legal realistic’ approach. This 
implies that we attempt to describe and explain the legal framework applicable to access to biobanks, 
but we do not evaluate the moral value of such legal framework. We will therefore not prescribe how 
the legal framework ‘ought to be’(55). We choose the ‘legal positivist’ approach, since this approach is 
                                                       
25 We would like to remark in this respect that it is not uncommon that a legal research project does not start from 
a particular theoretical perspective. A. Dyèvre remarks in this respect that “EU law scholars tend to comment on 
legal developments without feeling the need to ground their analysis in explicit theoretical assumptions(72).” The 
main aim of legal studies is often to (a) provide a thorough description of the applicable legislative framework, (b) 
study how the framework should be applied in a specific context, (c) try to explain the application of the legal 
framework. That is why legal research projects are often more descriptive in nature.  
26 Quigley, M. Property and the body: applying Honoré. J MED ETHICS 33, 631–4 (2007). 
28; Björkman, B. Different types--different rights. Distinguishing between different perspectives on ownership of 
biological material. Science and engineering ethics 13, 221–33 (2007) 
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most often applied in the study of continental law systems. The ‘legal realist’ approach is mainly 
applied to study the US ‘common law’ system. The ‘legal realist’ approach is not very often used by 
European legal scholars(72).   
Third, we decided to study the legal framework in the material – or broad – sense and not in a formal – 
or narrow – sense. This implies that we deliberately decided not to limit our analysis to the binding 
legal instruments – such as international treaties or national legislation – that apply to access to 
biobanks, but also to study non-binding normative instruments or soft law – such as recommendations 
or guidelines that determine the legal relationship between the custodian of a biobank and an 
applicant. We felt that the study would be incomplete, if we would restrict ourselves to an analysis of 
the law in the formal sense, i.e. the legal instruments or norms that are adopted by legislator in this 
area and that are binding on legal subjects. Afterall the formal legal norms that exists in relation to 
access to biobanks are limited. Furthermore one can argue that non-binding normative instruments 
have an equally important impact on the legal framework that applies to “access to biobanks”. One 
can refer in this respect to the Recommendation (2006)427 of the Council Of Europe. Although the 
Recommendation is a non-binding normative instrument, it nevertheless had an important impact on 
access arrangements developed by biobanks and legislation enacted by national legislator in relation 
to the use of HBM and data in biomedical research. 
Fourth we decided to study the legal framework applicable in one Benelux country and one 
Scandinavian country, since we are based in the Benelux and the Scandinavia countries are 
considered as pioneers in biobanking(18,73,74). We decided to compare Belgium and Denmark for a 
number of reasons. First, the comparison between both countries appeared interesting, since 
Denmark has a very strong reputation in biobanking, but explicitly decided not to develop specifically 
legislation on biobanks and the use of HBM and data in biomedical research. Belgium at the other 
hand did develop specific legislation on biobanks. Denmark is also an interesting country from a legal 
point of view, since the Danish Data Protection Agency has specific competence in relation to 
biobanks. This is not the case in Belgium and most other countries. Finally we choose to compare 
Belgium and Denmark for practical reasons. The PhD candidate has worked in both countries and 
therefore had the opportunity to gain deeper knowledge on the legal framework applicable to biobanks 
in Denmark and Belgium. Due to time constrains we were not able to study more countries.  
Fifth, we decided to define and use ‘key access conditions’ as benchmark criteria to study and 
evaluate the legal framework that applies to access to biobanks. This was inspired by the idea that an 
optimal legal framework “should be based upon a coherent set of principles (or conditions), to ensure 
that the law is consistent, effective and relevant for researchers and society”(75). Since no general 
consensus exists on such ‘key access conditions’, Chapter 1 started with a review of international 
literature and reports of P3G (4,76) and the Medical Research Council and The Wellcome Trust (69) 
on ‘access to biobanks’. This allowed us to determine a set of conditions that are key to ‘access to 
                                                       
27 Recommendation Rec (2006)4 of the Committee of Ministers to Member States on Research on Biomedical 
Materials of Human Origin 
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biobanks’ (see Chapter 1, Table 1). The key access conditions allowed us to determine which legal 
instruments to take into account when studying the legal framework applicable to access to biobanks. 
We decided in particular to study the combination of key access conditions (Chapter 1), access 
arrangements (Chapter 1), access practices (Chapter 2) and legislation (Chapter 3) to determine the 
legal framework applicable to ‘access to biobanks’ (see Figure 2). The ‘key access conditions’ were 
furthermore used (a) to describe the legal framework applicable to ‘access to biobanks’; (b) to 
evaluate how the different legal instruments address ‘access to biobanks’ and (c) to which extent 
those instruments contribute to the creation of a transparent, feasible and encouraging legal 
framework.  
We are aware that the set of conditions – used in the project – is not generally accepted. Some might 
argue that some ‘access conditions’ are missing – such as consent and cross border transfer of HBM 
and data – or that some conditions might not be considered as key to access to biobanks – such as 
intellectual property rights or the protection of personal data. We decided not to include the important 
principle of ‘consent’ in the set of access conditions, since we believe that consent mainly pertains to 
the relationship between the donor/patient and the biobank; it only indirectly relates to the relationship 
between the biobank and the applicant. Many previous research projects furthermore focused on 
‘consent’. Chapter 3 nevertheless looked into the legal framework applicable to ‘consent’ to the extent 
that this was relevant for ‘access to biobanks’. We decided not to include the ‘cross border transfer of 
HBM’ as key access conditions, since we believe that it does not directly relate to ‘‘legal relationship 
between the custodian of a biobank and an applicant’. The topic rather relates to the question whether 
a particular country allows the import or export of HBM and data. We did include the ‘protection of 
personal data’, since a biobank needs to comply with the legal rules in this respect in the development 
of access arrangements. We also included ‘intellectual property’ as a key access condition, since we 
believe that it might be considered as an important condition to protect the substantial investments 
made in biobanks and the results of research projects using HBM and data stored in biobanks.  
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2.3 Overview of PhD project 
Chapter 1 of the PhD reports on a comparative document analysis of access arrangements of 
organizations, biobank networks and biobanks. This analysis provides qualitative data on the extent to 
which access arrangements contain information on 21 selected access conditions. It furthermore 
studied to which extent access arrangements implement those access conditions in a harmonized 
way.  
Chapter 2 of the PhD reports on an empirical study of access practices in the context of biobanking. 
Interviews were conducted with stakeholders and experts to gain a more profound understanding on 
how access arrangements are applied in the daily practices of biobanks and biobank networks. This 
study aimed to gather practical experiences and personal opinions of the interviewees rather than 
factual information. The interviews provide qualitative data on the different perspectives held by 
stakeholders in relation to the rights and obligations of custodians, applicants and donors with respect 
to access to HBM and data stored in biobanks. This chapter allowed us to explain the lack of clear 
information on several ‘key access conditions’ and the high variation in the application of key access 
conditions. It also allowed us to investigate on which ‘access conditions’ consensus could be reached 
between stakeholders and which ‘access conditions’ remained unresolved. This might offer a deeper 
understanding on whether harmonization is possible on some key ‘access conditions’. 
Chapter 3 of the PhD reports on a comparative study of the legal framework that is applicable to 
access to biobanks. The comparative study started with a general overview of the national legislation 
applicable to biobanks in Belgium, Denmark and normative norms at the international level and at the 
level of the Council of Europe. It furthermore analysed the rights and obligations of custodians of 
biobanks, applicants and - to a lesser extent– donors in these different legal instruments. We 
investigated to which extent and how key ‘access conditions’ are regulated via the different legal 
instruments– in a broad sense – applicable to access to biobanks. That is also why we only describe 
and explain the different legal instruments to the extent that they are relevant for ‘access to biobanks’.  
Chapter 2 and 3 allowed us to determine which key ‘access conditions’ are sufficiently regulated via 
access arrangements or legislation and which are not sufficiently regulated. 
Chapter 4 of the PhD reports on a legal study on intellectual property rights (IPRs) in biobanking and 
to a lesser extent the ‘return and sharing of research results’. We studied those two key ‘access 
conditions’, since ‘access arrangements’ and legislation contain little information on those conditions, 
while they are nevertheless important for ‘access to biobanks’. This legal study provides an overview 
of the most relevant IPRs in biobanking and discusses the risks and opportunities associated with the 
identified IPRs for an effective protection and use of biobanks in translational research and innovation. 
It furthermore touches upon the question whether biobanks should require the return and sharing of 
research results. 
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Figure 3: Overview of the PhD project 
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Part 2: Qualitative studies 
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Chapter 1: Access to biobanks: Harmonization across 
biobank initiatives 
 
This chapter is based on: 
Verlinden M, Nys H, Ectors N, Huys H  
Access to Biobanks: Harmonization across biobanks initiatives.  
Biopreserv Biobank. 2014; 12(6):415–22.   
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1 Introduction 
Access to human biological materials (HBMs) and associated data stored in biobanks is crucial for 
biomedical research (14,16,17). Researchers need to be able to efficiently access different collections 
of HBMs and data (69,77,78). In order to guarantee their long-time sustainability as well as the 
scientific, legal and ethical correct use of HBMs and data, biobanks and biobank networks need to 
exercise control on the access to their resources (1,14,16,69,70,77). Taken into account the above, it 
is not surprising that several organizations and authors have stressed the importance of clear and 
transparent rules on access (4,16,63,69,77,79–85). 
Previous empirical studies focused on guidelines and policies in relation to (amongst others) 
governance, consent and return of incidental findings (23,63–68). Only a few empirical studies have 
focused on access arrangements (16,63,69,77,81,82), i.e. ‘guidelines, best practices, opinions, 
policies, agreements, etc. containing rules on access to and use of HBM and data collections stored 
within biobanks’ (a similar definition of access arrangements is used by S. Fortin et al. (16) and the 
OECD(86)).Previous empirical studies on access arrangements tended to focus on a limited number 
of access conditions or studied a limited number of access arrangements (4,63,69,76,77,81,82). 
The current study provides qualitative data on the extent to which access arrangements contain 
information on 21 selected key access conditions and the level of harmonization of these conditions. 
2 Methods 
2.1 Document selection and collection 
Twenty-seven international, regional and national organizations in the European Union, the United 
States, Canada and Australia were identified (see Annex 1). In addition, a literature review on access 
to HBMs or data, supplemented with information from the Public Population Project in Genomics and 
Society (P3G), the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI.ERIC), 
the Deutscher Ethikrat and the Institute for Prospective Technological Studies (IPTS) of the European 
Commission's Joint Research Centre (JRC), served as a basis to develop an overview of 51 biobank 
networks and 22 biobanks worldwide (see Annex 1)(4,76,87–89). The majority of the identified 
biobank initiatives28 were established and funded by not-for-profit institutions. Limited information was 
found for biobanks funded by for-profit institutions. The comparative study focused on access to HBMs 
or data or both for purposes of biomedical research. 
  
                                                       
28 The term ‘Biobank Initiatives’ covers biobanks, biobank networks as well as organizations 
Access to biobanks: Harmonization across biobank initiatives 
 
Page | 32  
 
2.2 Access to publicly available access arrangements  
Websites and (scientific) publications available in English, French, Dutch, German or Spanish were 
reviewed in order to retrieve publicly available access arrangements of the selected biobank initiatives. 
In case no access arrangement was found, the contact person of the biobank initiative was contacted 
via e-mail with the question whether it developed an access arrangement and could provide a copy of 
such arrangement. In the absence of a response, one reminder was sent. 
2.3 Identification of 21 key access conditions for biobanking 
In a preparatory phase, international literature in relation to access to HBMs or data was reviewed 
using online resources (PubMed, Embase and Web of Science). The terms ‘biological specimen 
bank’, ‘biobanking’, ‘biobank’, ‘biological repository’ and ‘research’ were used to review these 
resources. The literature (4,9,16,25,63,66,80,90) was supplemented with information found on the 
website of P3G (4,76) and a report drafted at the request of the Medical Research Council and The 
Wellcome Trust (69). This allowed us to identify 21 key conditions in relation to access to HBMs and 
data (see Table 1). It was decided not to focus on consent, since this has been investigated 
extensively in previous studies (23,63–66,69,70). 
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Table 1 Overview of key access conditions 
Key access conditions Description 
1. Access to data and/or HBM Does the access arrangement apply to data, HBM or both? 
2. Type of HBM To which type of HBM does the access arrangement apply? 
3. Type of data To which type of data does the access arrangement apply? 
4 & 5. Level of ownership of 
primary HBM and data 
Which level (biobank network, biobank or PI) holds ownership 
over primary HBM and primary data? 
6 & 7. Level of custodianship 
of HBM and data 
Which level (biobank network, biobank, funder or PI) holds 
custodianship over HBM and data? 
8. Access committees To which extent does the access arrangement provide for a committee to decide on access to HBM, data or both? 
9. Mandate access committee How is the mandate of the access committee specified in the access arrangement? 
10. Screening of scientific 
merit 
Does the access arrangement provide for a screening of the 
scientific merit of access requests and how? 
11. Access by industrial 
company 
What does the access arrangement provide in relation to 
access by industrial companies to the HBM and/or data? 
12 & 13. External/industrial 
applications: Different legal 
conditions and fees 
To which extent does the access arrangement provide 
different legal conditions and fees for external or industrial 
applications compared to internal applications? 
14. Priority setting 
Does the access arrangement provide criteria to prioritize 
parallel applications and if this would be the case, which 
criteria are stipulated? 
15. Intellectual property What does the access arrangement provide in relation to IP rights held by the biobank? 
16. Exclusive (access) right of 
applicant 
To which extent does the access arrangement provide the 
applicants exclusive access to certain HBM and data? 
17. Preferential (access) right 
of collector 
To which extent does the access arrangement provide 
preferential (access) to collectors who provided HBM and data 
to the biobank initiative? 
18. Benefit sharing 
To which extent does the access arrangement stipulate an 
obligation to share benefits resulting from the use of HBM 
and/or data? 
19. Sharing or returning 
research data or results 
To which extent does the access arrangement stipulate an 
obligation to return to the biobank initiative or share with third 
parties research data or results? 
20. Data protection To which extent does the access arrangement provide access to coded, anonymised or identifiable data? 
21. Return and/or destruction 
of tissue 
To which extent does the access arrangement stipulate an 
obligation to return and/or destroy leftover tissue? 
Note: We wish to clarify that the key access conditions are not listed in a hierarchical order in terms of 
importance. 
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2.4 Comparative analysis of access arrangements 
In the second phase (August 2011 and January 2013, at which time two extra copies of access 
arrangements were obtained) a comparative analysis was conducted of the access arrangements. 
Although access arrangements of organizations, biobank networks and biobanks might not be 
entirely comparable – taken into account their different characteristics and purposes –, access 
arrangements of each category of biobank initiatives, nevertheless, have an influence on the question 
whether access conditions are harmonized. We therefore studied the access arrangements of all three 
categories of biobank initiatives, investigating the trends and differences within as well as between 
each category, and addressing the question whether access arrangements promulgated by 
organizations influence those of biobank networks and biobanks. First it was investigated to which 
extent each of those arrangements contained information in relation to the 21 key access conditions 
identified in the literature review (4,16,63,69,76,81,82). If available, the information on the key 
conditions was summarized and compared using predefined templates29. When access arrangements 
did not explicitly refer to one or more of the 21 access conditions under study, the text of the 
arrangement was interpreted to discover implicit information on such conditions. It cannot be excluded 
that some of these interpretations might not fully correspond with the real (unexpressed) intentions of 
the concerned biobank initiative. The comparative templates30 allowed us to develop qualitative data 
illustrating the lack of clear information and harmonization in relation to the 21 selected access 
conditions (see Annex 2). Finally we investigated to which extent access arrangements of biobank 
initiatives applied the 21 selected access conditions differently depending on whether these initiatives 
were (rather) population- or hospital-integrated. 
3 Results 
We retrieved access arrangements of 26 organizations, 36 biobank networks and 20 biobanks. We 
were not able to obtain access arrangements of 1 organization, 15 biobank networks and 2 biobanks. 
Of those that we were not able to obtain, thirteen access arrangements were not publicly available and 
3 were under development (thus also unavailable) in 2011. One organization and 1 biobank did not 
(yet) develop an access arrangement. We observed relatively few differences in how access 
arrangements of population- and hospital-integrated biobank initiatives applied the 21 key access 
conditions. Therefore we decided not to focus on the distinction between both types. Hereafter we 
describe in detail the results concerning 6 selected conditions that, according to the authors, represent 
the most remarkable findings. An overview of all the results of the comparative analysis can be found 
in the Annex 2.  
  
                                                       
29 The template consists of a table enlisting the 21 key access conditions 
30 The comparative template consists of an excel sheeting that enabled us to compare the different access 
arrangements 
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3.1 Ownership  
None of the access arrangements provided that the principal investigators became owner of basic 
HBMs and/or data that they collected and provided to the biobank initiative. 
The majority of the access arrangements that provided access to HBM (14 organizations, 22 biobank 
networks and 13 biobanks) did not stipulate whether the biobank network, the biobank or the principal 
investigator held ownership rights in relation to the basic HBMs (see Figure 4).  
 
Figure 4: Ownership 
The majority of the access arrangements that provided for access to data (15 organizations, 23 
biobank networks and 10 biobanks) did not stipulate whether the biobank network, the biobank or the 
principal investigator held ownership rights in relation to the basic data (see Figure 4). 
Access arrangements of 8 organizations (whereof 5 are organizations from the United Kingdom) 
explicitly provide that neither the biobank network, nor the biobank nor the principal investigator hold 
ownership in relation to basic data (as such). 
The results revealed that the majority of access arrangements do not contain any information on 
whether any ownership is held in relation to HBM or data.  
3.2 Level of custodianship  
The level of custodianship over HBMs was not defined in the access arrangements of 11 
organizations, 6 biobank networks and 4 biobanks.  
With respect to biobank networks, 6 out of 31 access arrangements stipulated that the biobank 
network held (exclusive) custodianship over HBMs, while 15 stipulated that custodianship was held 
only at the level of the biobank (see Figure 5) and 4 stipulated that the biobank network and the 
biobank shared custodianship. 
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Figure 5: Custodianship 
The access arrangement of 1 biobank provided for shared custodianship over HBMs between the 
biobank and the principal investigator, while the access arrangements of 14 biobanks granted 
custodianship to the biobank; the access arrangement of 1 biobank stipulated that the principal 
investigator held custodianship over the samples collected by him/her. 
The level of custodianship over data was not defined in access arrangements of 16 organizations, 6 
biobank networks and 3 biobanks.  
With respect to biobank networks, 10 access arrangements stipulated that custodianship was held 
only at the level of the biobank network, while access arrangements of 11 biobanks networks 
stipulated that custodianship was held only at the level of the biobank. Access arrangements of 4 
biobank networks provided that the biobank network and the biobank shared custodianship over the 
data.  
3.3 Scope of custodianship  
The comparative analysis revealed differences in how access arrangements defined custodianship. 
The following (common) elements were identified on the basis of the comparison: (i) the responsibility 
to safeguard the confidentiality, integrity and security of the collection and the interests of the donors. 
Custodianship could furthermore consist of (ii) the right to control the preservation, access, use, 
transfer and/or disposal of collections. 
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3.4 Access committees  
The majority of the screened access arrangements (14 organizations, 23 biobank networks and 14 
biobanks; see Annex 2) provided for the establishment of an access committee. One organization and 
1 biobank network stipulated explicitly that no access committee should be established. 
When we looked specifically at access arrangements establishing an access committee, we noticed 
that access committees of 11 organizations, 16 biobank networks and 12 biobanks provided advice or 
decided on each request for access (see Figure 6). 
 
Figure 6: Mandate of access committee 
3.5 Screening of scientific merits  
The comparative analysis revealed that only half of the access arrangements (access arrangements of 
11 organizations, 18 biobank networks and 11 biobanks (see Figure 7)) stipulate explicitly whether the 
scientific merit of access requests is screened. One organization’s access arrangement stated 
explicitly that it did not screen the scientific merits, since it did not feel competent to conduct such 
screening. Access arrangements of 8 organizations explicitly provided a more extensive scientific 
screening, while only 4 biobanks and no biobank network provided such extensive screening. 
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Figure 7: Scientific screening of access requests 
3.6 Sharing or returning of research results  
Access arrangements of 14 organizations, 17 biobank networks and 15 biobanks (see Figure 8) 
stipulated explicitly the obligation to share and/or return research data or results. When focusing at 
biobanks considered as population-based, one noticed that 9 out of 10 access arrangements provide 
for an obligation to share or return research data or results. 
 
Figure 8: Sharing of research results 
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4 Discussion 
The comparative analysis provides empirical data on 21 selected conditions characterizing access 
arrangements for biobanks. It covers access arrangements developed by 26 organizations, 36 
biobank networks and 20 biobanks worldwide. Since we did not find evidence of trends or differences 
that specifically pertain to one of the three categories of biobank initiatives (i.e. organizations, biobank 
networks or biobanks), this section discusses trends and differences in access arrangements for the 
three categories together.  
4.1 Lack of clear information  
An important number of access arrangements does not contain (clear) information on how the 
concerned biobank initiatives define several of the 21 access conditions investigated in the current 
study. Such lack of information constitutes an important barrier for researchers who apply for access 
to biobanks (14,16,63,69,77,81,82,84,91). 
4.2 Ownership or custodianship  
The study revealed that the majority of the access arrangements do not stipulate anything in relation 
to ownership of HBM and associated data. This is probably due to the fact that it remains uncertain 
which ‘ownership’ rights can be held or claimed in relation to HBMs (14,23,69,83,84,92). Opinions in 
scientific literature differ on whether such rights can be held by the donor, the collector of HBM, the 
researcher using the HBM or a biobank (14,70,91–94) 
Taken into account the uncertain status of ‘ownership’ on HBM, we suggest to focus instead on the 
(bundle/compilation of) rights held by the custodian HBM or data – irrespective of the question 
whether such rights could be considered as ‘ownership’ rights (2). B. Björkman pointed out that rights 
on HBMs could be constructed in many different ways depending on the legal relations included in the 
bundle of rights. She argued that the most important question concerns the determination of the rights 
to be included in such bundle. The question of whether such bundle of rights would constitute 
ownership is – according to B. Björkman and the PhD candidate – of minor importance (95).  
It appeared from the comparative analysis that access arrangements contain different definitions of 
the rights and obligations of custodians (see section 3.3). Therefore, it remains – unfortunately – 
difficult for an applicant to know which rights a custodian holds over a collection of HBMs and data. 
4.3 Level of custodianship: biobank vs. principal investigator 
The results revealed a shift to provide custodianship of HBM and data to the biobank or biobank 
network and no longer to principal investigators. This shift is presumably due to the fact that biobanks 
increasingly store high numbers of HBMs and/or data, which cannot be managed in an optimal 
manner by an individual researcher/collector (23,65,81,91). One might argue that custodianship at the 
level of the biobank or biobank network can facilitate access to HBM and data, since it would no 
longer be necessary to obtain approval of each individual researcher or collector.  
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4.4 Level of custodianship of HBM: biobank network vs. biobank  
Some of the studied access arrangements provide custodianship of HBM at the level of the biobank 
network, while the majority provides custodianship at the level of the biobank. The different 
approaches might be due to the fact that some collections were created as collaborative efforts within 
the framework of a biobank network; in which case the participating biobanks might be more willing to 
allow the biobank network to exercise custodianship. In other networks, the individual biobanks 
created collections of HBM and data outside the network and subsequently decided to share those 
collections in the framework of the biobank network. In this case, the individual biobanks might want to 
maintain the possibility to decide on access to ‘their’ HBMs and/or data. Both approaches can be 
defended, but an applicant needs be clearly informed on whether the biobank network or the biobank 
decides on access to samples and data. 
4.5 Level of custodianship: data vs. HBM  
The comparison demonstrated that custodianship of data (in contrast to custodianship of samples) is 
more often held at the level of biobank network. This might be explained by the fact that different 
researchers can access data simultaneously. Since the biobank maintains the possibility to access 
and use ‘their’ data, it might be more comfortable allowing the biobank network to decide which 
researchers can access the data shared in the network. The sharing of data could be facilitated by the 
fact that biobank networks decide on access to data and an applicant, therefore, needs to obtain 
authorization from fewer biobank initiatives. 
4.6 Access committees  
When biobank initiatives claim custodianship over HBM or data, they have the responsibility to 
develop transparent access arrangements and to establish access committees to decide on access 
requests. Such access committees need to ensure that HBM and data are used in accordance with 
the initial consent. They furthermore verify that the HBM is only used for research projects that 
demonstrate sufficient scientific merits. It is therefore no surprise that the comparative analysis 
confirmed that the majority of the access arrangements establish an access committee. 
4.7 Screening of scientific merit and relevance  
Only half of the studied access arrangements stipulate explicitly whether the scientific merit of access 
requests is screened. This is unfortunate, since applicants need to have clear information on such 
screening. Screening the scientific merits of applications can ensure that HBMs and data are not 
wasted (16). This is even more the case in relation to rare HBMs (81,96). Finally the biobank initiative 
might want to verify whether the proposed use of HBMs and data corresponds with the scientific aims 
of the collection (81). 
Some biobank initiatives might not explicitly provide for the screening of the scientific merit of access 
requests, since they are of the opinion that such screening is the responsibility of an ethics review 
board or the organization funding the research project (69). Furthermore, access committees of 
biobank initiatives might not always have the capacity and/or specialization to screen the scientific 
merit of each application; especially in view of the wide range of disciplines of applicant researchers. 
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We recommend that clear information is provided to applicants on whether and how the scientific merit 
of their access requests is screened. 
4.8 Obligation to share or return research results  
The majority of the access arrangements require the returning and/or sharing of research results with 
the biobank or other researchers. This might be due to the fact that an increasing number of funding 
bodies require such sharing or returning of research results. Furthermore, this could be justified by the 
substantial (public) investment required to collect, store and manage in optimal manner HBM and 
data. However, the sharing or returning of research results is only useful, when the necessary capacity 
is available to store, correctly interpret and access the results. 
Since researchers invest a considerable amount of time and effort in generating research results or 
data, they could be allowed – during a limited period of time – the exclusive right to decide who has 
access to them.  
5 Conclusion  
Several authors active in the biobank field pointed out that an increased level of harmonization of 
access conditions could facilitate access to biobanks (11,14,16,65,66,70,76,77,80). Since many 
access arrangements do not contain clear information in relation to several of these conditions, it is 
difficult to draw final conclusions on the extent of harmonization. We nevertheless wanted to provide 
some preliminary conclusions. First, we noticed that a number of access conditions (access to data 
and/or HBM (condition 1), type of HBM (condition 2), type of data (condition 3) and level of ownership 
(condition 4 & 5)) might not be considered as key conditions to determine the legal framework 
applicable to access to biobanks. It seems that access arrangements do not attach a lot of importance 
to those access conditions to determine how access to biobanks is regulated. Second, we noticed that 
a certain level of harmonization exists on the level of custodianship (condition 6 & 7), the 
establishment of an access committee (condition 8), the mandate of an access committee31 (condition 
9) and the sharing and returning of research results (condition 19). The comparative analysis 
demonstrated a lack of harmonization of access arrangements in relation to the other examined 
access conditions. Chapter 2 reports on an empirical study that shed more light on how access 
conditions are applied in practice. It focused on the evaluation of access requests, the right to decide 
on leftover HBM, the right to participate in benefits of scientific research and the obligation to share 
research results. 
This could enable us to understand the lack of clear information and the lack of harmonization in 
relation to the majority of the key access conditions.  
A complete harmonization of all access conditions might be not be feasible, considering the different 
nature of biobank initiatives and the different legal frameworks applicable to these initiatives (studied 
in Chapter 3) (1). A certain level of harmonization might, however, be reached on a number of key 
access conditions. 
                                                       
31 The majority of the established access committees provide advice or decide on each request for access. 
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1 Introduction 
Researchers need to be able to access efficiently different collections of HBM and data(69,97). 
However, biobanks and biobanks networks, as custodians of HBMs and associated data, need to 
exercise a certain control on access to and use of their collections in order to guarantee its long-time 
sustainability and the scientific, ethical and legal correctness of its use(1,16,69,93). In addition, 
custodians need to ensure that access requests comply with the applicable legislation and the 
conditions stipulated in the consent of the donors/patients(70,82). Balancing the rights and obligations 
of custodians, applicants and/or patients in relation to access to biobanks is of utmost importance to 
guarantee trust and confidence. 
After many years of discussions there is still no answer to the question whether ‘ownership’ rights can 
be held or claimed in relation to HBMs (and associated data) collected for research purposes 
(14,23,69,83,84,92). Considering the uncertain status of ‘ownership’ on HBM, some suggested 
focusing instead on the concept of ‘custodianship’(2), ‘stewardship’(98) or charitable ‘trust’(99). 
However, replacing the concept of ownership with new concepts does not automatically provide an 
answer to the practical question as to which rights and obligations can be held on HBM and data, as 
rightfully indicated by J. Conley e.a. (100). 
R. Yassin et al. defined custodianship – in rather general way – as “a caretaking obligation for 
biospecimens from initial collection to final dissemination of research findings” (2), but they did not 
define which specific rights and obligations the custodian holds on HBM or data.  
According to the ‘social constructivist theory’32 “ownership is the result of a series of social choices 
and events that could well have been different.” This theory does not aim to answer the absolute 
question whether a particular stakeholder – such as the custodian, the applicant or donor – can be the 
‘owner’ of HBM. Instead, the theory considers it more useful to see ownership as bundles of rights and 
obligations of different stakeholders in relation to a particular object. This chapter studied the different 
perspectives of stakeholders in relation to the bundles of rights and obligations held by the custodian 
and the applicant in relation to access to HBM and associated data. The aim of the study was not to 
determine whether the custodian or the applicant should be considered as the ‘owner’ of HBM, since it 
appeared not possible to define the complete bundle of rights and obligations of both stakeholders. 
Previous empirical research on biobanks focused on consent, public perception and participation in 
biobanks, etc. (56–59,61,62). Few research projects focus on custodianship of HBM stored in 
biobanks (11,17,101). 
  
                                                       
32 Quigley, M. Property and the body: applying Honoré. J MED ETHICS 33, 631–4 (2007). 
28; Björkman, B. Different types--different rights. Distinguishing between different perspectives on ownership of 
biological material. Science and engineering ethics 13, 221–33 (2007) 
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The qualitative study described in this paper, looked into the following research questions: 
What are the different perspectives held by stakeholders in relation to the (bundle of) rights and 
obligations held by the custodian33 and the researcher34 applying for access to HBM and data? 
Which topics divide the different stakeholders, when one tries to determine the (bundle of) rights and 
obligations held by the custodian and the applicant? 
2 Methods 
Data were collected via key informant, face-to-face (and some Skype) interviews. The aim of the 
interviews was to gain an in-depth understanding on how access arrangements are applied in the daily 
practice of biobanks and biobank networks. We also wanted to collect data on the hopes and 
concerns of the different stakeholders in this respect35. A qualitative research method was chosen to 
gather information on practical experiences and personal opinions of informants rather than factual 
information. Semi-structured interviews were conducted to collect information about a number of pre-
defined topics (enlisted in the interview guide (Annex 3), but also to allow the interviewers to probe 
deeper when required. In addition, the interviews allowed us to validate the answers with the 
interviewees, reducing potential misunderstandings. That is why interviews were preferred above 
questionnaires. At the start of each interview the interviewers briefly explained the context of the 
study. This was done in such way as to not influence how the informants responded to the questions. 
The interview questions deliberately did not explicitly refer to legal concepts such as rights and 
obligations, in order to avoid that the informants would focus their answer on such concepts. 
2.1 Interview guide 
The topics of the interview guide (Annex 3) were determined on the basis of the results of the 
comparative analysis of access arrangements (Chapter 1) and a literature review on access to HBMs 
or data. The interview guide consisted of 8 structured, open questions. The interviewers used a pre-
defined set of questions to be able to compare the answers of the different informants. The informants 
were first asked to explain their professional relationship and experiences with biobanking (Q1). A first 
topic related to the question how biobanks and biobank networks handle requests for access to HBM 
and data (Q2). After all, a lot of access arrangements studied in a previous comparative analysis 
(Chapter 1) did not define the specific mandate of access committees. A next topic touched upon the 
question whether different conditions apply for access to HBM and access to data (Q3). The majority 
of the interviewees did not attach much importance to the distinction between both. The question was 
                                                       
33 The custodian is defined – by the authors – as the person(s) – such as the biobank manager of the access 
committee – and/or institution that exercises custodianship on HBM and data stored in a particular biobank. 
34 The term ‘researcher’ refers to researchers from the public and private sector.  
35 During the conduct of the interviews and the subsequent analysis, it appeared rather difficult to distinguish 
whether the informants were providing information about how custodianship works in daily practice or whether 
they expressed their opinions, hopes and concerns about how it should work. To the extent possible we used the 
verbs ‘should’ or ‘could’ in the result section to indicate when we refer to opinions, hopes and concerns of 
stakeholders rather than the current state of affairs.  
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therefore not longer raised in subsequent interviews. The third topic related to the question why 
biobanks and biobank networks develop different policies in relation to the return or destruction of 
leftover HBM (Q4). A fourth topic was the sharing of benefits. Several organizations suggest that a 
policy should be developed regarding the sharing of benefits of biobank research. However, the 
majority of biobanks and biobank networks do not provide anything in this respect. Prior to asking 
informants about their experiences and personal opinions on benefit sharing, the general question was 
posed what kind of benefits may accrue from using HBM and data (Q5). The question was posed in a 
general way in order to avoid suggesting particular types of benefits and benefit sharing, such as IPRs 
on HBM and data. Some informants suggested that returning and sharing ‘research results’ could be 
an example of benefit sharing. If this was not the case, the interviewers specifically inquired about the 
experiences and personal opinions of the informants on the return and sharing of research results 
(Q6). One of the informants suggested that information on which applicants are granted access to 
HBM and/or associated data in the framework of a particular research projects should be publicly 
available (Q7). Finally the topic was raised whether (publicly funded) biobanks and biobank networks 
should allow industrial companies access to their collections of HBM and data (Q 8). At the end of the 
interview the informants were given the opportunity to discuss ideas or concerns regarding access to 
biobanks that had not been discussed in the interview.  
2.2 Data collection: Key informant interviews 
2.2.1 Sampling strategy for the key informant interviews 
Twenty-eight informants in Europe were selected by means of ‘purposeful/purposive’ 
sampling(102,103) and snowball sampling based on the information provided by previous informants. 
These sampling technics were chosen to capture the different perspectives of 7 types of 
stakeholders36 – in particular (i) custodians of biobanks, (ii) representatives of biobank networks, (iii) 
clinical, (iv) academic and (v) industrial (research) applicants, (vi) patient representatives and (vii) 
representatives of industry –. We also conducted interviews with legal, ethical and biomedical experts 
(see Figure 9). The interviews with the 7 types of stakeholders enabled us to acquire a deeper 
knowledge of the current practices applied in biobanks and biobank networks and HBM research in 
general. Interviewing legal, ethical and biomedical experts provided a more in-depth understanding of 
the (ethical, legal and scientific) background and context wherein biobanks operate.  
                                                       
36 Some of the informants fulfilled a double role, such as applicant and representative of stakeholders within an 
access committee. The interviewers considered those double roles in the analysis, but focused on the main role 
of the informant. 
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Figure 9 Distribution of informants per type of stakeholder or expert 
We wanted to study variations in perspectives between the different types of stakeholders and experts 
in relation to the rights and obligations held by the custodian and the researcher/applicant. That is why 
we attempted to select at least two informants to represent each type of stakeholders and experts37 38.  
During the analysis of the interviews, however, we discovered fewer variations in opinions than we 
would have expected. We also noticed that specific variations of opinions could not be contributed to 
specific types of stakeholders or experts. Informants who represent the same types of stakeholders or 
experts expressed as much variation in their opinions as informants who belonged to different types of 
stakeholders or experts. That is why we decided not to describe separately opinions per type of 
stakeholder or expert. Contributing variations of opinions to particular types of stakeholders or experts 
– instead of individual informants – could have distorted the representation of the results, since most 
variations were not linked to particular types of stakeholders or experts. 
That we discovered fewer variations than we expected, might be due to the fact that some of the 
topics discussed during the interview were relatively new for some informants. For instance, some 
informants explicitly mentioned that they did not yet have a fully developed opinion on the right to 
share in benefits, the obligation to share research results and IPRs. It might also be due to the fact 
that we were only able to interview 28 informants. It would be interesting to interview more informants 
to discover more variations in opinions. However, it was not possible to interview additional informants 
due to time constraints.  
                                                       
37 We were unfortunately only able to interview one informant representing a biobank network. The other selected 
informant in this respect informed us during the interview that he would rather answer the questions as custodian 
of a biobank and not as representative of a biobank network.  
38 We only interviewed one purely ‘academic’ applicant, since the majority of the applicants that we contacted, can 
be considered as both academic and clinical applicants. 
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2.2.2 Pilot interviews 
The data collection started with pilot interviews with 3 informants. These were, in particular, (a) an 
academic bioethicist previously involved in research projects on biobanking; (b) a legal advisor on 
biobank projects, legislation and policies; and (c) a custodian of a biobank. The pilot interviews 
allowed to validate the interview guide (Annex 3) and to acquire first insights on the most important 
topics in relation to the rights and obligations held by the custodian and the applicant in relation to 
access to HBM and data.  
2.2.3 Geographical scope of the interviews 
Between October 2013 and January 2014 21 informants were interviewed in the Benelux. Informants 
were chosen in the Netherlands and Luxemburg because both these countries host ambitious national 
biobank initiatives such as the Parelsnoer Institute, BBMRI.NL, LifeLines in the Netherlands and 
Integrated BioBank of Luxemburg (IBBL). In February and March 2014 interviews were conducted with 
five informants in Denmark, Sweden and Norway (see Figure 10). The interviewers chose to compare 
the Benelux with the Scandinavian countries because the latter are considered pioneers in the 
development of biobanks and biobanks networks and in epidemiologic research(32). This pioneering 
role is, amongst others, due to the fact that these countries have a long tradition in storing HBM and 
health data of patients/donors in the framework of health care services and population-based studies. 
An interesting dimension of the Swedish biobank landscape is the well-documented cooperation 
between university biobanks and pharmaceutical companies, such as AstraZeneca and Pfizer. 
Additionally a representative of an Italian patient organization was interviewed, since this organization 
represented patients with a rare disease. We combined the interviews with on-site visits of biobanks in 
Belgium, Denmark and Sweden to observe their existing policy and practices in relation to access to 
biobanks. 
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Figure 10 Geographical distribution of stakeholders and experts39 
2.2.4 Interviews 
The interviews were recorded and entirely transcribed ad verbatim. For each interview, a short report 
was created about the context and the interviewee’s characteristics. The interview data are handled 
with confidentiality and the informants’ identity remains anonymous in reports and publications 
accruing from the study. 
2.3 Data analysis of the interviews 
The data analysis phase consisted of an inductive analysis according to the Qualitative Analysis Guide 
of Leuven (QUAGOL)(104). 
First, the transcriptions of the interviews were thoroughly reread by two members of the research team 
to familiarize themselves with the data and to get a sense of the interview as a whole. During the 
reading process, the key phrases were underlined. Thoughts or reflections evoked in some passages 
were noted in margins. Secondly, a narrative interview report was drafted in order to articulate the 
essence of the interviewee’s story in answer to the research questions. This resulted in a brief abstract 
of the key storylines, including a summary impression of the characteristics of each interview. In a 
third stage, conceptual interview schemes were created. Those schemes provide an overview of the 
concepts that appear relevant to get an insight into the research topic. In the fourth stage, the 
interviews were reread to verify whether the content of the conceptual interview schemes reflected the 
most important concepts aimed at in the research questions. This enabled us to adapt, complete and 
refine the conceptual interview schemes. The fifth stage consisted of a comparison of the conceptual 
interview schemes of the different interviews to identify and adjust common themes, concepts or 
hypotheses. 
                                                       
39 One informant was active in two different countries 
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The actual coding process started with the drawing up of a common list of concepts (see Annex 4) 
(stage six). This was done without imposing a hierarchical order and based on conceptual interview 
schemes. The research team evaluated and discussed the list of concepts. Overlap or vagueness was 
remedied by mutual consensus. The resulting list of concepts was introduced as preliminary codes in 
the software program ‘Dedoose’40. In the seventh stage, each interview was read again with the list of 
concepts/codes at hand. Each significant passage of the interview was linked to one of the 
concepts/codes of the list. If a particular passage in a particular interview could not be linked to a 
specific concept, the list of concepts was adapted. In stage eight, every concept was analysed through 
a careful exploration and study of all citations associated with each concept. The researchers tried to 
understand and articulate the meaning of the concepts in their own words. The ninth stage consisted 
of the extraction of the essential structure of all the interview data. Starting from the conceptual 
interview schemes of all interviews, the researchers formulated a conceptual framework that organizes 
and structures all concepts in a meaningful way. Based on the conceptual framework (stage 9) and 
the in-depth analysis (stage 8), the researchers were able to systematically and carefully describe 
essential findings in answer to the research questions. Significant quotes were added where 
necessary and relevant. Finally, a formal peer debriefing with the other members of the research team 
was conducted to discuss and check the results in answer to the research questions. 
3 Results 
3.1 Evaluation of access requests and decision on access to HBM and data 
3.1.1 Which committee or body should evaluate access requests? 
During the interviews the question arose to which extent access committees should evaluate access 
requests, when an ethics committee also evaluates the research project. Some informants were in 
favour of the idea that only an ethics committee should make such evaluation. In their opinion, the 
role of the access committee should be limited to questions related to the availability and suitability of 
HBM and data for the research project. The majority of the informants felt that the access committee 
could also evaluate the quality and/or usefulness of the research proposed in the access request.  
In this respect a custodian of a biobank in the Benelux stated the following:  
“The medical ethics committee is according to me not capable to evaluate the scientific part. It 
can evaluate whether something is ethical acceptable; that is why they are there, but not to 
evaluate the scientific content. (…) They are not equipped for it. Because every time you have 
a new specialisation, you need new expertise … this is also why we have stakeholders41.” 
                                                       
40 http://www.dedoose.com/ 
41 Translation by the authors of the following excerpt in Dutch: “De medische ethische commissie is volgens mij 
niet in staat om over het wetenschappelijke deel te oordelen. Ze kan wel oordelen of iets ethisch verantwoord 
gaat, daar zitten ze ook voor, maar niet om een wetenschappelijke inhoud te gaan beoordelen. (…) daar zijn ze 
niet voor toegerust. Want dan moet je iedere keer voor ieder specialisme, moet je dan toch de kennis 
hebben…Dat is ook waarom we stakeholders willen hebben.” 
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Some informants stressed the importance of an increased interaction and collaboration between the 
access committee and the ethics committee (and possible also the funding body) in the evaluation of 
an access request.  
Several informants stressed that the access committee and/or an ethics committee should avail 
themselves of the necessary expertise and experience to evaluate access requests. They questioned 
whether this was always the case. If one access committee is established for the entire collection of 
HBM and data from a particular institute, such access committee should comprise representatives 
from different medical disciplines (such as pathology, surgery) as well as clinicians that collected HBM 
and data for the biobank, patient representatives and legal, ethical and biomedical experts.    
Some informants suggested that external experts could or should be consulted in case the access 
committee does not have access to the necessary expertise and experience to evaluate an access 
request.  
Another important requirement advanced by the informants is the need for profound guarantees that 
the committee or body that evaluates access requests can act sufficiently independent from the 
researcher/principle investigator that requests access to HBM and data from the biobank. Such 
independence could be ascertained by involving one or more external experts in the evaluation of 
access requests42. 
3.1.2 Which criteria should be applied in the evaluation of access requests? 
Most informants felt that the evaluation of an access request should not be limited to the verification 
of administrative formalities. The most important criteria suggested by the informants during the 
interviews related to (1) the availability and suitability of HBM and data for the proposed research 
project; (2) the quality and scientific value of project; (3) the scientific, societal or medical usefulness 
of the project; (4) the research merits of the applicant; (5) the ethical value of the access request; (6) 
the priorities of the biobank; (7) whether the requested HBM is rare (see Table 2). Several informants 
mentioned that only the access committee disposes of the required information on the collection of 
HBM and data to evaluate the first criteria.  
The majority of the informants suggested that one should evaluate the quality and/or scientific value 
of a research project. Such evaluation will take into account whether the research question and 
hypothesis, the research method and the study design are solid. The evaluation will also check 
whether it can lead to valid and reliable results. It should furthermore look into the feasibility of the 
study and the chances of a successful outcome. Another question that should be assessed, in order 
to avoid under- or overpowering of the study, is whether the requested amount of HBM and data is 
statistically significant to obtain relevant results.  
  
                                                       
42 One should, however, make sure that no conflict of interest exists, when such external experts evaluate access 
request.  
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According to the informants, an access request may also be evaluated on its scientific, societal or 
medical usefulness. This could be related to the question whether the suggested project (i) 
contributes to the improvement and/or accessibility of health care (in particular clinical practice, 
treatment, survival, quality of life); (ii) corresponds to a high medical need; (iii) differs from previous 
research; (iv) adds value to the existing state of the art; and (v) leads to new (scientific) insights or 
outcome. Several informants commented that it might be difficult to (objectively) predict the outcome 
of proposed research projects and whether a future research project would use HBM and data in a 
more useful way. They therefore suggested that one should not be too strict in evaluating the 
usefulness of a research project, when the evaluation of the other criteria is positive.  
In this respect, a representative of industrial applicants in the Benelux stated the following: 
“ Nobody can predict the future to foresee whether we will receive within 6 months … a 
research application that is more relevant in relation to the (useful) knowledge that it will 
provide us. (…); Such request might never come and in this case you possibly deny access to 
a valuable project. So, I think it constitutes an important responsibility and a difficult exercise. 
(…) If all evaluation criteria are positive, I feel that one should move ahead (with the 
project).43” 
In their evaluation of access requests, the informants attach quite some importance to the expertise, 
experience, research merit and/or credibility of the applicants and their research group and/or 
research institute. In this respect, the informants suggest that one could take into account the track 
record, publications and previous research projects of the applicants, their research group and/or 
research institute. They furthermore suggested taking into consideration the fact that the applicant is 
affiliated to a renowned institute/research group or an institute that disposes of excellent research 
facilities. However some informants commented that it could be quite difficult to objectively evaluate 
this aspect, since one needs to dispose of the necessary scientific knowledge and expertise in the 
particular domain of the application. Several informants mentioned that within a particular research 
field or country, access committees, ethics committees, researchers/PI and research institutes know 
each other and their merits and that therefore access request of known researchers or research 
institutes could be dealt with more favourably. It therefore appears difficult to evaluate access requests 
in a completely neutral manner. Two informants suggested creating an accreditation system/research 
passport for researchers. This could enhance transparency and trust and rule out that the evaluation 
of the research merits has to be repeated for every new access request. It remained unclear, however, 
which institute or organization could develop such accreditation system or research passport. 
  
                                                       
43 Translation by the authors of the following excerpt in Dutch:: “Niemand heeft een glazen bol natuurlijk om te 
zien van “oké, misschien gaan we binnen 6 maanden (…) een onderzoeksaanvraag krijgen die ons qua 
informatie dat het project gaat opleveren, nog veel relevanter is. (…) mogelijks komt die vraag er ook nooit en dan 
ontzeg je een mogelijk ook heel waardevol project toegang. Dus ik denk dat dat een heel belangrijke 
verantwoordelijkheid is maar ook een heel moeilijke oefening. (…) Als alle evaluatie-criteria positief zijn, dan vind 
ik dat je er ook voor moet gaan. (…).” 
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Another dimension described by the informants is the so-called “ethical value” of an access request. 
This implies that the access committee would verify whether the research use, as described in the 
access requests, corresponds to the informed consent and/or ethical approval that were obtained in 
relation to the requested HBM and data44. Secondly, the applicant may be evaluated on the measures 
it will take to protect the personal data of the donors.  
Several informants indicated that many of the existing biobanks focus their collection of HBM and data 
on certain pathologies. That is why, according to some of the interviewees, it is not unusual that 
priority is given to research that corresponds to the mission or focus of the biobank or the (research) 
strategy of the research institute or company, such as a particular disease. It was stated that biobanks 
might also prioritize research request that relate to health care priorities of their country of origin. The 
biobank may also limit access to HBM and data collected in the framework of prospective studies or 
clinical trials.  
Several informants suggested that a biobank could be stricter in evaluating requests for access to rare 
HBM, such as for example brain tissue. While some types of HBM are clearly rare, it may not always 
be easy to make a distinction between ‘rare’ and ‘commonly available’ HBM.  
Table 2 Overview of evaluation criteria suggested by informants45 
1.   Availability and suitability of  HBM and data 
2.   Quality and scientific value of project 
            i. Research question, hypothesis, method and study design 
            ii. Possibility of valid and reliable results 
            iii. Feasibility of study and chances of successful outcome 
            iv. Statistical significance of requested amount 
3.   Scientific, societal or medical usefulness of project 
            i. Contribution to improvement and accessibility of health care 
            ii. Corresponds to high medical need 
           iii. Differs from previous research 
           iv. Adds value to state of the art 
             v. New (scientific) insights or outcome 
4.   Research merits of applicants 
       i. Expertise and experience of applicants 
       ii. Credibility of applicants 
       iii. Affiliation with renowned institute/research group 
5.   Ethical value of access request 
       i. Corresponds to informed consent 
       ii. Corresponds to ethical approval 
       iii. Sufficient measures to protect personal data 
6. Priorities of biobank 
7. Rare or common HBM 
                                                       
 
45 This overview does not provide all possible evaluation criteria. There might be an overlap between some of the 
evaluation criteria. 
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Two informants, with a legal background, pointed to an extra dimension: the legal nature of the 
evaluation criteria to allow access to HBM and data. First of all, they posed the question to which 
extent the biobank could exercise a discretionary power to decide on access requests and whether 
some or all of the evaluation criteria should be determined by the national legislator. They highlighted 
the importance of motivating the decision on access. They stressed the fact that equitable and 
proportionate sets of access criteria should be provided. The criteria should be applied in a non-
discriminatory, objective and transparent manner. They also suggested that some kind of appeal body 
should verify whether the access committee respected the conditions determined by the legislator 
and/or the procedural criteria in relation to the motivation and the evaluation of the access request. All 
informants seemed to agree that no different evaluation criteria should apply for academic and non-
academic applicants and between external applicants and applicants affiliated to the biobank. They 
did feel that different access fees could be justified (see hereunder).  
3.1.3 Motivation of access requests 
All informants agreed that the applicant could have legitimate interest to protect the confidentiality of 
some information. They all agreed that he should therefore not provide all details of the research 
project in the access request. Several informants pointed out that the information to be provided in the 
access request is, to a large extent, determined by the criteria used to evaluate the access request. It 
appeared difficult to reach a consensus on which information should be made available to the 
committee or body that evaluates the access request. Informants mentioned that no guidelines are 
available in this respect. One informant referred to the Good Clinical Practices (GCP) that provides 
guidance on which information needs to be provided in a protocol in the framework of a clinical study. 
Since the GCP were developed in a clinical context, some of the information will not be useful for use 
of HBM and data in research projects. The information to be provided could be different depending on 
the type of research. 
A topic raised during the interviews is to which extent the applicant should specify which type of 
research would be conducted. One informant representing an industrial applicant felt that it should be 
sufficient to indicate that the HBM and data will be used for scientific research or research and 
development and not for diagnostic or therapeutic purposes. If necessary, he felt, the type of research 
in wide pharmacologic terms, such as neuroscience or virology could be added. Other informants 
suggested that the applicant should provide more specific information on the type of research.  
A further topic was how much information applicants should provide on their research project in the 
access request. Most informants felt that the applicant should provide a short synopsis of the research 
project. This synopsis could be supplemented with a more elaborated description of the research 
question or hypothesis and the scientific, societal and/or medical objectives of the project. This 
description would enable the access committee or ethical committee to evaluate whether the research 
project complies with the informed consent and the ethical approval of the research project. They 
could further check whether it complies with the notification of the activities and aims of the biobank to 
the ethical committee and the national agencies for medicinal products, such as the FAGG (Belgium), 
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as provided in the future article 22 § 1 of the Belgian Act on HBM46. One informant raised the question 
whether it would be sufficient if the applicant confirmed that the research project complies with the 
ethical approval and the informed consent. In this case the custodian would not further verify such 
compliance.  
The majority of the informants suggested that the applicant should describe – in more or less details – 
his research methods and/or study design to evaluate the quality of the research project and the 
chances of successful outcome of the project. Some informants highlighted that it may be difficult to 
predict the research methods that will be used, since these could evolve in the course of the project. 
This would be especially the case for prospective studies.  
Some informants suggested that the applicant could be required to provide a technical motivation of 
the (statistical) relevance of the requested amount, the sample size and the specific type of HBM and 
data. This could, for example be the use of HBM and data from specific groups of patients and fresh 
HBM. The more elaborated outline of the research project could also contain a description and/or 
motivation of the additional medical or biomedical data that the applicant wants to use in the research 
project.  
3.2 Decision on fate of leftover HBM at end of project 
Most informants felt that the custodian of the biobank and the applicant have to agree upon the return 
and/or destruction of the leftover HBM before the applicant is granted access to the HBM and data. 
Alternatively the access policy of the biobank could contain general rules on leftover HBM; however 
several informants considered it difficult to determine in general whether one should return or destroy 
leftover HBM after the research project. They felt that such decision should be taken on a case-to-
case basis. Informants suggested, as first criterion for deciding on the return or the destruction of 
leftover HBM is the type of HBM. Some HBM, such as serum, is much more vulnerable to quality 
changes than others, such as DNA. Another criterion relates to the question whether the type of HBM 
used in the project is rare or can be recollected relatively easily. One could also take into account the 
amount of leftover HBM after the end of the project, since it may not be worth the effort to request the 
return of small amounts of HBM. All informants agreed that the most important criterion is the quality 
of the leftover HBM and the extent to which the HBM can be re-used in a new research project. Quite 
some informants expressed concern that the biobank cannot have sufficient control on how the 
applicant stored the HBM and how often and under which circumstances frozen HBM had been 
thawed. If HBM is not managed in a proper way, it could pollute the collection of HBM and data of the 
biobank. It could also have an important impact on the quality/credibility of future research with leftover 
HBM. Some custodians only allow the return of leftover HBM and data in the biobank in case of 
previous experiences and/or collaborations with the applicants. A number of informants mentioned 
that the cost and complexity of the return of leftover HBM could be a factor to decide on whether or not 
to have HBM returned. Several informants are in favour of a trend to share HBM only between 
                                                       
46 Act of 19 December 2009 concerning the obtaining and use of human biological material for medicial 
applications on human beings and for research purposes (Act on use of HBM), as modified by the act of  23 
December 2009, 19 March 2013 and 30 April 2014. 
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biobanks and not to provide them directly to individual researchers, since the exclusive exchange 
between biobanks would increase the chances that the HBM and data is stored in a proper way. 
However, some individual researchers are not affiliated to an institution that hosts a biobank.  
 
Table 3 Overview of criteria suggested by informants to decide on leftover HBM 
Type of HBM 
Rare or common HBM 
Amount of leftover HBM 
Quality and reusability of leftover HBM 
Previous experiences and/or collaborations 
Cost and complexity of return 
 
A related question is whether the applicant could use the leftover HBM and data in new or follow-up 
research projects. The majority of the informants pointed out that applicants are only granted access 
for a limited period of time and for research use specified in the access request. That is why the 
applicant should certainly inform the access committee and/or the ethics committee of the fact that 
HBM is left over and that he wants to use this HBM for a new purpose. Most informants felt that the 
applicant could only use leftover HBM in a new or follow-up project after submitting a new request or 
an amendment to the initial request. The access committee or ethics committee should then approve 
such amendment. An amendment to the initial request could suffice, if the new project falls within or is 
closely related to the scope of the initial research project. Regarding this, the informants referred to 
the fact that similar rules are applicable in relation to the approval of research projects by ethics 
committees. Since, at this stage, the applicant has already been evaluated, several custodians stated 
they are relatively flexible in the evaluation of the new use of leftover HBM. All informants agreed with 
the possibility to stipulate in the access arrangements the prohibition to transfer the HBM and/or data 
to third parties without permission of the biobank. One informant suggested that the initial application 
could already describe additional research hypothesis or methods that could be used if the initial ones 
did not work. This would have the advantage that such alternatives would already have been 
approved. 
Some informants were sceptical about the possibility to verify whether the applicant had returned or 
destroyed all leftover HBM. They pointed out that it would be very burdensome and difficult – or 
impossible – to verify whether the applicant still has some of the HBM stored in his facilities. That is 
why it was argued that the return (or destruction) should be the exceptional situation. Biobanks should 
– to the extent possible – divide HBM in different aliquots and provide only the minimum amounts of 
HBM that is statistically relevant to obtain a successful outcome. Additional amounts of HBM could be 
provided in the course of the project.  
 
Table 4 Level of consensus on fate of leftover HBM 
Return or destruction No consensus 
Re-use Approval of access committee (and REC) 
Transfer to third party Approval of access committee (and REC) 
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3.3 Participation in benefits of research project 
The informants were asked whether it would be desirable that some of the financial or non-financial 
benefits obtained from the results of the research projects would be shared with the biobank and the 
community at large. Several informants pointed out that a lot of different stakeholders – such as 
researchers from different disciplines, funding agencies, donors or developers of research tools –
contribute to research projects. This makes it very difficult to predict in advance or evaluate at the end 
the importance of different contributions for the final result/outcome. One informant mentioned that the 
contribution of HBM and data in the creation of benefits can be very long term and uncertain. That is 
why several informants mentioned that it could be very burdensome or even impossible to grant every 
contributor a certain – even small – percentage in the financial or non-financial benefits of research 
projects. Quite some informants did, however, argue in favour of developing ways to feed some of the 
benefits back into the biobank infrastructure. 
In this respect, a custodian of a biobank in Scandinavia stated the following:  
“So we should be able to find ways of feeding some of the benefit back into the infrastructure, 
but not to make a profit (…). But I think it’s highly justifiable that some of the financial benefit 
that comes out of research based on biobanking should be fed back into the infrastructure, just 
like you use some of your profit in a company to feed back into development.” 
“I’ll never be able to cover total costs, so I need to get money from central sources, and that’s 
where I would want some kind of public sector, health-economic analysis and mechanism to 
feed some of the benefit back in. Because if we do it right, there are big winnings for 
healthcare authorities.” 
“It’s the same with the development of vaccines against human papilloma virus. (…) Some of 
these benefits take a long time to work through (…) It’s nevertheless there and there must be 
economic models that help you calculate it or plan investment. (…) Make no mistake, that 
impact of HPV vaccine would not have happened at that speed without biobanks.” 
One informant observed that the initial contractual agreement should clearly define – prior to the 
beginning of the research project – if and under which conditions one may participate in the benefits of 
a research project. This prior agreement should then also specify who will be able to use the research 
results and for which purpose.  
The next question was which criteria should apply to determine which contributors could participate in 
the benefits from a research project making use of HBM and data from a biobank. In answer, most 
informants referred to the (scientific) contribution of the different stakeholders in a research project. 
There was a consensus that the mere delivery of HBM is insufficient to participate in the benefits of a 
research project. Nonetheless, everybody agreed that one should be compensated for the costs of 
collecting, storing and providing HBM and data to the research project. Possible scientific contributions 
to a research project mentioned during the interviews were (a) an inventive step; (b) participation or 
advice in the development of the research hypothesis or method or execution of research project; (c) 
advice on the optimal selection and use of HBM and data to respond to a particular research question; 
(d) the initial idea or initiative to collect a particular type of HBM and/data; (e) the creation of a 
collections of HBM; (f) an extensive characterisation of HBM; (g) the development of modified HBM 
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(such as cell lines, plasmids); and/or (h) the preparation and cleaning up of data sets. Several 
informants mentioned that, in case it wants to participate in the benefits, the biobank could position 
itself more as a partner in research projects and not merely as supplier of HBM and data. 
The interviews also dug deeper into the informant’s opinions about possible mechanisms to share 
benefits of research projects with the biobank or the public at large. It became quite clear that most 
informants were rather sceptical about the idea that the biobank or the collectors of HBM and data 
would hold intellectual property rights (IPRs) on the research results. Nor did they think that the 
biobank or the collectors of HBM and data should receive royalties in relation to the exploitation of 
such IPRs.  
A custodian from a biobank in Scandinavia – with previous experience in the pharmaceutical industry 
– stated the following in this respect:  
“For me, with my background, it’s hard to see how a royalty mechanism would work. Even 
though biobanks have compressed the time taken to getting the value, it’s still a long 
development time to get a drug to the market.” 
Most informants referred to the fact that biobanks charge a user or access fee. In the best-case 
scenario, this fee covers all development, investment and maintenance costs in relation to the creation 
of the collection of HBM and data. It also covers the provision of additional services, such as data 
management and analysis. An additional overhead is sometimes charged to guarantee the self-
sustainability of the biobank and to enable the enhancement of its services to future applicants. One 
informant mentioned that organizations that fund biobank infrastructure, sometimes explicitly require 
that user fees should compensate part of the costs. Most informants indicated that biobanks currently 
often have problems to recover all costs via access fees. Nevertheless, they indicate that it is difficult 
to justify a combination of (higher) user fees and a participation – in term of rights or royalties – in the 
final results of research. 
Most informants indicated that the same access conditions apply to all applicants. They did agree that 
different access/users fees for public and private or internal and external applicants could be justified 
by the fact that biobanks are mostly funded with public investments or by the research institution 
affiliated to biobank. Both (academic) custodians and (industrial) applicants indicated that an industrial 
applicant may prefer paying a higher, but all-inclusive access fee at the beginning of the project. In 
doing so, they would not have to negotiate about royalties at a later stage, when certain research 
results become commercially valuable. The applicant bears the risk of the research project being 
unsuccessful, but has certainty that he will not have to pay additional royalties later. Some informants 
suggested that such up-front payments could guarantee fewer conflicts and uncertainty later in the 
project.  
A number of informants in Sweden, Norway and the Netherlands argued in favour of a public 
contribution fee that applicants would be required to pay to obtain the right to (commercially) exploit 
the potential benefits of their research project. The applicant would pay such an extra fee or tax for the 
use of a common good/infrastructure. Those fees would go into a central fund and could be allocated 
back into research (infrastructure), health surveys, and the improvement of public health care. The aim 
of such fee would not be to generate profits, but to provide a (fair) return for the contribution of the 
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common good/infrastructure after (possible) commercialisation of research projects. One informant 
made a parallel with the public contribution fee or tax charged for the exploitation of natural resources, 
such as gas fields.  
Other benefit sharing mechanisms that were discussed were the BRIF (Bioresource Research Impact 
Factor) initiative47, co-authorship or participation in the research project by the initial collector and the 
sharing of non-financial benefits with groups of patients (not individual patients) that donated HBM and 
data and mechanism to guarantee that health care improvements become available to patients.  
3.4 Sharing research results 
There seemed to be consensus amongst the informants that research results generated within publicly 
funded research projects should – under certain conditions mentioned above – become publicly 
available. The majority of the informants were in favour of the idea that the custodian would require 
the applicant to share the research results with the biobank and/or other researchers. Several 
informants suggested that it could be a way to maximize the use of HBM and data. This would 
certainly be the case for HBM and data that are quite rare or require a lot of effort or investment to 
collect and analyse, such as whole genome sequencing data. They felt that it would optimise the use 
of gained knowledge and expertise in relation to the collection of HBM and data. Some informants 
suggested to investigate the possibility to generate multipurpose data that would not only be useful for 
the applicant, but also in future research projects. Combining research results from different projects 
may speed up future research and avoid that particular research is conducted several times. 
Another reason to require the sharing of research results is the possibility to enrich the collection of 
HBM and data. Such enrichment could be realized by obtaining additional information in relation to the 
HBM and data stored in the biobank and extending the characterization and understanding of HBM 
and data. Additional information on HBM and data could also be useful for the improvement of the 
quality of the collection of HBM and data. It could provide the access committee or the ethics 
committee with additional information to evaluate future access request. It could also allow future 
applicants to make more informed decisions on which HBM and data are optimal for their research 
project. Finally the biobank could use this information to target specific subgroup of donors for the 
collection of new data based on information from previous research projects.  
Access to research results from previous projects could allow researchers from multiple disciplines 
and with different experiences to reinterpret and question the results. It would allow them to study the 
generated data from new entry points or perspectives while working on new research questions. This 
is particularly important since biomedical research increasingly depends on multidisciplinary 
approaches and no researcher or research institute can avail of all possible expertise.  
  
                                                       
47 http://www.gen2phen.org/groups/brif-bio-resource-impact-factor  
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Finally the requirement to share research results corresponds with requests of an increasing number 
of scientific journals to deposit the raw data of publications in public databases to verify the quality of 
research and to avoid fraud. Furthermore, several funding agencies – such as NIH, Wellcome Trust 
and the Dutch cancer association “KWF Kankerbestrijding “ – require that the results of research 
projects are made publicly available.  
Whether or not the researcher should share the research results with the biobank and other 
researchers is determined in the first place by what has been agreed upon in the access arrangement 
or in the material transfer agreement. Informants indicated that it is only useful to return research 
results, if the researcher can guarantee that the results have been managed in a proper way and that 
sufficient quality control has been conducted on the results. Without such guarantee, it could be 
dangerous and misleading to use results from previous research projects.  
The majority of the informants highlighted that a biobank could only require the return of research 
results, if it disposes of sufficient infrastructure and resources not only to store the results, but also to 
make them available and allow other researchers to use the research results in future projects. 
Biobanks should furthermore have clear arrangements on who could access the results and under 
which conditions. They should have the necessary capacity to evaluate requests for access to 
research results. Some informants suggested that different levels of access could be provided to 
different stakeholders, such as biobanks, funding agencies and future researchers. Another possibility 
could be that third parties would only be granted access to a limited part of the research results. For 
example, the biobank would only access results that specifically pertain to the characterisation and 
quality of HBM, while researchers would only be allowed access to specific raw data that are relevant 
for their research. Some informants raised the question whether it is desirable or optimal that 
individual biobanks store all research results generated with their collection of HBM and data. A first 
suggestion was that specialized biobanks or biobank network with the necessary scientific expertise 
and knowledge may be more suited to store and provide access to the research results in a 
meaningful way. Another possibility would be that the researcher would only return metadata on 
research results to the biobank and that future researchers would be able to conduct queries in 
catalogues with such metadata. The research results could also be stored at the level of biobank 
networks or central research facilities, such as the European Genome-Phenome Archive (EGA).  
Several informants pointed out that it could be difficult to correctly interpret research results without 
the necessary background and knowledge on how the research results have been generated.  
In this respect, a custodian in Scandinavia remarked the following:  
 “Raw data can be so vast and enormous, and unless you understand how to interpret it, it 
 can be just meaningless ”  
That is why several informants suggested involving the researcher that generated the research results 
in new research projects. After all, this researcher formulated the initial research hypothesis and 
developed the research protocol and could provide valuable information on how the research results 
have been obtained and how they can be interpreted and used in further research. 
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The majority of the informants agreed that the applicant who generated the research results, would 
only accept sharing research results if their legitimate interests were respected. The initial researcher 
could be given a preferential or priority right to use, publish or obtain IPRs in relation to the research 
results, for a certain period of time – for example 1,5 to 3 years – after the end of the research project. 
During this period of priority, other researchers could only access the results with the explicit 
agreement of the initial researcher. After this period the initial researcher maintains all rights to use his 
results and may require that he/she is informed and/or consulted when another researcher wants to 
use “his” research results (see hereunder).  
The majority of the informants did express the opinion that the final decision to grant access to the 
research results should not be taken by the initial researcher, but rather by the access committee or 
the ethics committee. This was amongst other motivated by the fact that the initial researcher may 
have a conflict of interest, when having to decide whether a new research project – possibly in the 
same or similar research domain – could use his research results.  
Finally the initial researcher may be entitled to a recognition and/or compensation for his/her 
investments in creating the research results and making them available to others. The biobank could 
motivate or suggest the new researcher, who requested access to research results, to discuss the 
possibility of collaboration with the initial researcher and/or co-authorship. 
Another topic discussed during the interviews was whether one could make access to HBM and data 
dependent upon return of research results. Several informants supported such requirement, while 
others felt that it should be agreed on a case-to-case basis and such condition could not be 
mandatory. 
The majority of the informants agreed that the publication of results of research involving HBM and/or 
data is insufficient to comply with the obligation to return or share the research. After all, very often 
only a limited selection of the research results is actually included in publications. Some informants 
were in favour of returning and/or sharing negative results of research projects.  
3.5 Preferential or priority access to collection of HBM and data 
A new topic that arose during the interviews was the fact that quite some collections of HBM and/or 
data are driven by specific research projects. These are created at the initiative of specific principle 
investigators or researchers.  
Those principle investigators perhaps created a historical collection of HBM and data. They may have 
taken the initiative to start – in collaboration with the biobank – the collection of particular HBM and 
data for future research projects. This could be the case, when researchers applied for funding and 
want to make sure that they will have access to sufficient amounts of HBM and data to conduct their 
project.  
Several informants suggested that a researcher that took such initiative could dispose of more rights 
on the collection of HBM and data, since the collection may not have existed without his/her initiative 
and/or contribution. First of all, this researcher could request and be granted a preferential or priority 
right to conduct research with the collected HBM and data and to publish the results. This priority right 
would of course not have an absolute character because the researchers will still need to comply with 
the informed consent and will need to obtain approval from an ethics committee. The biobank also 
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needs to have a clear policy on how it will evaluate a request to initiate a particular collection of HBM 
and data and a subsequent request to use the collection in a research project.  
The right to decide whether and under which conditions other applicants can access the collection of 
HBM and data, may be partially and temporarily transferred to the principle investigator. This could 
imply that the principle investigator would be given – together with the biobank or alone – the 
“disposition right” over the HBM and data collected at his initiative. The disposition right, however, 
returns to the access committee after the expiration of the period of priority (or exclusivity or embargo), 
for example at the end of the project in the framework of which the HBM and data was collected. 
Some biobanks provide a priority setting in their access policies between different types of 
applications and restrict access to HBM and data collected in the framework of prospective studies, 
longitudinal population based studies or clinical trials. Several informants considered it quite common 
that particular HBM and data are predisposed for specific research projects to ensure that sufficient 
amounts are available. Such predisposition is limited in time and will often only exist for the duration of 
the research project. It may furthermore be limited to a certain percentage of the available HBM and 
data. 
3.6 Exclusive access to collection of HBM and data 
The interviews revealed that none of the informants was in favour of the idea of granting applicants an 
exclusive right to use and exclude others from using particular types of HBM and data. Some argued 
that it would be unethical to allow such exclusive access. Several informants argued that exclusivity 
unnecessarily limits access to HBM and data and could slow down or hinder scientific research and 
the development of new scientific or medical knowledge. They furthermore shared the view that 
collections of HBM and data created with public funding should be accessible to all researchers. 
3.7 Biobank as scientific partner or collaborator of a project 
Several informants expressed the desire that in the future the biobank would become a scientific 
partner in research projects and would participate in the drafting of research protocols, the execution 
of research projects and the interpretation of research results. They feel that the role of biobanks 
should not be limited to the delivery of HBM and data. According to them, the biobank and the 
applicant could also share existing knowledge and expertise and clinical follow-up data. In this case 
both parties could conclude a collaboration agreement that goes beyond the mere regulation of use of 
HBM and data. Such agreement could also govern the provision of additional services (medical 
imaging, genetic sequencing), the rights and obligations of both parties in the research project and the 
sharing of benefits and co-authorship. Such a more elaborated collaboration could constitute an 
additional motivation for biobanks and collectors to collect and share HBM and data. Some informants 
suggested that it is easier to share HBM and data within existing (long-term) collaborations or 
consortia.  
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One of the informants stated the following in this respect:  
“I participate now in a large consortium with pharmaceutical companies and they in fact make 
their samples easily available. They share with each other the samples collected in the 
framework of this study. But, it has to be sharing in two directions. And clear arrangements 
are made from the first day on who receives what and who will be mentioned on which 
position in publications.48”  
4 Discussion 
4.1 Right of custodian to decide on access to HBM and data 
The legal framework of many countries – including the countries that were the object of this study – 
stipulate that RECs need to provide an independent opinion on studies on human beings. More 
recently, REC were also given the competence to provide an opinion on research projects that use 
HBM and data stored in biobanks. A previous empirical study (see chapter 1) revealed that the 
majority of the biobanks establish their own committees to exercise a certain control on access to their 
collections of HBM and data (hereafter called “access committee”). The interviews investigated to 
which extent custodian – often represented by access committees – and RECs should evaluate 
access requests. 
All informants agreed that custodians can evaluate the availability and suitability of HBM and data for 
particular research projects and the impact of the provision of HBM and data on the existing collection. 
They could prioritize particular types of research. 
There was no consensus on whether custodians should evaluate the quality, the scientific and medical 
usefulness and the ethical value of research projects. Some informants suggested that the custodian 
would follow the advice of an ethics committee or funding body. They proposed that the custodian 
would consult external experts or would delegate such decision to subcommittees in relation to 
specific collections of HBM and data. Two informants suggested that the applicable criteria would be 
determined via binding legislation and that the custodian would only dispose of a limited discretionary 
power to apply such criteria. Custodians could also be required to demonstrate that their access 
committee disposes of sufficient relevant expertise, that it can evaluate access requests in an 
independent, non-discriminatory and objective manner. They could furthermore be expected to 
sufficiently motivate their decision and policy.  
These different requirements imply that the custodian is not entirely free to decide how to allow access 
to his collection of HBM and data. The custodian would have to fulfil certain conditions in the 
evaluation of an access request; those conditions could be justified by the need to protect the rights 
and interests of the donor and/or the applicant. 
                                                       
48 Translation by the authors of the following excerpt in Dutch: ”Ik zit nu in een groot consortium met 
farmaceutische firma’s en zij stellen eigenlijk heel gemakkelijk hun stalen ter beschikking. Die verzameld zijn in 
het kader van die studie, men deelt dat met elkaar. Maar, het moet een delen aan de twee kanten zijn. En er 
worden vanaf dag één inderdaad (…) goede afspraken over gemaakt, over wie wat krijgt, over wie waar staat op 
de publicaties.” 
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Quite some authors shared the opinion that access requests should be evaluated by independent 
committees that dispose of the necessary multidisciplinary expertise (11,23,105,106). This 
requirement was motivated by the desire to avoid potential conflicts(2), to protect the interests, safety 
and wellbeing of the donors and to ensure that HBM and data is used in a meaningful way (106). 
Article 19 of the Recommendation 2006(4) of the Council of Europe49 contains the requirement to 
establish an independent oversight of population biobanks, as well as regular audits of the 
implementation of the procedures that apply to access to and use of HBM. Article 24 of the 
Recommendation 2006(4) stipulates the obligation to conduct an independent examination of the 
scientific merit of a research project, the importance of the aim of research and the verification of the 
ethical acceptability50. 
Authors stressed the importance of clearly defining the mandate of access committees and the criteria 
and procedures used to evaluate access request (11,16,105). One will notice in this respect that 
article 14 (c) of the Recommendation 2006(4) provides that one should specify the conditions 
governing access to and use of the HBM. Several authors are in favour of giving the access 
committee a rather broad mandate to evaluate access requests, including the scientific quality of the 
research project (81,96,106). One author argued that only a biobank – represented by the custodian – 
has the right to finally decide on access request (25). Other authors stressed the importance of 
clarifying and stimulating the interaction between ethics committees and access committees (105). 
One possibility would be that the activities of access committees would be supervised by ethics 
committees (23). One could refer in this respect to the fact that the future article 22 § 1 of the Belgian 
Act on HBM provides that the aims and the activities of a biobank have to be reviewed by an ethics 
committee. 
The conditions imposed on the custodian with respect to the evaluation of access requests, raises the 
question whether an applicant could claim a fair or equal right to access and use (publicly funded) 
collections of HBM and data. If such right would exist, it would in any case not be absolute. The 
applicant can only use HBM and data for a certain period of time and for a research project that 
corresponds with the informed consent and the approval by the ethic committee. The project 
furthermore needs to comply with other legal requirements in relation to the conduct of biomedical 
research. The informants supported the idea that the custodian could require that applicants provide a 
short synopsis of the research project. There was no consensus on the extent to which applicants 
could be required to submit a more elaborate protocol with a description of the objective(s), design, 
methodology, statistical considerations and organization of a project. Such requirement is often 
applied in the framework of clinical studies on human beings and was suggested in a report of the 
National Cancer Research Institute, the National Cancer Intelligence Network and onCorde UK(96).  
 
                                                       
49 Recommendation Rec (2006) 4 of the Committee of Ministers to Member States on Research on Biological 
Materials of Human Origin 
50 The current text of the Recommendation 2006(4) only contains rules on ethics committees and does not relate 
to access committees. 
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4.2 Priority access right of collector/applicant  
The right of the custodian to decide on access to HBM and data could be influenced by the fact that a 
clinician/researcher has taken the initiative to start a specific collection of HBM and data. Such 
clinician/researcher may expect to be informed and/or consulted in the decision to grant access to 
others to the collection of HBM and data(25). Such clinician/researcher could furthermore be granted a 
priority right – compared to other researchers – to use the HBM and data and to publish the results of 
his research(16,106). Finally access might be restricted to HBM and data collected in the framework of 
prospective studies, longitudinal population based studies or clinical trials.  
There was a consensus that priority rights should only be granted for a limited period of time and that 
the custodian holds the final right to decide on access to the specific collection of HBM and data.  
One should be aware that granting priority rights to particular collectors/applicants should not 
unnecessarily restrict access to collections of HBM and data. Article 101 TFEU51 prohibits “all 
agreement between undertakings, decision by associations or undertakings and concerted practices 
which may affect trade between Member States and which have as their object or effect the 
prevention, restriction or distortion of competition within the internal market52.” The prohibition of article 
101 TFEU applies amongst others to agreements that “(a) directly or indirectly fix purchase or selling 
prices or any other trading conditions; (…) (d) apply dissimilar conditions to equivalent transactions 
with other trading parties, thereby placing them at a competitive disadvantage; (…) (e) make the 
conclusion of contracts subject to acceptance by the other parties of supplementary obligations which, 
by their nature or according to commercial usage, have no connection with the subject of such 
contracts.” Article 101 § 3 TFEU contains a number of exceptions to the general prohibitions. The 
prohibition of article 101 § 1 does not apply to agreements, decisions and concerted practices, which 
“contribute to improving the production or distribution of goods or to promoting technical or economic 
progress, while allowing consumers a fair share of the resulting benefit, and which does not: (a) 
impose on the undertakings concerned restrictions which are not indispensable to the attainment of 
these objectives; or (b) afford such undertakings the possibility of eliminating competition in respect of 
a substantial part of the products in question.” One should therefore be careful not to grant too 
extensive priority rights to particular researchers or research institutes that collect HBM and data for 
the biobank. Such priority right should not result in a situation where other researchers or research 
institutes no longer have the possibility to access the collection of HBM and data of a particular 
biobank and where such researchers or research institutes are placed at a competitive disadvantage. 
It this case, the priority right would in reality results in exclusive access to the collection. Article 101 
TFEU has been applied to many different types of agreements – including material transfer 
agreements – that contain an element of exclusivity(107). Article 101 TFEU might also apply to 
agreements among (custodians of) banks of HBM or agreements, concerted practices or decisions of 
                                                       
51 Treaty on the Functioning of the European Union 
52 The national competition legislations of the different Member States of the European Union provide similar 
prohibitions of agreements, decisions and concerted practices that have as object or effect to prevent, restrict or 
distort competition. 
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biobank organizations that would result in limitations on access to biobanks or exclusive access for 
particular applicants. Finally article 102 TFEU might apply when one could demonstrate that a biobank 
with a dominant position would abuse this position in refusing access or giving access under certain 
(unreasonable) conditions to applicants. 
4.3 Right of custodian to decide on leftover HBM 
Nearly all informants agreed that the applicant should, at least, inform the custodian when HBM is 
leftover at the end of the project. There was furthermore consensus that an applicant that wants to use 
leftover HBM in a new or follow-up project, has to submit a new request or an amendment to the initial 
request. The access committee or ethics committee will need to approve such new request or 
amendment. All informants agreed on the fact that the custodian could prohibit the applicant from 
transferring HBM (and data) to a third party. A. Boggio came to a similar conclusion in a previous 
study (108). Taken into account the above, we are of the opinion that the informants recognize the 
right of the custodian to decide – whether or not in collaboration with the ethics committee – upon the 
fate of leftover HBM. 
There was no consensus on the criteria that should apply to determine whether the biobank should 
require the return or destruction of leftover HBM. This may not be surprising, since other studies 
revealed that different policies are applied by biobanks in this respect(17,67). Quite some informants 
referred to the fact that custodians and applicants agree on the return or destruction of leftover HBM at 
the time of approval of the access request. This would imply that the custodian would (have to) 
negotiate with the applicant at the time of the access request on a case-by-case basis on the return or 
destruction of leftover HBM. The “International Charter of principles for sharing bio-specimens and 
data” however suggests that ”control of the bio-specimens remains with Provider, who can at any time 
demand the return or destruction of data and bio-specimens if a breach in the agreement occurs.” 
(106) The final decision whether to return or destroy research results would thus remain with the 
custodian of the biobank. 
Considering the fact that it does not seem possible to formulate general criteria to decide on the return 
or destruction of leftover HBM, it seems undesirable to regulate it via legislation. Biobanks could 
however clarify in their access arrangements, which criteria the biobank will take into account to 
decide on the return of destruction of leftover HBM, such as the type, quality, reusability and amount 
of leftover HBM. A general policy would limit the possibilities to negotiate on a case-by-case basis on 
the return or destruction of leftover HBM. 
4.4 Right of biobank to participate in benefits 
The interviews confirmed that the access fees charged by biobanks are often not enough to recover all 
costs in relation to the collection and storage of HBM and data. Some authors confirmed that it could 
be justified to charge higher access fees to external or industrial applicants that did not contribute 
(directly or indirectly) to the collection of HBM and data(16,25). One should, however, make sure that 
charging different access fees does not does not violate the principle of the free movement of goods 
(art. 30-36 TFEU). This could be the case if those different access fees would constitute an unjustified 
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hindrance to the import or export HBM and data between the different Member States of the European 
Union. Article 30 TFEU prohibits customs duties and charges having equivalent effect. Article 34 and 
35 on TFEU prohibits quantitative restrictions on imports and exports of goods and all measures 
having equivalent effect. The prohibition to enact “measures having equivalent effect” implies that one 
should not enact measures or rules that discriminate domestic goods compared to foreign goods. It is 
furthermore prohibited to impose measures that would hinder the import or export of “goods” between 
Member States of the European Union, even though those measures would apply both to foreign and 
domestic goods. Article 36 contains exceptions to article 34 and 35 and does allow quantitative 
restrictions or measures having equivalent effect, if such restrictions or measures are justified on a 
number of grounds enlisted in article 36, such as “public morality, public policy or public security” or 
“the protection of health and life of humans, animals or plants.” Prohibitions or restrictions can only be 
justified under article 35, if they do not “constitute a means of arbitrary discrimination or a disguised 
restriction on trade between Member States.” The prohibitions or restrictions also have to 
proportionated compare to the targeted aim. M. Peeters (109) and S. Panis (110) have argued that the 
free movement of goods presumably also applies to HBM (16,25). 
One should furthermore ensure that charging higher access fees to external or industrial applicants 
does not violate article 101 TFEU. Article 101, § 1, d) TFEU prohibits agreements, decisions or 
concerted practices that “apply dissimilar conditions to equivalent transactions with other trading 
parties, thereby placing them at a competitive disadvantage.”  
Others suggested that some of the benefits of research projects using HBM and data could be fed 
back into the biobank infrastructure(23,111). There was no consensus as to under which conditions 
the applicant would be required to share benefits of research projects. All informants seemed to agree 
that only stakeholders that provide a scientific contribution would be entitled to participate in the 
benefits of a research project. This may be in line with the fact that most IPR legislations only grant 
IPRs to those individuals that provided an intellectual contribution(106). Furthermore, guidelines of the 
International Committee of Medical Journal Editors and the Committee on Publications Ethics only 
grant authorship to individuals that participated in “drafting the article or revising it critically for 
important intellectual content” and “the final approval of the version to be published” (ICMJE, 2009). 
The provision of HBM or data for a research project is not considered a sufficient ground to grant (co-
)authorship. In some cases biobanks may provide important contributions to research projects via the 
collection, processing and organization of unique collections of HBM and data or the provision of 
scientific advice or assistance to the project. We would argue that the biobank should be recognized 
for such contribution(106,112,113).  
Some authors promote in this respect the Bioresource Research Impact Factor (BRIF) initiative that 
aims to ”promote the sharing of bioresources by creating a link between their initiators or 
implementers and the impact of the scientific research using them.” (106,114) Some informants 
suggested that applicants that intend to commercialize the results of the research project would pay 
an additional fee or tax for the use of publicly funded collection of HBM and data. Such public 
contribution fee could avoid discussions about how important the delivery of the HBM and data was for 
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the final outcome of the project. The generated fees or taxes could be dedicated to the funding of 
public healthcare and research infrastructure, including biobanks. The HUGO Ethics Committee has 
recommended in its Statement on Benefit Sharing that “profit-making entities dedicate a percentage 
(e.g., 1-3%) of their annual net profit to healthcare infrastructure and/or to humanitarian efforts.” J. 
Bovenberg argued in favour of a specific tax on tissue and cell products directly developed from HBM 
and data ”as an effective, if indirect, mechanism for letting a community share in the benefits resulting 
from the efforts of the taxpayer concerned and to make a licensee pay for the exclusive use of natural 
resources”(111). The author suggested that such tax would only be due when a research project 
resulted in actual profit for the applicant.  
4.5 Obligation of applicant to share research results 
There was consensus among the informants that applicants could be requested to share the results of 
research projects using HBM and data from publicly funded biobanks. Some informants doubted 
whether the custodian should impose it as a condition to allow access to the collection, since this 
could discourage researchers to use the collection(108). Previous studies confirmed that an increasing 
number of biobanks(67) and funding bodies(115) require researchers to make their research results 
publicly available. Such requirement is motivated by the desire to maximize the use of results of 
publicly funded research(113,116). Some authors also invoke the principle of reciprocity: researchers 
could be expected to share their results with stakeholders that contributed to the collection of HBM 
and data, such as biobanks and donors(106,108). One of the first documents to introduce such 
requirement in the field of genomic research was the data release policy of the Human Genome 
project (HGP), known as the ‘Bermuda Principles’ (1996) (115). Afterwards, several other international 
documents promoted sharing research results with other researchers and the community at 
large(105,106), such as the Fort Lauderdale Agreement (2003)(117), the OECD Principles and 
Guidelines for Access to Research Data from Public Funding (2007) (86), the Toronto Statement on 
Pre-publication Data Sharing (2009), and the Global Alliance for Genomics and Health’s White Paper 
(2013)(118). However, a number of conditions need to be fulfilled to make the sharing of research 
results useful and acceptable for the researcher that generates the results. Infrastructure needs to be 
available to store the research results in a proper way and to allow other researchers to access and 
use the results(116). Clear rules should be created to evaluate requests for access to such research 
results. Researchers may be hesitant to share their research results if they do not receive recognition 
for their investments in generating the results(106). Several authors pointed out that the legitimate 
interests of the researchers and the institutions and funders supporting the project should be 
respected. These interests may be the right to keep some research results confidential, to obtain IPRs 
in relation to research results and a priority right to publish research results(105,106,108,116,119).  
Table 5 Pre-conditions to share research results 
Infrastructure to store and share research results Consensus 
Rules on access to research results Consensus 
Recognition of researcher that generated results Consensus 
Respect interest of researcher that generated results Consensus 
Custodianship on HBM and data stored in biobanks 
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5 Conclusion  
The interviews with different stakeholders revealed a rather complex web of rights and obligations 
allocated to the custodian and the applicant in relation to access to HBM and data stored in biobanks 
and used for research projects (see Annex 5). The results did not allow creating a complete overview 
picture of the rights and obligations that the custodian and the applicant hold or should hold in relation 
to access to and use of HBM and data. Some rights and obligations are negotiated on a case-by-case 
basis, while others are stipulated in access arrangements. Furthermore, custodians and applicants 
can only exercise certain rights, when they fulfil particular obligations and conditions. There did seem 
to be a consensus on the attribution of certain general rights to the custodians and the applicant (see 
also Table 6). First, the informants agreed that the custodian of a biobank can, under certain 
conditions, evaluate access requests. There was however no consensus on how extensive the 
evaluation of an access request should be and to which extent the custodian of biobank should 
evaluate the scientific merits of an access request. Second, the informants agreed that industrial and 
external applicants could access biobanks under the same conditions as internal applicants. Different 
access fees might however be applied to industrial or external applicants. Third, there was a general 
consensus that one should not grant exclusive access to collections of HBM and data. One can, 
however, provide a preferential or priority right to collectors of HBM and data during a limited period of 
time. Fourth, most informants agreed that a custodian of a biobank could request the sharing and 
return of research results and that some of the benefits of research projects should be fed back into 
biobanks. There was, however, no consensus on how the custodian would exercise such rights in 
practice and which conditions the custodians would have to fulfil in this respect. Finally there seemed 
to be consensus that the custodian of the biobank has the final right to decide on whether leftover 
HBM should be destroyed or returned.  
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Table 6 Overview of main rights and obligations of custodians and applicants53 
1. Rights and obligations in relation to decision on access to HBM and data  
A. Rights of custodian 
Evaluate access request and decide on access to HBM 
Evaluate availability and suitability of HBM and data for project 
Evaluate impact on existing collection of HBM and data 
Determine priorities between different research projects  
B. Obligations of 
custodian 
Dispose of sufficient expertise/experience 
Act independently 
C. Rights of applicant 
Access collection of HBM and data 
Use HBM and data in research project 
Keep certain information confidential 
Priority access in case applicant collected HBM and data 
D. Obligations of applicant 
Use for specific project and certain time period 
Provide synopsis of project 
2. Right to decide on leftover HBM  
A. Rights of custodian 
Decide on return or destruction 
Decide on use in new or follow-up project 
Verify leftover HBM 
Provide minimum amount of HBM 
B. Obligation of applicant 
Inform biobank about leftover HBM 
Return or destroy leftover HBM 
Submit new request for new use of HBM 
Prohibition to transfer to third party 
3. Right to participate in benefits of research project 
A. Rights of custodian 
Charge access fee 
Request return of some of the benefits 
Share in benefits of research project 
B. Right of applicant Enjoy benefits of research project 
C. Obligations of applicant Pay access fee 
Return some of the benefits to biobank 
4. Right to request the return of research results 
A. Rights of custodian Request return and sharing of research results 
B. Rights of applicant 
Be informed and/or consulted on access to research results 
Receive sufficient recognition for returning research results 
Respect his legitimate interests 
 
  
                                                       
53 We only included the rights and obligations on which most stakeholders agreed. 
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1 Introduction 
The intention of the legal study on access to biobanks is to provide an overview of the legal framework 
applicable when (both academic and industrial) researchers want to access and use HBM and 
associated data stored in biobanks for research purposes. The study does not look into the conditions 
that apply to the use of HBM and data for diagnostic or therapeutic purposes. It should be noted 
however that some legislation affects all 3 of these different purposes. 
2 Methodology 
This legal study provides an overview and analysis of the most important legal instruments that apply 
to access to biobanks in Belgium and Denmark, at the international level and at the level of the 
Council of Europe.  
We start the analysis from the legal framework in Belgium, since the PhD project was conducted 
within a Belgian research institute. We included legal instruments at the international level and at the 
level of the Council of Europe, since they might influence the Belgian legal framework. We chose to 
study the legal framework in Denmark, since it is considered as a pioneer in the development of 
biobanks networks, as well as in epidemiologic research. Denmark furthermore decided not to 
introduce specific legislation on biobanks54.  
The different legal instruments were analysed on the basis of the key access conditions defined in the 
previous empirical studies (Chapter 1 and 2) and supplemented with access conditions found in the 
different legal instruments. The ‘key access conditions’ were used to select the relevant legal 
instruments and describe and evaluate how the different legal instruments address ‘access to 
biobanks’. We organized the evaluation of the legal instruments according to the following conditions: 
(a) the aims, activities and policies of biobanks; (b) custodianship; (c) the evaluation of access 
requests by access committees and research ethics committees; (d) intellectual property and 
commercialization; (e) benefit sharing; (f) sharing and returning of research results; and (g) the 
protection of personal data. 
The legal study starts with a description of the legal framework applicable to access to biobanks55 in 
Belgium (section 2), at the international level (section 3) and at the level of the Council of Europe 
(section 4). Section 5 contains a comparison of the Belgian legal framework with the international 
normative instruments and Recommendation (2006)4 and the Working Document of the Council of 
Europe. Section 6 describes the legal framework applicable to access to biobanks in Denmark and 
compares it with the legal framework applicable in Belgium. In the conclusion we summarize to which 
extent the rights and obligations of the custodian and the applicant are regulated via the existing legal 
framework. 
                                                       
54 The methodology section (2.2) of the General Introduction contains a more detailed explanation why we have 
chosen Denmark. 
55 We do not aim to provide a complete description of the applicable legal framework, but rather focused on 
access to biobanks. 
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3 Belgian legal framework applicable to access to biobanks 
3.1  Act of 19 December 2008 on the procurement and use of human bodily material 
3.1.1 Introduction 
The Belgian Act of 19 December 2008 on the procurement and use of human bodily material 
(hereafter the Act on HBM) has been enacted to implement the EU Directives 2004/23/EC56, 
2006/17/EC and 2006/86/EC. The latter itself implemented EU Directive 2004/23/EC. The Act on HBM 
entered into force on 1 December 2009, with the exception for the provision on biobanks.  
Directive 2004/23/EC only relates to human tissues and cells intended for application on humans. The 
Act on HBM on the other hand, also intends to regulate the use of HBM and data for research 
purposes. 
The initial text of the Act on HBM contained legal rules on the procurement and use of HBM by 
biobanks for research purposes. These initial rules never entered into force and have been replaced 
by an Act of 19 March 2013 containing diverse provisions in relation to health. An Act of 14 April 2014 
containing diverse provisions in relation to health introduced a specific legal framework for biobanks 
created in the framework of a clinical study. The legal framework for (research) biobanks – stipulated 
in both acts – will only enter into force after the publication of one or more executive Royal Decrees in 
relation to biobanks (art. 124 of the Act of 19 March 2013 and art. 139 of the Act of 14 April 2014). It is 
uncertain when such Royal Decrees will be published.  
3.1.2 Scope 
The Act on HBM provides a legal framework for the procurement and use of HBM for medical 
applications on humans or for research purposes (art. 3 § 1). It does not apply to the removal of 
organs for transplantation (art. 3, § 3, a) or autologous applications within the same surgical procedure 
(art. 3, § 3, c). Nor does it apply to the removal and other operations conducted on HBM for pure 
diagnostic purposes – in favour of the donor – and to the extent that such HBM is not intended for any 
other purpose (art. 3, § 3, d)(35).  
The Act on HBM applies to every operation relating to the donation, removal, procurement, testing, 
processing, preservation, storage or distribution of HBM. The distribution includes the import and 
export of HBM (art. 3 § 1). 
The Act on HBM in principle applies to all human biological/bodily material (hereafter ‘HBM’). It 
particularly applies to human tissues and cells and all derived substances irrespective their degree of 
transformation (including stem cells) (art. 2, 1° and 3 §2). The Belgian Act on HBM is thus in principle 
also applicable to DNA and proteins (120). The Act on HBM also applies, to a limited extend, to 
gametes, embryos and foetuses (art. 3 § 4). It equally bears upon the removal, donation, procurement 
and testing of HBM for advanced-therapy medicinal product (ATMP), but not to other operations in this 
                                                       
56 EU Directive 2004/23/EC of the European Parliament and the Council as regards certain technical 
requirements for the donation, procurement and testing of human tissues and cells 
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respect (art. 7 § 4). Legislation on medicinal products applies in this respect. The Act on HBM only 
applies to regenerative HBM, such as blood, blood substances, (body) hair, nails, urine, mother milk, 
faeces, tears and sweat, when such HBM is procured, stored or provided for scientific research (future 
art. 3 § 3).  
The Act on HBM applies when the removal of HBM occurs on the Belgian territory(110,120).  
3.1.3 Different organisations 
The Act on HBM established four types of organizations in relation to the procurement and use of 
HBM. These four types of organizations are banks for HBM, intermediate structures, production 
establishments and biobanks (art. 2, §1, 24°-27°). The distinction between the four types of 
organizations is quite unique and does not exist in other countries. The first three types of 
organizations – banks for HBM, intermediate structures and production establishments – are 
established to conduct operations on HBM to the extent that they relate to diagnostic or therapeutic 
applications on humans. The fourth type of organization – a biobank – was established to conduct 
operations that pertain to the use of HBM for research purposes.  
A bank for HBM can conduct all operations in relation HBM. It has the exclusive competence to 
procure HBM – for applications on humans – and to decide on the allocation of HBM to a particular 
patient in the framework of a therapeutic application (art. 2, §1, 24°).  
An intermediate structure for HBM has a more limited competence, since it cannot procure, test or 
decide on the allocation of HBM. The custodian of a bank for HBM will have to authorize the 
procurement and allocation of HBM by an intermediate structure (120). An intermediate structure can 
procure HBM for the production of advanced-therapy medicinal products (ATMP), if it concludes a 
collaboration agreement with a bank for HBM (art.8, §2).  
A production establishment can only conduct operations in relation to the industrial production of 
autologous medicine57. Furthermore it cannot decide on the allocation of HBM58.  
A biobank can conduct all operations in relation to the procurement, storage and provision of HBM and 
possibly also associated data exclusively for research purposes. It cannot conduct any operations or 
research relating to (medical) applications of HBM on humans (art. 2, §1, 27°). Since the specific legal 
provisions on biobanks have not entered into force yet, no hospital or company formally established a 
biobank up to this day.  
  
                                                       
57 These are products relating to somatic cell therapy, gene therapy or tissue engineering intended for therapeutic 
and prior determined mere autologous use. 
58 A production establishment was initially not entitled to test HBM, but was given the right to conduct such testing 
in the Act of 19 March 2013. 
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3.1.4 Aims and activities 
In the future an ethics committee will need to provide a positive advice on the aims and activities of a 
biobank. As opposed to the other type of organizations, the biobank does not have to obtain an 
accreditation from the Medicine Agency. It only has to notify the Medicine Agency of its establishment 
and activities (future art. 22, § 1, first section). An Act of 14 April 2014 introduced an exception on this 
rule. The exception applies to biobanks that are created in the framework of a clinical trial – as 
regulated by the Act of 7 May 2004 on experiments on humans. In this case, the approval of the 
clinical trial by the Medicine Agency would replace the requirement to notify the establishment and 
activities of a biobank to the Medicine Agency (future art. 22, § 1, section 2). Furthermore, the positive 
advice of the ethics committee on the clinical trial will also be considered as a positive advice on the 
activities and aims of the biobank (future art. 22, § 1, section 6). However biobanks created in the 
framework of a clinical trial can only procure, process, store and make HBM available for the aims and 
the design of the clinical study as defined in the protocol. 
3.1.5 Rights and obligations of the custodian59  
According to the Act on HBM, the custodian has many different rights and obligations in relation to 
HBM. Some of those obligations can only be exercised by the custodian of a bank for HBM. In the 
future a custodian of a biobank will have similar obligations in relation to HBM used for research 
purposes. Other obligations can be exercised by custodians of the four different types of 
organizations. We will focus on the obligations of a custodian of a biobank. 
In the future the custodian of a biobank will have the obligation and right to decide on the allocation of 
HBM for research purposes (art. 2, 27°). The custodian will also be responsible for the return of 
information on traceable HBM to the donor (art. 11). The custodian will have to ensure that the 
informed consent of the donor is respected (art. 15 and art. 22 § 3). Furthermore, the custodian will 
have to make sure that the ethics committee provides a positive advice on the secondary use of HBM 
(art. 21, last section). The custodian of the biobank will act as contact person towards the Medicine 
Agency(121) and the ethics committee. She/he will have to verify the quality of the HBM and the 
safety and quality of operations conducted with the HBM (art. 16). The custodian will need to conclude 
the necessary insurances (art. 17 § 4). 
Finally, the custodian of the biobank will be responsible for the processing of personal health data. In 
case the biobank procures traceable HBM, the custodian needs to be a physician. In case the biobank 
procures non-traceable HBM, the custodian has to be a physician or a pharmacist (art. 22, § 3). 
  
                                                       
59 The Act on HBM uses the terms ‘beheerder’ in Dutch and ‘gestionnaire’ in French’ 
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3.1.6 The removal of HBM 
The Act on HBM regulates the removal of HBM for medical applications as well as for scientific 
research. The removal of HBM is only permitted on the condition that it corresponds to a specific 
finality or purpose (art. 8, § 1, section 1, 1°). When HBM is removed for scientific research, the aim of 
the removal should be precise and relevant for this scientific research. The finality should be specified 
(art. 8, § 1, section 1, 1° and 2°). Specific rules are applicable to the removal of HBM from minors or 
persons incapable to consent (art. 10 § 3).  
HBM can only be removed from the donor with his prior consent (art. 10 § 1). Such consent should be 
informed, conscious and free. The consent should be given in writing and should be dated and signed 
(art. 10 § 5). Consent is not required in case HBM is removed for a direct preventive, diagnostic or 
therapeutic purpose in favour of the donor (art. 9). The donor has the right to withdraw his consent at 
any moment and does not have to motivate such withdrawal (art 10 § 5, section 4). When HBM is 
removed from a deceased donor, the Act on HBM creates a presumption that the donor consented to 
such removal unless he or she explicitly objected to it before (art. 12).  
3.1.7 The use of HBM 
Article 2, 19° of the Act on HBM defines the use of HBM as any application of HBM that follows the 
last operation conducted with the HBM (such as the distribution of HBM). The Act on HBM regulates 
the use of HBM pertaining to medical applications on humans or in scientific research. The use of 
HBM for medical applications requires a preventive, diagnostic or therapeutic purpose that is based on 
a precise scientific foundation. The use of HBM in scientific research requires that the purpose is 
relevant for such research and has a precise finality (art. 8 § 1, 2°).  
The Belgian legislation distinguishes between primary use and secondary use of HBM (art. 10 § 1 and 
20). Primary use of HBM is defined as every use of HBM to which the donor explicitly consented in the 
framework of the removal of the HBM (art. 2, 29°). Primary use requires the consent of the donor – 
prior to the removal of HBM. This consent should be informed, conscious and free (art. 10 § 1 and § 
5). The consent should be in writing, dated and signed by the donor. The donor in principle has the 
right to withdraw his consent at any moment. The donor should however express such withdrawal 
before the moment that the HBM undergoes any operation after the procurement (art. 10 § 1 & 5 
section 4). We agree with other authors that the right of withdrawal becomes rather symbolic, since 
the donor loses such right as soon as the custodian stores or processes the HBM (120). 
Secondary use of HBM is defined as any other use of HBM than the use to which the donor explicitly 
consented in the framework of the removal (art. 2, 30°). Secondary use of HBM also requires a prior 
consent of the donor that should be informed, conscious and free (art. 20 § 1). The consent should be 
in writing and dated and signed by the donor (art. 10 § 5). The requirement to obtain informed consent 
for the secondary use of HBM does not apply in 2 exceptional situations: (i) when requesting such 
consent is impossible – for example when the donor passed away – (art. 20, § 1, second section); (ii) 
when requesting such consent is exceptionally inappropriate – for example because of the critical 
health status of the donor –; (art. 20, § 1, second section).  
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An ethics committee of a university hospital or another competent ethics committee60 has to provide a 
positive advice on both the secondary use of the HBM and the specific aims of such use (art. 21). It 
evaluates the relevance of the secondary use and the design. It also evaluates the adequacy of the 
information provided to the donor, the scope of the informed consent (if required) and whether it is 
sufficiently specific (art. 21, section 3, 1° and 2°). Finally it will evaluate whether it appears impossible 
or exceptionally inappropriate to request consent from the donor (art. 21, section 3, 3°). The future art. 
22, § 1, section 7 and 8 stipulates an exception to the required positive advice of an ethics committee 
for the secondary use of HBM for research purposes. This advice will not be required, if the proposed 
use of HBM falls within the scope of the aims and activities of the biobank and the ethics committee 
provided a positive advice on those aims and activities.  
Finally the Act on HBM created a presumption that the donor consents to the use of residual HBM61 
for scientific research, when he does not object to such use prior to the conduct of any operation on 
the HBM. The donor or his representative has to be informed in advance about the use of his residual 
HBM. He must be informed of the possibility to object to such use (art. 20, § 2). An ethics committee 
will have to provide a positive advice on the use of residual HBM for research purposes (art. 21).  
3.1.8 Traceability  
When HBM is used in the framework of scientific research in biobanks, the donor or his representative 
regarding the removal of HBM can decide whether the HBM should remain traceable.62 In case the 
donor passed away or in case of residual HBM, the provider of the HBM to the biobank can decide on 
the traceability (future art. 22, § 4). Such provider could be, more particularly, the custodian of a bank 
for HBM, an intermediary structure or a production establishment, a physician in the concerned 
laboratory or the chief physician in the concerned hospital. The custodian of a biobank shares the 
obligation to guarantee the traceability with all persons that use HBM originating from a biobank. They 
should make sure that all necessary measures are taken and all necessary information is provided to 
guarantee the traceability of HBM, unless it has been decided to abandon such traceability (future art. 
22, § 5). It seems advisable that biobank policies or the agreements with their users would contain 
clear arrangements on how to share this obligation. 
  
                                                       
60 Such committee has to comply with the conditions set out in art. 2, 4° (and art. 11 ter) of the Act of 7 May 2004 
relating to experiments on human beings. 
61 Residual HBM is defined as the part of HBM that was removed for diagnostic purposes or treatment of the 
donor and that – after a sufficient and relevant part has been stored to conduct, refine or complete the diagnosis 
or treatment of the donor on the basis of new scientific data – has become redundant for such purposes and 
therefore could be destroyed (art.2, 33°). 
62 The traceability is the capacity to localize and identify the HBM during all step of the process, in particular the 
procurement, processing, preservation, storage and distribution of HBM in order to be used or destroyed. 
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3.1.9 No (commercial) advantage 
Article 6 prohibits offering or receiving any financial or material advantage in exchange for the 
donation of HBM. The donor can receive a reimbursement of costs or loss of income incurred as a 
direct consequence of the donation. The banks for HBM – or the biobank in the future – and the 
persons responsible for the removal of HBM can receive a reimbursement of costs caused by the 
removal and operations conducted in the concerned bank for HBM. Condition here is that the removal 
and operations are not conducted with the aim of generating profit. Article 8, § 1, 9° prohibits the 
payment or receipt of a material compensation for the transfer, procurement or receipt of HBM that 
has not been subject to any transformation/processing – in a bank for HBM, an intermediate structure 
or a biobank – to make the HBM suitable for an application on humans or scientific research. HBM as 
such cannot result in the payment of any material compensation. One can however request a financial 
compensation for the operations of the transformation/processing and manipulation of HBM.  
3.1.10 Distribution of HBM by the biobank 
Prior to the distribution of HBM, the custodian of biobank will have to conclude an agreement with the 
person or institute(s) to whom HBM is distributed. This agreement needs to contain amongst others 
rules on the possible processing of personal data by the person of institutes to whom the HBM is 
distributed (future art. 22, §2, section 3 and 4). The modalities of such an agreement have not been 
defined (yet)  
3.1.11 Transfer of HBM across national borders  
The import of HBM into Belgium from a country outside the EU or the export of HBM to a country 
outside the European Union is – in principle – only allowed when such import or export is conducted 
under the supervision of an organization – such as a bank for HBM or a biobank – established in the 
European Union (3).  
The import of HBM from another country (inside our outside the EU) into Belgium or the export of HBM 
towards another country (inside or outside the EU) is only allowed, when the custodian of the bank for 
HBM demonstrates that the HBM complies with the – quality – requirements stipulated in the Act on 
HBM and the Royal Decrees in execution of the Act on HBM63(110).  
When HBM imported in Belgium is finally destined for exportation to another country (inside or outside 
the EU), the HBM only has to comply with the quality requirements imposed in the final country of 
destination. This is due to the fact that the HBM will only be stored in Belgium for a limited period of 
time and the HBM will not be used in Belgium.  
A bank for HBM – and in the future a biobank – has in principle the exclusive competence to import 
HBM into Belgium. HBM can only be exported outside Belgium under the supervision of a bank for 
HBM – or in the future a biobank – or an intermediate structure that obtained authorization from the 
custodian of a bank of HBM for such export (art. 8, § 1, 7° of the Act on HBM) (110,121).  
                                                       
63 Art. 18 of the Royal Decree of 28 September 2009 containing quality and safety norms for the donation, 
removal, procurement, testing, processing, storage and distribution of HBM. 
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3.1.12 Future Royal Decrees in relation to biobanks 
The specific provisions in relation to biobanks will only enter into force upon the publication of one or 
more executive Royal Decree in relation to biobanks (art. 124 of the Act of 19 March 2013 and art. 139 
of the Act of 14 April 2014). Such royal decrees may contain more detailed provisions on (a) the 
notification procedure to the Medicine Agency; (b) the positive advice of an ethics committee in 
relation to the activities and aims of the biobank; (c) the registry that a biobank should maintain in 
relation to its activities; (d) the traceability and identification of donors; (e) the specific conditions 
applicable to the removal of HBM for research purposes. An initial proposal of Royal Decree had been 
circulated to different stakeholders. It is uncertain whether this proposal and/or the specific provisions 
on biobanks will ever enter into force. A new government has taken office in October 2014. The new 
Minister of Health announced in her policy note that the legal framework applicable to biobanks would 
further be modified and approved.  
3.2 Privacy and data protection legislation 
3.2.1 Introduction 
Most biomedical research does not only require access to HBM. It also requires access to associated 
data about the characteristics of the HBM and the health status and other data related to the donor, 
such as demographic data and data on previous diseases and treatments. Researchers need access 
to this data to be able to choose the right type of HBM for their research project and to interpret the 
research results in a correct manner. 
At the level of the European Union Article 29 Data Protection Working Party64 considered “the 
extraction of information from human tissue samples a collection of personal data, to which the rules 
of the Data Protection Directive apply”65. 
In its Opinion n° 10/200966, the Belgian Privacy Commission pointed out that the Act on HBM and the 
executive Royal Decrees stipulate that every time an operation is conducted on HBM, information has 
to be provided about a number of biological and medical characteristics of the donor. The Privacy 
Commission concluded that (data about) those biological and medical characteristics of the donor 
should be considered personal data. This is in relation to the health of the donor in the sense of art. 7 
of the Privacy Act67 to the extent that the identity of the donor becomes available or accessible (121). 
Both opinions confirm the importance of the protection of personal data for biobanks. That is why we 
decided to discuss the most important provisions of the Belgian Privacy Act that apply when HBM and 
data are processed in the framework of scientific research. 
                                                       
64 The Article 29 Working Party is an advisory working party at the level of the EU made up of a representative 
from the data protection authority of each EU Member State, the European Data Protection Supervisor and the 
European Commission.  
65 Opinion n° 4/2007 of on the concept of personal data of the Article 29 Data Protection Working Party, p. 9 
66 Opinion n° 10/2009 of the Belgian Privacy Commission on the 4 Royal Decrees executing the Act on HBM. 
67 The Privacy Act is the Act of 8 December 1992 on the protection of privacy in relation to the processing of 
personal data 
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3.2.2 Definitions 
Article 1 of the Privacy Act defines a number of key concepts. Personal data is defined as “any 
information relating to an identified or identifiable natural person, while an identifiable person is 
defined as “a person who can be identified, directly or indirectly, in particular by reference to an 
identification number or to one or more factors specific to his physical, physiological, mental, 
economic, cultural, or social identity” (art. 1, § 1 Belgian Privacy Act).  
Processing of personal data is defined as “any operation or set of operations which is performed upon 
personal data, whether or not by automatic means, such as the collection, recording, organization, 
storage, adaptation or alteration, retrieval, consultation, use, disclosure by transmission, dissemination 
or otherwise making available, alignment or combination, blocking, erasure or destruction of personal 
data”; (art. 1, § 2 Belgian Privacy Act) 
The controller is the “person or organization that determines, alone or in collaboration with others, the 
purposes and means of the processing of personal data.” The custodian of the biobank would be 
considered as controller, when personal data is processed in the framework of a biobank. The 
processor is “the person or organization that processes personal data on behalf of the controller” (art. 
1, § 4 Belgian Privacy Act).  
3.2.3 General principles 
Article 4 of the Privacy Act contains a number of general principles that apply to the processing of all 
kind of personal data. First, the personal data has to be processed in a fair and lawful manner. 
Second, the personal data has to be collected and processed for specific, explicitly defined and 
legitimate purposes and the controller (and/or processor) has to make sure that the personal data is 
accurate, adequate, relevant and not excessive. Finally the personal data should be stored in a secure 
and confidential manner and no longer than necessary. 
3.2.4 Rights of the data subject68 
Personal data have to be processed in accordance with the data subject’s rights. These rights more 
particularly cover the right to information, the right to consent and the right to access the personal 
data.  
Each fully or partially automated processing of personal data should also be notified to the Privacy 
Commission. Such notification should occur prior to the processing of personal data. For each 
separate purpose a new notification has to be conducted, unless different purposes are connected 
(art. 17).  
  
                                                       
68 When personal data is processed in the framework of the biobank, the data subject will be the donor of HBM 
and data to the biobank.  
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3.2.5 The processing of health data in the framework of scientific research 
The processing of health data is in principle prohibited on the basis of article 7, § 1 of the Privacy Act, 
since such data is considered particularly sensitive personal information. 
Article 7, § 2, k does allow the processing of health data if such processing is necessary for scientific 
research and if the processing is conducted in compliance with the Royal Decree of 13 February 2001. 
This exception makes it possible under certain conditions to collect and process health data in the 
framework of biomedical research, clinical trials or biobanks. 
The Privacy Act provides different rules depending on whether the personal health data is initially or 
subsequently processed in the framework of scientific research. 
The initial processing of data for scientific research can occur when the participant provided an 
informed consent to participate in the research project or clinical trial. It may be advisable, but it is not 
a legal requirement to obtain a separate consent of the participant to process its personal data for this 
purposes. 
Another possibility is that personal health data was initially processed in the framework of health care 
and only subsequently processed and used for scientific research. This situation is regulated by a 
Royal Decree of 13 February 2001, which in principle only allows the processing of anonymised health 
data (art. 3 Royal Decree).  
Subsequent processing of coded data is exceptionally allowed, when one demonstrates that it is 
impossible to use anonymised data. In this case the notification to the Privacy Commission has to 
contain an explanation why anonymised data could not be used (art. 4 Royal Decree). Prior to the 
coding of the data, the data controller and/or data processor furthermore has to communicate the 
following information to the data subject: (1) the identity of data controller; (2) the categories of 
processed personal (health) data; (3) a detailed description of scientific purpose of processing; (4) the 
recipients or categories of recipients of personal data; (5) the existence of right to access and rectify 
his/her personal data and to oppose processing of personal data (art. 14 Royal Decree). In case it 
would appear impossible to provide such information to the data subject, the data controllers has to 
explain to the Privacy Commission why this is impossible. The Privacy Commission can provide a 
recommendation in this respect and can require additional conditions for processing coded information 
under these conditions (art. 16 Royal Decree). 
Subsequent processing of non-coded or identifiable personal data is only possible, when one 
demonstrates that it is impossible to use anonymised or coded data (art. 5 Royal Decree). In this case, 
the notification to the Privacy Commission has to explain why anonymised or coded data could not be 
used and the data controller or processor has to communicate the information mentioned above to the 
data subject. Finally the data controller or processor has to obtain the prior and explicit consent of the 
data subject for subsequent processing of non-coded personal data for scientific research. A prior and 
explicit consent of the data subject does not have to be sought in case the data is manifestly made 
public by the data subject or if it is impossible or unreasonably burdensome to obtain a prior and 
explicit consent (art. 18-21 Royal Decree). 
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3.2.6 Access to health data by the data subject (or donor) 
The data subject in principle has the right to access health data processed in the framework of 
scientific research (art. 10 § 2, section 1 Privacy Act). At the request of the data subject or the data 
controller such access to health data can occur with the assistance of a healthcare professional. 
Exceptionally the controller can postpone access to health data processed in the framework of 
medical scientific research – for example in the framework of a double blinded tests, if (i) there is no 
risk of an infringement on the privacy of data subject; (ii) such access would be detrimental to medical 
scientific research; and (iii) if data subject explicitly consented to the postponement (art. 10 § 2, 
section 2 Privacy Act).  
3.2.7 Transfer of health data to a third party 
The transfer of health data by the data controller to a third party – such as an applicant – is subject to 
several conditions. First, the data controller has to demonstrate that the transfer of health data is 
justified on legitimate grounds. This would for example be the case if the transfer occurs on the basis 
of written permission of the data subject or is necessary for purposes of a medical diagnose or 
scientific research.  
In case health data is subsequently transferred for scientific purposes, the data subject has to be 
informed of the transfer of coded data or has to provide informed consent for the transfer of non-
coded/identifiable data. Second, health data can in principle only be transferred to health 
professionals. Third, one should provide sufficient security measures in case of the electronic transfer 
of health data (for example E-Health Services). An important extra condition is the fact that one should 
in principle obtain a prior authorization by the Health section of the Sectorial Committee on Social 
Security and Health (art. 42, § 2, 3°, of the Act of 13 December 2006 containing miscellaneous 
provisions in relation to health) for each transfer of health data. This includes the transfer of health 
data in the framework of an experiment or clinical trial. Such prior authorization is not required, when 
the transfer occurs between health care professionals that are bound by a professional obligation of 
secrecy and are personally involved in diagnostic, preventive of health care acts relating to the patient.  
3.2.8 The transfer of personal data across national borders 
The EU Directive 95/46/EC69 attempted to create a harmonized framework for the protection of 
individuals with regarding to the processing of personal data70. Under this harmonized framework 
personal data can be transferred between EU Member States. Article 1, paragraph 2 of the EU 
Directive 96/46/EC provides in this respect that EU Member States “shall neither restrict nor prohibit 
                                                       
69 Directive 95/46/EC of the European Parliament and of the Council of 25 October 1995 on the protection of 
individuals with regard to the processing of personal data and on the free movement of such data 
70 On 25 January 2012, the European Commission published a Proposal for a Regulation on the protection of 
individuals with regard to the processing of personal data and on the free movement of such data (General Data 
Protection Regulation). The Proposal for a Regulation has been the object of a very strong debate between the 
European Parliament, the European Commission and the Council. No consensus has been reached yet on a final 
text. A General Data Protection Regulation would create one uniform privacy regulation that is directly applicable 
in the whole EU. 
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the free flow of personal data between Member States for reasons connected with the protection 
afforded under the Directive.” 
The transfer of personal data to countries outside the European Union is only allowed, when such 
countries offer an adequate level of protection and if the provisions of the Belgian Privacy Act are 
respected (art. 21 of the Belgian Privacy Act)(122). The European Union has concluded agreements 
with, amongst others, Andorra, Argentina, Canada, Switzerland and Israel confirming that they offer an 
adequate level of protection. The transfer of personal data to the US is only allowed, when the 
recipient of the personal data in the US is certified under the ‘Safe Harbor’ framework. The transfer of 
personal data to other countries can be authorized via Royal Decree and after the advice of the 
Privacy Commission, when the data controller provides sufficient guarantees for the protection of the 
personal data (art. 22 of the Belgian Privacy Act)(123).  
4 International normative instruments applicable to access to biobanks 
This section reviews a number of international normative instruments that are relevant for access to 
biobanks. The documents were selected after a review of the BBMRI report “Biobanks and the public: 
Governing biomedical research resources in Europe”(124) and an overview article of A. Cambon-
Thomson et. al. describing trends in the ethical and legal framework for the use of human 
biobanks(23):  
1. The Universal Declaration of Human Rights, proclaimed by the United Nations General 
Assembly in Paris on 10 December 1948.  
2. The World Medical Association Declaration of Helsinki71 entitled “Ethical Principles for Medical 
Research Involving Human Subjects72” (hereafter the “Helsinki Declaration”). The Helsinki 
Declaration contains ethical principles for medical research involving human subjects, 
including research on identifiable human material and data (§ 1). 
3. The UNESCO Universal Declaration of 1997 on the Human Genome and Human Rights 
(hereafter UNESCO declaration) 
4. The OECD Guidelines for Human Biobanks and Genetic Research Databases (2009) 
(hereafter “OECD Guidelines”) 
5. Recommendation of the European Society of Human Genetics, entitled “Data Storage and 
DNA Banking for Biomedical Research: Technical, Ethical and Social Issues” (2001) 
(hereafter ESHG Recommendation). 
These international normative instruments do not have a binding legal force (except for the Universal 
Declaration of Human Rights), but they do have an important moral value. 
The description and evaluation of the international normative instruments was conducted taken into 
account the “key access conditions.” 
                                                       
71 The declaration has been adopted by the 18th WMA General Assembly in Helsinki (Finland) in June 1964 and 
has been amended at several occasions. The last amendments have been adopted by the 64th WMA General 
Assembly in Fortaleza (Brazil) in October 2013 
72 The declaration has been updated on several occasions and the most recent version dates from 2013: 
www.wma.net/e/policy/b3.htm 
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4.1.1 Aims, activities and policies of biobanks 
Several international normative instruments suggest that an independent Research Ethics Committee 
(REC) should review the establishment, governance, management, operation, access to, and use of 
biobanks and its protocols and processes for research activities (best practice 1.2 OECD Guidelines; 
see also § 19 ESHG Recommendation). 
4.1.2 Custodianship  
Custodians of biobanks should develop and maintain clearly documented operating procedures and 
policies for the procurement, collection, labelling, registration, processing, storage, tracking, retrieval, 
transfer, use and destruction of HBM, data and/or information (principle 1.F OECD Guidelines).  
4.1.3 Evaluation of requests for access to HBM and data for research purposes 
The international normative instruments contain an important number of rights and obligations in 
relation to how access requests should be evaluated. 
The custodian should make the access policy and procedures publicly available (best practice 7.1 
OECD Guidelines). He should create mechanism to review applications for access to HBM and/or 
data and the envisaged use of the HBM and/or data for consistency with the types of research uses 
agreed to by a participant (best practice 7.2-3 OECD Guidelines).  
Access to HBM and data should be based on objective and clearly articulated criteria. It should be 
consistent with the research subjects’ informed consent (principle 7.A. OECD Guidelines; see also § 
21 ESHG Recommendation). The custodian of HBM should formulate criteria for prioritizing 
applications for access to HBM and data (principle 7.E. OECD Guidelines).  
The custodian of a biobank has to ensure that any stratified access conditions and fees are fair, 
transparent and do not inhibit research (best practice 7.4 OECD Guidelines). The conditions of access 
of researchers to HBM and data should be set out in a material transfer agreement or another 
appropriate agreement (best practice 7.6 OECD Guidelines).  
The researcher should draft a research protocol that describes and justifies the design and 
performance of the research study. The protocol should furthermore contain information about the 
funding and/or sponsors of the project, the institutional affiliations of the researcher, potential conflicts 
of interest, incentives provided to research subjects and information relating to the treatment and 
compensation of research subject who suffered harm due to the participation in the research study 
(§22 Helsinki Declaration; see also principle 7.B OECD Guidelines). 
Each research protocol and amendments to such protocol have to be submitted for approval to a 
REC. (§23 Helsinki Declaration; see also art. 5 d) and 16 UNESCO Declaration). Such REC must act 
in a transparent and independent way and must be duly qualified. The REC can monitor on-going 
research project (§23 Helsinki Declaration; see also best practice 3.3 OECD Guidelines).  
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4.1.4 Intellectual property and commercialization 
Custodians of biobanks should develop a clearly articulated policy on (i) the commercialization of 
HBM, associated data and research results and (ii) intellectual property rights (principle 9.D-E OECD 
Guidelines). 
It is generally accepted that the donation, collection and provision of HBM and associated data, as 
such, should not give rise to any financial gain (125,126). Article 4 of the UNESCO Declaration 
stipulates in this respect “the human genome in its natural state shall not give rise to financial gains.”  
4.1.5 Sharing in the advancement of scientific research and its benefits 
Article 27 § 1 of the Universal Declaration of Human Rights states that “everyone has the right (…) to 
share in scientific advancement and its benefits” (see also art. 12 (a) of the UNESCO declaration and 
principle 9.B OECD Guidelines). 
The best practice 9.1 of the OECD Guidelines stipulates that the custodians of a biobank should 
develop a clearly articulated policy on benefit sharing. 
4.1.6 Sharing and returning of research results 
Several international documents promote the sharing of research results with others researcher and 
the community at large, such as the ‘Bermuda Principles’ (1996)(115), the Fort Lauderdale Agreement 
(2003)(117), the Toronto Statement on Pre-publication Data Sharing (2009), and the Global Alliance 
for Genomics and Health’s White Paper (2013)(118). 
The Helsinki Declaration and the OECD Guidelines equally address the sharing and returning of 
research results. Both international normative documents provide that researchers – together with 
sponsors, editors, publishers and custodians of biobanks – have an ethical obligation to publish and 
disseminate the results of research studies. Researchers should publish or make available in other 
ways both positive, negative and inclusive research results. (§35 Helsinki Declaration; see also 
principle 1.H of the OECD guidelines). 
The OECD Guidelines furthermore suggest that custodians of biobanks should have a clearly 
articulated policy on whether and how the results of research and analyses carried out using HBM and 
data stored in biobanks should be returned to the biobank and be incorporated into its databases. 
They should also clearly articulate how access to such results for further research will be managed 
(principle 5.C OECD Guidelines). 
4.1.7 Protection of personal data 
Every precaution has to be taken to protect the privacy of the research subjects and the confidentiality 
of their personal information (§24 Helsinki Declaration; see also principle 1.D OECD Guidelines).  
4.1.8 Consent 
The international normative instruments contain several principles in relation to the requirement to 
obtain the informed consent of the donor for the use of his HBM and data for research purposes.  
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Paragraph 32 of the Helsinki Declaration formulates the general principle that one should seek 
informed consent for its collection, storage and reuse, when identifiable HBM or data is used in a 
research project. In case seeking such consent would be impossible or impracticable, the study may 
be done only after consideration and approval of a REC (see also best practice 3.1 OECD Guidelines 
and § 12 ESHG Recommendation). 
The custodian of a biobank should inform donors of their right to withdraw. Donors should be informed 
of the nature, modalities, implications and limits to exercise that right. The donors in principles do not 
have to explain their withdrawal. The withdrawal should not have any negative consequences for the 
donors or their family in regards to the provision of healthcare services (principle 4.G. and best 
practice 4.13 OECD Guidelines; see also § 7 of ESHG Recommendation). 
4.1.9 Balancing the rights and interests of the donor with the freedom of research 
Paragraph 8 of the Helsinki Declaration provides that ‘medical research cannot take precedence over 
the rights and interests of the research subject/donor’ (see also art. 10 UNESCO Declaration and 
principle 3.C OECD Guidelines). This is an important principle, since it draws the attention to the fact 
that the rights of donors should be respected at any time. The principle is however not absolute and 
has to be weighed against other principles, such as the ‘freedom of research’. Article 12 (b) of the 
UNESCO Declaration stipulates that the freedom of research “is necessary for the progress of 
knowledge” and even declares that such freedom “is part of freedom of thought.”  
The legal framework applicable to biobanks should aim to balance both principles. On the one hand, 
the interests of the donors should be protected in an optimal manner. On the other hand, one should 
not unnecessary hinder the possibility to use HBM and data in research projects. The optimal balance 
between both principles cannot be determined in a general way. Such balance can only be determined 
in each specific situation. One could refer in this respect to the fact that several international normative 
instruments – such as paragraph 32 of the Helsinki Declaration – require an informed consent of the 
donor for the use of his HBM and data for research purposes. However, the REC can authorize 
researchers to use the HBM and data without an informed consent, when it would be impracticable to 
obtain such consent.  
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5 Recommendation 2006 (4) of the Council of Europe 
5.1 Introduction 
A number of legal documents have been created in the framework of the Council of Europe in relation 
to biomedicine and biomedical research. We will not discuss the Convention on Human Rights and 
Biomedicine73, since it applies to biomedical medicine and not to biomedical research on HBM. We will 
also not go into the Additional Protocol concerning Biomedical Research74 that applies to biomedical 
research involving interventions on human beings. 
We will instead focus on the Recommendation 2006(4)75, since it specifically applies to use of HBM 
and data in biomedical research. Recommendation (2006)4 is not a legal binding document. The 
Recommendation, nevertheless, has an important moral value and could influence Belgian legislation 
in an indirect manner.  
We will first discuss the most important provisions in relation to access to biobanks in the original text 
of Recommendation (2006)4. Afterwards we will have a look at the most important modifications 
suggested in the Working document on research on biological materials of human origin (hereafter the 
“Working Document’”). The Committee on Bioethics76 published the Working Document on 18 March 
2014 and elicited comments from the public by 15 August 2014. The revised text of Recommendation 
2006(4) should be published in the beginning of 2015. We decided to discuss the most important 
modifications suggested in the Working Document, since they are particularly relevant for access to 
HBM and data stored in biobanks.  
5.2 Overview of Recommendation 2006(4) 
5.2.1 Protection of donors 
Article 1 of Recommendation 2006(4) stipulates that member states should protect the dignity and 
identity of all human beings and guarantee everyone, without discrimination, respect for their integrity, 
right to private life and other rights and fundamental freedoms with regard to any research governed 
by this recommendation.  
Article 5 stipulates that the risk related to the research activities, in particular the risk to the private life, 
should (a) be minimized for the persons concerned and possible also their family; (b) not be 
disproportionate to the potential benefit of the research activities.  
5.2.2 Prohibition of financial gain 
Article 7 contains the important provision that HBM, as such, should not give rise to financial gain.  
                                                       
73 The Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the 
Application of Biology and Medicine (1997) 
74 Additional protocol to the Convention on Human Rights and Biomedicine, concerning biomedical research 
(2005) 
75 The Recommendation Rec (2006) 4 of the Committee of Ministers to Member States on Research on Biological 
Materials of Human Origin 
76 The Committee on Bioethics is an intergovernmental body within the Council of Europe 
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5.2.3 Use of anonymised or identifiable HBM 
Article 8 contains the principle that HBM and associated data should be anonymised77 if possible for 
the concerned research activities. A researcher, who wants to use HBM and associated data in an 
identified78, coded79 or linked anonymised80 form, should justify such use. 
5.2.4 Consent 
Article 10, §2 provides that the information and consent to obtain HBM for research should be as 
specific as possible with regard to any foreseen research use and the choices that the donor can 
make in this respect. 
Article 12 stipulates that HBM removed for purposes other than storage for research (called residual 
HBM) should only be made available for research with the appropriate consent of the donor or an 
authorization of his representative. HBM can only be used without a consent or authorization if 
contacting the donor is not possible with reasonable efforts. There should also be an independent 
evaluation of the fulfilment of the following conditions: (a) the research addresses an important 
scientific interest; (b) the aims of the research could not reasonably be achieved using HBM for which 
consent can be obtained; and (c) there is no evidence that the person concerned has expressly 
opposed such research use.  
Article 15 confirms that the donor has the right to withdraw or alter the scope of the consent for the 
storage of identifiable HBM for research purposes. It further confirms that such decision should not 
have any negative consequences for this donor, in particular regarding the right to medical care. When 
identifiable HBM are stored for research purposes only, the donor should have the right to request the 
destruction or the anonymisation of the HBM. These rights only apply to identifiable HBM, since it is no 
longer possible to link anonymised HBM to a specific donor.  
Article 21 stipulates as a general rule that HBM should only be used within the scope of the consent 
given by the donor. Whenever a researcher wants to use identifiable HBM for a purpose that does not 
fall within the initial consent, he should make reasonable efforts to obtain a new consent. In case it 
would not be possible to obtain a new consent, the HBM could only be used for a new research 
purpose after an independent evaluation of a number of conditions. Unlinked anonymised HBM can be 
used in research without an explicit consent on the condition that the donor did not object to such use 
prior to the anonymisation of the HBM.  
                                                       
77 HBM is considered ‘anonymised’ if does not allow, alone or in combination with associated data, with 
reasonable efforts, the identification of the person concerned (art. 3, ii). 
78 HBM is considered as ‘identified’ if it allows, alone or in combination with associated data, the identification of 
the person concerned directly (art. 3, i). 
79 HBM is considered as ‘coded’ if it allows, alone or in combination with associated data, the identification of the 
person concerned through the use of a code and if the user has access to such code (art. 3, i). 
80 HBM is considered as ‘linked anonymised’ if it allows, alone or in combination with associated data, the 
identification of the person concerned through the use of a code and if the user does not has access to the code 
and the code is under control of a third party (art. 3, i). 
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5.2.5 Information in relation to the collection of HBM and data and the access conditions 
Article 14 provides that one should specify (a) the person and/or institution responsible for the 
collection, (b) the purpose(s) of the collection; (c) the conditions governing access to and use of 
samples; (d) quality assurance measures.  
5.2.6 Independent examination of access requests 
Article 24 stipulates the obligation to conduct an independent examination of the scientific merit, the 
importance of the aim and the ethical acceptability of a research project.  
5.3 Overview of the most important modifications suggested in the Working Document  
5.3.1 Protection of personal data 
Appropriate security measures should be taken to ensure the confidentiality of any information of a 
personal nature. These measures should ensure confidentiality at the time of removal, storage, use 
and, where appropriate, transfer of biological materials (art. 8).  
5.3.2 Public information 
Article 9 provides that Member States “should take appropriate measures to facilitate public access to 
general information on the nature and objective of research collections and on conditions relating to 
the obtaining, storage and use of HBM for research purpose.”  
5.3.3 General rules on use of HBM and data in a research project 
Article 17 § 1 stipulates that research on HBM and data should only be undertaken if it falls within the 
scope of the consent or authorisation given by the donor, in particular the consent given to remove 
and/or store HBM and data for future research. 
Article 17 § 2, i) stipulates that a new consent or authorization should be sought if the proposed use of 
the identifiable HBM (residual and non-residual) and data in a research project do not correspond to 
the scope of the prior consent or authorization. Sufficient efforts should be made to contact the donor 
and attempt to obtain a new consent. In case the donor expressed the wish not to be contacted, such 
wish should be respected. Unfortunately article 17, § 2 does not specify what should happen when 
one does not have clear information on whether the donor explicitly expressed the wish not to be 
contacted.  
Article 17 § 2, ii) stipulates that, in case the attempt to contact the donor proved unsuccessful, the 
HBM can only be used in a research project, when they have been subjected to an independent 
evaluation. This evaluation could be done by a REC for instance, which would evaluate the fulfilment 
of the following conditions: (a) sufficient efforts have been made to contact the donor; (b) the research 
addresses an important scientific interest and is in accordance with the principle of proportionality; (c) 
the aims of the research could not reasonable be achieved using biological materials for which 
consent or authorization can be obtained; (d) there is no evidence that the donor expressly opposed 
such research use.  
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Article 17 § 3 stipulates that anonymised HBM and/or data may be used in a research project provided 
that such use does not violate any restrictions placed by the donor prior to the anonymisation of the 
HBM and/or data and subject to authorization provided for by law – for instance by a REC. This 
provision provides a possibility to apply presumed consent for the use of anonymised HBM and/or 
data.  
5.3.4 Availability of results 
Art. 19 § 1 stipulates that on completion of the research, a report or summary should be submitted to 
the REC or the competent body. Art. 19 § 2 stipulates that appropriate measures should be taken to 
make the research results public within a reasonable timeframe.  
5.3.5 General principles in relation to governance of collections 
Article 20 § 2 provides that the purpose(s) of collections should be specified and that collections 
should be governed on the basis of the principles of transparency and accountability.  
Article 20 § 7 stipulates that information about the management and use of the collection should be 
made available to the donors and should be regularly updated.  
Article 20 § 8 stipulates that the conclusions of research should be publicly available. 
Article 20 § 9 requires the annual publication of reports on past and planned activities and access to 
the collection by third parties.  
5.3.6 Access 
Article 22 stipulates that clear conditions governing access to, and use of, HBM should be established. 
Member states should furthermore take measures to facilitate appropriate access by researchers to 
collections of HBM and data. Access policies should include arrangements for oversight of access and 
transfer procedures. Finally appropriate access mechanisms should be developed to maximize the 
value of collections. These mechanisms should include traceability of the uses granted by the 
collection. It is unclear how the different terms used in article 22, namely conditions governing access, 
access policies, access arrangements, access mechanisms, … relate to each other. It would be more 
transparent to define the different terms, for example in the explanatory memorandum. 
5.3.7 Oversight  
Article 24 stipulates amongst others that each collection of HBM and data should be subject to an 
independent oversight; such oversight should include amongst others the publication of reports on 
past and planned activities, including information on access by third parties. 
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6 Comparison of the access conditions formulated at the international level, the level of the 
Council of Europe and the Belgian level  
The section compares the most important rights and obligations of custodians, applicants and – to a 
lesser extent – donors in relation to access to biobanks. Those rights and obligations were found in 
the different legal documents studied at the international level, the level of the Council of Europe and 
in Belgium. One should, however, keep in mind that the international normative instruments and 
Recommendation 2006(4) are not legally binding in Belgium. They can however be considered an 
important inspiration for the development of a legal framework in relation to access to biobanks. 
6.1 Aims, activities and policies of biobank 
The legal instruments that have been studied at the international level and at the level of the Council 
of Europe, suggest that an independent REC should review the establishment, the activities and/or 
access to biobanks (best practice 1.2 of the OECD Guidelines; § 19 ESHG Recommendation; art. 24 
of the Working Document81 of the Committee of Bioethics). 
The Belgian Act on HBM provides that a REC should provide (in the future) a positive advice on the 
activities and aims of the biobank (future article 22, § 1, section 5) and that the establishment of a 
biobank should be notified to the Medicine Agency (future art. 22, § 1, first section). Furthermore, a 
REC has to provide a positive advice on the secondary use of HBM and the specific aims of such use 
(art. 21). One could argue that the Belgian Act on HBM to a large extent provides the review by an 
REC as suggested by the international normative instruments. However, it is not certain how the REC 
and the FAGG will perform the independent oversight of biobanks, since the rules in this respect need 
to be published in an executive Royal Decree.  
6.2 Custodianship  
The OECD Guidelines suggest that biobanks should develop and maintain clearly documented 
operating procedures and policies for the different operations including access conducted in the 
framework of the biobank (principle 1.F. OECD Guidelines) 
The Belgian Privacy Act and the Act on HBM do not contain any specific provisions in relation to the 
development of operating procedures and policies including access of biobanks. Considering the fact 
that many different types of biobanks exist, it is doubtful whether the national legislation should contain 
detailed provisions in this respect. It might be preferable to address this topic in specific access 
arrangements. 
The Belgian Act on HBM, the Belgian Privacy Act, the OECD Guidelines, the Recommendation 
2006(4) and the proposal in the Working Document do contain several rights and obligations of the 
custodian of a biobank. The custodian of a biobank should take into account those rights and 
obligations, when he/she develops access arrangements and/or operating procedures. The 
requirement to obtain a positive advice of an Ethics Committee in relation to the aims and activities of 
                                                       
81 The Working document on ‘research on biological materials of human origin’ was published by the Committee 
on Bioethics – an intergovernmental body within the Council of Europe – on 18 March 2014 
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the biobank might for instance have an influence on how the biobank develops its operating 
procedures and access arrangements. 
6.3 Evaluation of requests for access to HBM and data for research purposes 
The different international/European legal frameworks applicable to biobanks agree that the use of 
HBM in biomedical research should be subject to a review and/or positive advice of a REC. The 
international normative instruments and the Working Document of the Committee of Bioethics contain 
an important number of additional principles on the development of policies, procedures and 
mechanism to evaluate request for access to HBM and data. The legislation applicable in Belgium 
does not provide anything in relation to the development of access policies, procedures and 
mechanism. One might argue that this could be regulated via access arrangements developed by 
biobank initiatives. 
However, the Belgian Act on HBM does stipulate a limited number of rights and obligations of 
custodians that are suggested in the international normative instruments. Article 2, 27° provides that 
the custodian of a biobank will have the obligation and the right to decide on the allocation and use of 
HBM for research purposes. The custodian will also have to ensure that the informed consent of the 
donor is respected (art. 15 and art. 22 § 3). Finally the custodian will have to make sure that a REC 
provides a positive advice on the secondary use of HBM and the specific aims of such use (art. 21).  
The international normative instruments formulate a number of additional conditions on how the 
custodian should exercise his right to decide on the allocation and use of HBM. Although the Helsinki 
Declaration and the OECD Guidelines are not legal binding in Belgium, we are of the opinion that 
custodians of biobanks should take those additional conditions into account in the development of 
access arrangements. We would like to refer in this respect, for instance to the obligation “to ensure 
that any stratified access conditions and fees are fair, transparent and do not inhibit research” (best 
practice 7.4 OECD Guidelines).  
6.4 Intellectual property and commercialization 
The OECD Guidelines suggests that a biobank should develop a policy in relation to the 
commercialization of HBM and data and in relation to intellectual property rights (IPR) (principle 9.D-E 
OECD Guidelines). 
Recommendation (2006)4, the Working Document and the Belgian legal framework applicable to 
access to biobanks do not contain any provisions on policies.  
The UNESCO Declaration, Recommendation 2006(4) – and the new provisions in the Working 
Document – and the Belgian Act on HBM confirm the generally accepted principle that one should not 
generate profit on HBM.  
Article 6 of the Belgian Act on HBM stipulates that the donor cannot receive any financial or material 
advantage for the donation of HBM. It furthermore stipulates that the custodian of a biobank cannot 
pay or receive any material compensation for the transfer, procurement and receipt of HBM that has 
not been subject to any transformation. The donors and custodians can only receive a reimbursement 
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of costs caused by the donation, the removal and operations conducted on the HBM. Unfortunately 
there are no guidelines on how to calculate the costs of a biobank. This implies that biobanks have a 
certain discretionary power to calculate those costs.  
The applicable framework in principle prohibits access fees that would give rise to financial gains. 
Biobanks can only recover their costs in relation to the collection and provision of HBM and associated 
data. However, biobanks can charge additional fees for other services. It is unclear to which extent 
those additional fees could give rise to financial gains. 
6.5 Sharing in the advancement of scientific research and its benefits 
The Universal Declaration of Human Rights states that everyone has the right to share in scientific 
advancement and its benefits. The OECD Guideline for Human Biobanks and Genetic Research 
suggests that a biobank should develop a policy on the sharing of benefits.  
Until this day, no legally binding document has stipulated the possibility to share in the advancement 
of scientific research and its benefits. The previous chapters revealed that no consensus exists on 
how to share the benefits of scientific research. That is why we would suggest that such sharing 
should not be regulated via binding legislation. Biobanks could address this topic in their access 
arrangements in consultation with the different concerned stakeholders.  
6.6 Sharing and returning of research results 
The Helsinki Declaration and the OECD Guidelines formulate an ethical obligation for researchers, 
sponsors, editors, publishers and custodians of biobanks to disseminate the results of research 
studies. The OECD Guidelines suggest that a biobank should develop a policy on whether and how 
the results of research and analyses carried out using HBM and data stored in biobanks should be 
returned to the biobank. It stresses the need to develop a policy on how to incorporate them into its 
databases and on how to manage access to such results for further research. Finally article 20 § 8 of 
the Working Document stipulates that the results and conclusions of the research project should be 
publicly available within a reasonable period of time. 
The binding legislation in Belgium does not provide anything in this respect. We would argue that 
biobanks should develop a policy in this respect in their access arrangements; they would preferably 
involve the different concerned stakeholders in the development of such policy. 
6.7 Protection of personal data 
The different legal frameworks studied in this chapter stress the importance of protecting the privacy 
and the personal data of the donors. Recommendation 2006(4) – and the new provisions in the 
Working Document – and the Belgian Privacy Act stipulate specific provisions on the processing and 
use of personal data in the framework of research projects and in the framework of a biobank. One 
could therefore argue that the Belgian Privacy Act provides a clear legal framework on the protection 
of personal data. 
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6.8 Balancing the rights and interests of the donor with the freedom of research 
A number of international normative instruments as well as the Danish Act on Research Ethics 
reviews stipulate the important principle that ‘medical research cannot take precedence over the rights 
and interests of the research subject/donor’ (§ 8 Helsinki Declaration, art. 10 UNESCO Declaration, 
principle 3.C OECD Guidelines and section 1 of the Danish Act on Research Ethics Review). The 
principle is however not absolute and has to be weighed against other principles, such as the ‘freedom 
of research’.  
The legal framework applicable to biobanks should aim to balance both principles. On the one hand, 
the interests of the donors should be protected in an optimal manner. On the other hand, one should 
not unnecessary hinder the possibility to use HBM and data in research projects. The optimal balance 
between both principles cannot be determined in a general way. Such balance can only be determined 
in each specific situation. 
7 Danish legal framework applicable to biobanks  
We do not aim to provide an extensive overview of the Danish legislation. We limited ourselves to 
highlight a number of legal rules specifically relevant for access to biobanks. We then compare the 
legal framework applicable in Denmark – a country without specific legislation on biobanking – with the 
legislation applicable in Belgium – a country with specific (future) legislation on biobanking.  
7.1 Overview of the legal framework applicable to biobanks in Denmark 
In 1999 the Danish Ministry of Interior and Health appointed a working group to identify whether 
specific legislation had to be created in relation to biobanks. In May 2002 the ‘biobanking’ working 
group published the “Report on biobanks – proposal for a legal regulation of biobanks within the health 
field” (Report no. 1414/2002)(39).  
Biobanks was defined in Report no. 1414/2002 as “a structured collection of human biological material 
available according to specific criteria and where the information contained in the samples can be 
traced to identifiable persons.” (38). A collection is not considered a biobank, when samples in the 
collection cannot be traced back directly or indirectly to identifiable persons, for example via an 
encryption key (39). 
Report no. 1414/2002 came to the conclusion that the existing Danish legislation “is well suited to 
cover also biobanks, since confidentiality and safety would be secured if biobanks were considered as 
other collections of data, e.g. registries.” Consequently no new legislation was created and biobanks 
are covered by the general legislation and institutions applicable to biomedical and health research, in 
particular: (1) the Data Protection Act82; (2) the Health Act83; (3) the Act on Research Ethics Review84. 
                                                       
82 Act n° 429 on Processing of Personal Data of July 1, 2000 
83 the Health Act n° 913 of 13 July 2010 
84 The Act n° 593/2011 on Research Ethics Review of Health Research Projects of 14 June 2011. This Act on 
Research Ethics Review entered into forced on 1 January 2012 and repealed a previous Act no. 402 on a 
scientific ethical committee system and the handling of biomedical research projects of May 28, 2003. A 
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7.1.1 Data Protection Act 
The Danish Data Protection Act constitutes an important legal instrument for biobanks. That is 
because the Danish Data Protection Agency concluded in a statement of 23 February 2001 that 
“collections of human biological material fulfilling the criteria to (be considered) a biobank listed by the 
working group may be comprised by the definition of a manual register in the Personal Data Act, cf. s. 
1(1).” This implies that the Data Protection Act does not only apply to identification data and personal 
data derived from HBM, but also to collections of HBM (containing personal data) (39,127).  
7.1.1.1 Processing of health data for scientific or statistical purposes  
The Data Protection Act considers health data – such as data included in biobanks – sensitive 
personal data and therefore in principle prohibits the processing of such health data. 
Health data may be processed for the sole purpose of carrying out scientific or statistical studies. 
Condition hereto is that such studies are of significant public importance and the processing is 
necessary to carry out the studies (s. 10(1)). Data processed for scientific or statistical purposes 
cannot be processed for other purposes afterwards (s. 10(2)). This is due to the fact that the rules that 
apply to the processing of health data for scientific or statistical purposes are different – and less 
stringent – than the general rules that apply to the processing of health data for other purposes.  
Health data processed for scientific or statistical purposes may only be disclosed to third parties with 
the prior authorization of the Data Protection Agency (s. 10(3)). 
The Data Protection Act thus allows researchers to collect, process, register and use personal data for 
scientific purposes and transfer them to (another) researcher without an explicit consent of the data 
subject. This includes identification data, derived data and tissues. The researcher should first obtain 
the authorization of the Data Protection Agency (39). 
7.1.1.2 Authorization of Data Protection Agency  
The processing of personal health data requires a notification and a prior authorization by the Data 
Protection Agency (s. 50 (1)(1)) 
The processing, the collection and storage of identifiable HBM in the framework of a biobank – i.e. 
when the HBM is stored for a period of time that exceeds the time required to collect and analyse the 
HBM – is subject to a notification and authorization by the Data Protection Agency prior to any 
processing of such data (39). The Data Protection Agency furthermore requires that the storage and 
use of biobanks comply with special guidelines. One has to define a specific purpose for such storage 
and use (127). 
 
                                                                                                                                                                             
translation of the Act on Biomedical Research can be found on this website: 
http://www.cvk.sum.dk/English/actonabiomedicalresearch.aspx  
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The processing of HBM in the framework of a public research project has to be notified to the Data 
Protection Agency. The Data Protection Agency has to issue an opinion before the processing can 
take place. Since 2012, the processing of HBM in the framework of a private research project no 
longer need to be notified to the Data Protection Agency, when the project has been approved by a 
research ethics committee. 
HBM stored outside the framework of a biobank has to be destroyed or anonymised when the project 
is finished or when the HBM will not be used anymore. (127) 
7.1.2 The Health Act 
7.1.2.1 Consent for collection of HBM in the framework of patient care 
The collection of HBM in the framework of patient care – treatment or diagnosis – requires the 
informed consent of the patient. The consent can be written, oral or implied and the patient has the 
right to revoke the consent at any moment (s. 15). 
7.1.2.2 Patient’s right of self-determination regarding HBM 
The patient has the right to decide that HBM stored in the framework of patient care (hereafter residual 
HBM) cannot be used for other purposes, such as research. Such decision will be registered in the 
Use of Tissue Registry (s. 29(1)). When residual HBM would be used in a research project, the health 
professional is expected to verify, whether the concerned donor has been registered in the Registry (s. 
29 (4). Only a limited number of patients made such registration85. When no such registration exists, 
the residual HBM can be used for research purposes without the patient’s consent. An opt-out system 
thus applies for residual HBM.  
In case HBM was initially collected for therapeutic purposes, the donor can opt-out for the use of such 
HBM for research purposes (s. 29 Health Act). Article 20 § 2 of the Belgian Act on HBM contains a 
similar opt-out system for the use of residual HBM – removed for diagnostic of therapeutic purposes – 
for scientific research purposes.  
The patient can require that residual HBM is destroyed (s. 33) or returned to the patient (s. 34). In the 
latter case, the patient has to demonstrate that he or she has special interest in the return of the HBM. 
In case the HBM has been transferred to a third party, the person (initially) responsible for the storage 
of the HBM has to inform such third party of the request of the patient. The right to destroy or return 
HBM may be denied, when vital public or private interests override the patient’s interest (s.33-34).  
  
                                                       
85 The number of people that made such registration can be found on the following website:  
http://www.ssi.dk/Sundhedsdataogit/Registre%20og%20kliniske%20databaser/De%20nationale%20sundhedsregi
stre/Dodsaarsager%20biologisk%20materiale/Vaevsanvendelsesregisteret.aspx
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7.1.2.3 Confidentiality and disclosure of health information by health professionals 
Information about the health of individuals and other confidential information from medical records 
may only be disclosed to a researcher for use in a specific research project, when the national or a 
regional REC has approved the research project as such (not the specific disclosure of the 
information) (s. 46 § 1).  
The REC does not need to approve a research project that does not make use of personal health 
data, but other personal data. In this case, the National Board of Health and Medicine has to approve 
the disclosure of such data to a researcher. Such information can furthermore only be used in relation 
to a specific research project of particular interest to society (s. 46 § 2).  
Information obtained under section 46 cannot be processed for other than statistical or research 
purposes. Furthermore the information can only be published in an anonymous manner, i.e. that does 
not allow the attribution to an individual patient (s. 48). 
7.1.3 The Act on Research Ethics Review 
7.1.3.1 Introduction 
The Act on Research Ethics Review regulates the ethical review, the approval and the follow up of 
health research projects that use HBM and data. It also applies to clinical trials on medicinal products 
and clinical investigations of medical devices.  
Section 1 stipulates the general principle that “consideration for the rights, safety and well-being of the 
research participant come before (/take precedence over) scientific and societal interests to gain new 
knowledge and investigate existing knowledge that may justify the undertaking of a research project.”  
Section 1 (13) defines a Research Biobank as “a structured collection of human biological material 
that is kept with a view to a concrete health research project, and which may be accessed according 
to defined criteria and where information bound in the biological material may be traced to 
individuals.” 
7.1.3.2 Review and approval by Research Ethics Committee (REC) 
All health research projects in Denmark involving human beings or any kind of HBM have to be 
reviewed and authorized by a REC prior to starting such project (s. 14(1)). Questionnaire surveys and 
medical database research projects only need such authorization when the project includes HBM (s. 
14(2)86. The REC will take into account the following criteria in granting an authorization: (1) the risks 
and benefits of the trial; (2) the expected benefits from a therapeutic and public health perspective; (3) 
the projects’ scientific standard; (4) the expectations of the project’s conclusions (s.18). The collection 
of HBM and data in the framework of a biobank – without a specific scientific aim or hypothesis – is 
not subject to a notification or authorization of a REC(127). 
                                                       
86 Health research projects that only involve anonymous HBM collected in accordance with the applicable 
legislation at the place of collection should only be notified to the ethics committee system, if the research is 
regulated by Section 25 of the Act on artificial insemination in connection with medical treatment, diagnosis and 
research, etc. (s. 14(3). 
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The National Committee on Health Research Ethics acts as a board of appeal against the decisions of 
regional committees (s. 26). 
7.1.3.3 Consent 
A REC will only authorize a research project on the condition that the donor has given his informed 
consent to participate in such project and if the donor was given access to information about the 
content of the project and its foreseeable risks and benefits (s. 3-5 and 17). This consent requirement 
applies when HBM is removed for a specific research project and stored in a biobank (s. 6). When 
HBM stored in a biobank is not removed for a specific research project, the Data Protection Act 
applies.  
The regional REC could waive the obligation to obtain an informed consent for medical database 
research projects. This is the case if the project does not create any health risk or other strain for the 
research subject/donor or if it appears impossible or disproportionately difficult to obtain an informed 
consent (s. 10)(39). A presentation of prof. dr. M. Hartlev at the Nordic Bioethics Committee 
Conference ‘Nordic Biobank Research - Obstacles and Opportunities’ of 3-4 May 2011 in Uppsala 
mentioned that a lot of research projects obtained a waiver to obtain an informed consent of the 
donor(128).  
The donor has the right to revoke his consent at any moment (s. 3 (4)). A 2014 Report of the Nordic 
committee of Bioethics mentions in this respect that the “withdrawal of consent has not been accepted 
in practice by the research ethics committees for samples collected for clinical research.” 
7.2 Comparison of legal framework applicable to biobanks in Denmark and Belgium 
7.2.1 Aims, activities and policies of the biobank 
The Danish Data Protection Agency conducts an important role in the oversight of biobanks. The 
Agency is competent to authorize (1) the processing of identifiable health data (2) the processing of 
identifiable HBM in the framework of a biobank; (3) the processing of HBM in the framework of a 
public research project; (4) the transfer of HBM stored in biobanks to other researchers (s. 10 and 50 
Data Protection Act). However, this competence to deliver an authorisation only applies when data or 
samples can be traced back to an individual. It does not apply to anonymous HBM or data. The Data 
Protection Act after all does not apply to anonymous HBM or data. 
The role of the Belgian Privacy Commission in the oversight of biobanks is much more limited. The 
Privacy Act does not contain any provisions on the processing of HBM. The Act only provides that the 
processing of health data is subject to a notification to the Privacy Commission (art. 17).  
In Denmark, the REC has to approve the collection of HBM in the framework of a research project with 
a specific scientific aim or hypothesis (s. 14 Act on Research Ethics Review). The REC is not 
competent to approve the creation of a biobank(127).  
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In Belgium the REC has to provide a positive advice on the aims and activities of the biobanks and on 
the secondary use of HBM (future art. 22 § 1, section 5). The establishment of the biobank 
furthermore has to be notified to the Federal Agency for Medicine and Health products (future art. 22, 
§ 1, section 1). 
7.2.2 Custodianship  
The Belgian Privacy Act and the Act on HBM attach a lot of importance to the role of the custodian of 
a collection of HBM and/or data. Both acts assign several rights and obligations to the custodian. 
These rights and obligations relate to operations conducted on HBM and associated data and to the 
processing of personal data for research purposes. 
In the Danish Data Protection Act, the Health Act and the Act on Research Ethics Review, the rights 
and obligations of the custodian of a biobank are defined in a more fragmented manner.  
7.2.3 Evaluation of requests for access to HBM and data for research purposes 
All health research projects in Denmark involving HBM have to be reviewed and authorized by a REC 
prior to starting such project (s. 14(1) of the Danish Act on Research Ethics Review). A REC (or the 
National Board of Health) furthermore has to approve the disclosure of health information to 
researchers for use in a research project (s. 46 of the Danish Health Care).  
Article 21 of the Belgian Act on HBM provides that an ethics committee has to give a positive advice 
on the secondary use of the HBM and the specific aims of such use. In the future a positive advice of 
an ethics committee will not be necessary for the secondary use of HBM for research purposes. This 
is true at the condition that the proposed use of HBM falls within the scope of the aims and activities of 
the biobank and the ethics committee provided a positive advice on those aims and activities (future 
art. 22, § 1, section 7 and 8). 
7.2.4 Intellectual property and commercialization 
We did not find any specific provision on IPRs and the commercialization of HBM and data in the 
Danish legal framework applicable to biobanks. 
7.2.5 Sharing in the advancement of scientific research and its benefits 
We did not find any specific provision on the sharing in the advancement of scientific research and its 
benefits in the Danish legal framework applicable to biobanks. 
7.2.6 Sharing and returning of research results 
We did not find any specific provision on the sharing and returning of research results in the Danish 
legal framework applicable to biobanks. 
7.2.7 Protection of personal data 
The Belgian Privacy Act provides that the processing of health data is subject to a notification to the 
Data Protection Authorities (art. 17). The Act makes a distinction between personal data initially 
collected in the framework of health care or personal data collected in the framework of a research 
project. The initial collection of personal data in the framework of the research project is subject to the 
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consent of the data subject to participate in the project. There is however no requirement for a specific 
consent to process the personal data. When a researcher wants to subsequently process and use 
coded or identifiable health data that was initially collected in the framework of health care, he has to 
notify such processing and use to the Belgian Privacy Commission (art. 3-5, 14, 16 and 18-21 of the 
Royal Decree of 13 February 2001). The subsequent processing of health data is only subject to a 
notification and not to a prior authorization of the Belgian Privacy Commission. The Health Section of 
the Sectorial Committee on Social Security and Health in Belgium has to authorize the transfer of 
health data to a third party – such as the applicant – (art. 42, § 2, 3°, of the Act of 13 December 2006 
containing miscellaneous provisions in relation to health). The Belgian Data Protection Act does not 
contain any rules in relation tot the processing and transfer of HBM stored in biobanks.  
The Danish Data Protection Act applies both to personal data and collections of HBM (containing 
personal data)(39,127).The Data Protection Agency has to authorize the processing of personal health 
data for research purposes, as well as the transfer to another researcher (s. 10 of the Danish Data 
Protection Act).  
7.2.8 Balancing the rights and interests of the donor with the freedom of research 
Section 1 of the Danish Act on Research Ethics Review stipulates the important principle that the 
rights, safety and well being of the research participant takes precedence over scientific and social 
interests in relation to biomedical research projects.  
8 Conclusion 
The analysis of the legal framework applicable to access to biobanks allowed us to complete the 
picture of the rights and obligations – drawn up at the end of Chapter 2 – held by the custodian and 
the applicant in relation to access to and use of HBM and data. Certain rights and obligations are 
clearly regulated via the different legal instruments. First, the review of biobanks by REC is stipulated 
in the different legal frameworks. Second, the different legal frameworks define an important number 
of rights and obligations of the custodian. Third, the different legal frameworks stipulate that a REC 
should review and approve the use of HBM and data in research projects. Fourth, there is a general 
consensus that one should not generate profit on HBM (as such). Fifth, the protection of personal data 
is regulated via binding legislation.  
Others rights and obligations are insufficiently regulated via the international normative documents 
and the binding legislation in Belgium and Denmark. One can refer in this respect to the fact that 
several international normative instruments provide that a biobank should develop a policy in relation 
to (a) the commercialization of HBM; (b) IPRs; (c) the sharing and returning of research results; and 
(d) the sharing in the advancements of scientific research and its benefits. None of the international 
normative instruments (or the binding legislation) contain detailed provisions on how to develop such a 
policy. Chapter 4 will dig deeper into the question how IPRs and the ‘return and sharing of research 
results’ could be regulated. 
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The international normative instruments contain quite detailed provisions on the development of 
access policies, procedures and mechanism. Those provisions constitute an important source of 
inspiration for the development of access arrangements. 
  
Chapter 3 
 
Page | 107  
 
Table 7 Overview of most important rights and obligations in different legal frameworks87 
 
Belgium International 
Council of 
Europe Denmark 
     1. Aims, activities and policies of biobanks 
    A. Obligation of custodian 
    Obtain positive advice of REC on aims and 
activities of biobank Yes Yes 
 
No 
Notify establishment and activities to Medicine 
Agency Yes 
   
     2. Custodianship 
    A. Obligation of custodian 
    Decide on allocation and use of HBM Yes 
   Obtain and ensure respect of informed consent Yes Yes Yes Yes 
Ensure respect of ethical approval of research 
project Yes Yes Yes Yes 
Ensure that aim of use of HBM is precise and 
relevant Yes 
 
Yes 
 Ensure that finality of use of HBM is specified Yes 
 
Yes 
 Conclude prior agreement for distribution of HBM Yes Yes 
  Develop and maintain clearly documented SOPs 
 
Yes Yes 
 Develop and maintain clearly documented access 
policies 
 
Yes Yes 
 Make access policies and procedures publicly 
available 
 
Yes Yes 
 Return or destroy HBM at request of donor 
   
Yes 
B. Rights of custodian 
    Decide on allocation and use of HBM Yes 
   Procure, store and provide HBM for research 
purposes Yes 
   
     3. Evaluation of access requests 
    A. Obligation of custodian 
    Create mechanism to review access requests 
 
Yes Yes 
 Establish clear criteria governing access 
 
Yes Yes 
 Ensure that access is based on objective and 
clearly articulated criteria 
 
Yes 
  Ensure that stratified access conditions and fees 
are fair, transparent and do not inhibit research 
 
Yes 
  Formulate criteria for prioritizing applications 
 
Yes 
  Provide oversight of access and transfer 
procedures 
  
Yes 
 
       
                                                       
87 This table provides an overview of which rights and obligations are regulated in the different legal 
frameworks applicable to access to biobanks. When a particular right or obligation is regulated in a 
particular legal framework, we indicated ‘yes’. We did not indicate when a particular right or obligation 
is not (explicitly) regulated in a certain legal framework. Specific information on how a particular right 
or obligation is regulated can be found in the description of the different legal frameworks. 
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B. Obligations of applicant 
    Obtain positive advice of REC on use of HBM in 
research project Yes Yes Yes Yes 
Draft research protocol 
 
Yes 
  Respect informed consent Yes Yes Yes Yes 
Respect ethical approval of research project Yes Yes Yes Yes 
     4. Intellectual Property and commercialization 
    A. Obligation of custodian 
    Develop policy on commercialization 
 
Yes 
  Develop policy on IPRs 
 
Yes 
  Prohibition of financial gain Yes Yes Yes 
 B. Rights of custodian 
    Receive reimbursement of costs Yes 
   C. Obligation of applicant 
    Reimburse cost of biobanks Yes 
   
     5. Benefit sharing 
    A. Obligation of custodian 
    Develop policy on benefit sharing 
 
Yes 
  
     6. Sharing and returning of research results 
    A. Obligation of custodian 
    Develop policy on returning and sharing research 
results 
 
Yes 
  B. Obligation of applicant 
    Ethical obligation to publish and disseminate 
results 
 
Yes 
  Take appropriate measures to make research 
results public available 
  
Yes 
 
     7. Protection of personal data 
    A. Rights of custodian 
    Process personal data in the framework of 
biobank Yes Yes Yes Yes 
B. Obligations of custodian 
    Ensure protection of personal data Yes Yes Yes Yes 
Notify processing of personal data Yes 
  
Yes 
Obtain authorization of Privacy Commission/Data 
Protection Agency Yes 
  
Yes 
C. Rights of applicants 
    Process and use personal data in research project Yes Yes Yes Yes 
D. Obligation of applicants 
    Ensure protection of personal data Yes Yes Yes Yes 
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9 Overview of the studied legislation 
9.1 Belgium 
Act of 19 December 2008 on the procurement and use of human bodily material, Belgian Official 
Journal of 30 December 2008 
Royal Decree of 28 September 2009 stipulating the general conditions that banks for HBM, 
intermediate structures and production establishments need to fulfil in order to obtain an approval from 
the Medicine Agency, Belgian Official Journal of 23 October 2009 
Royal Decree of 28 September 2009 on the supervision on the compliance with the Act of 19 
December 2008 on the procurement and use of human bodily material, Belgian Official Journal of 23 
October 2009 
Royal Decree of 28 September 2009 with quality and safety norms for the donation, removal, 
procurement, testing, processing, storage and distribution of HBM, to which banks for HBM, 
intermediate structures and production establishments have to comply, Belgian Official Journal of 23 
October 2009 
Royal Decree of 28 September 2009 stipulating provisions on the notification of serious adverse 
events or reactions in relation to HBM, Belgian Official Journal of 23 October 2009 
Act of 22 August 2002 concerning the rights of patients, Belgian Official Journal of 26 September 2002 
Act of 8 December 1992 on the protection of privacy in relation to the processing of personal data, 
Belgian Official Journal of 18 March 1993 
Royal Decree of 13 February 2001 in execution of the Act of 8 December 1992 on the protection of 
privacy in relation to the processing of personal data, Belgian Official Journal of 13 March 2001 
9.2 International 
The Universal Declaration of Human Rights, proclaimed by the United Nations General Assembly in 
Paris on 10 December 1948.  
The World Medical Association Declaration of Helsinki entitled “Ethical Principles for Medical 
Research Involving Human Subjects”  
The UNESCO Universal Declaration of 1997 on the Human Genome and Human Rights 
The OECD Guidelines for Human Biobanks and Genetic Research Databases (2009) 
Recommendation of the European Society of Human Genetics, entitled “Data Storage and DNA 
Banking for Biomedical Research: Technical, Ethical and Social Issues” (2001)  
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9.3 Council of Europe 
The Recommendation Rec (2006) 4 of the Committee of Ministers to Member States on Research on 
Biological Materials of Human Origin 
Working document on ‘research on biological materials of human origin’ published by the Committee 
on Bioethics on 18 March 2014 
9.4 Denmark 
Act n° 429 on Processing of Personal Data of July 1, 2000  
Health Act n°913 of 13 July 2010 
The Act n° 593/2011 on Research Ethics Review of Health Research Projects of 14 June 2011. 
 
  
Chapter 3 
 
Page | 111  
 
  
 
  
Page | 112 
 
  
Chapter 3 
 
Page | 113  
 
Chapter 4: IPRs in biobanking: Risks and opportunities for 
translational research  
This chapter is based on: 
Verlinden M, Minssen T, Huys H  
IPRs in biobanking: Risks and opportunities for translational research.  
Intellect Property Q. 2015 [Accepted for publication] 
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1 Introduction88  
The worldwide focus on biobanks has increased considerably due to several reasons. Large-scale, 
interoperable biobanks make it possible for researchers with different backgrounds and scientific 
expertise to analyse large and diverse collections of biospecimen, as well as genetic, clinical, health 
and other personal data of the donor. Those analyses could allow them to identify novel biomarkers or 
to validate the clinical significance of genomic mutations. After discovering – for example – a certain 
gene that could correlate with the severity of a given disease or condition, researchers can use HBM 
to test new drug candidates that target this mutation(21).  
Thus biobanks can provide a crucial platform for international and interdisciplinary cooperation. They 
can act “as key drivers for next generation biomarker (diagnostics) research and drug discovery”(21). 
Since size and quality really matters in this field, translational research increasingly requires 
cooperation between top quality biobanks in different countries. There has been a gradual shift from 
traditional closed innovation systems to more “open” and “transparent” innovation models. At the same 
time there were rapid technological advances and bio-pharmaceutical innovation gaps. These factors 
have highlighted the increasing importance of an effective establishment, governance and use of 
large-scale longitudinal biobanks(129). Biobanks, and in particular public biobanks, are often 
constructed to operate for several decennia and to be used by numerous research projects. They 
could potentially be used by a great variety of stakeholders with different objectives. Such 
stakeholders could be private companies, university researchers, bio hackers, research foundations, 
patient groups, governmental bodies or "hybrid" consortia in the framework of Private Public 
Partnerships (PPPs). This great variety of stakeholders and the increasing significance of biobanking 
require substantial investments in the creation, organization and maintenance of the HBM and data 
stored in biobanks.  
This raises important organizational, regulatory and ethical questions for any type of biobank. It also 
raises legal questions such as how to deal with intellectual property rights (‘IPRs’) that could arise out 
of the creation or later use of the collected HBM and data. This is a complicated question that often 
involves both IPRs and contractual rules and interests. As a starting point, the IPR legislation identifies 
(amongst other) the subject matter and the beneficiaries of the protection. In patent law, only subject 
matter that is not considered as pure discoveries is patentable. The (exclusive) rights arising under 
IPR can then in principle be transferred by a contract. Research collaborations between stakeholders 
often would involve such technology- or information transfer. 
It is therefore also a specific issue under which conditions a biobank could or should become 
(co)owner of IPRs resulting from the use of the HBM and data which it provided, selected and possibly 
processed for the specific research (so-called downstream IPRs). This entails investigating how to 
reach a balance between the exclusive nature of IPRs to exclude others from using protected material 
without consent of the owner, and the requirement of funding agencies to share as widely as possible 
                                                       
88 This Chapter was written together with prof. dr. Timo Minssen (University of Copenhagen) and prof. dr. Isabelle 
Huys (KU Leuven) 
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(with minimal restrictions) the data which result from research on the basis of HBM and associated 
data.  
Another issue concerns the modalities and conditions for use of the data derived from the biobank. It 
pertains to the choice between an “open” and “closed” collaboration model or a combination thereof. 
Even though there are built-in tensions between the rules of IPR and the norms underpinning the 
principles of “openness” and “data sharing”, it is important to bear in mind that IPRs do not imply the 
establishment of closed collaboration models. Instead, right holders could use the IPRs provided to 
them to find the right balance. This balance lies somewhere in what has been described as “the 
spectrum between free use of knowledge by anyone for any purpose and exclusive use by one entity 
for its own use”(130). The mere acquisition of IPR does not necessarily imply any specific modalities 
for rights administration and user-generated solutions. Instead it necessitates to make decisions and 
agreements about the way IPRs are/can be used, and to be aware of the consequences of the 
different choices(129).  
Developing biomedical treatments or diagnostics can be very costly and industry involvement is thus 
often essential. Therefore, an appropriate balance in the user modalities of IPRs appears particularly 
important within the area of translational medicine. In order to obtain the necessary knowledge to 
develop new drugs (or new uses of existing/approved drugs), access to large-scale biobanks is 
crucial. For this reason (international) cooperation between different institutions is needed. The 
industry has realized that the development of truly innovative biologics and “cutting edge” personalized 
therapies is complex and difficult to achieve within the traditional “closed innovation” model. New 
strategic partnerships with competitors, smaller specialized biotech companies or with governmental 
institutions through Public Private Partnerships (PPPs) are often necessary to develop breakthrough-
drugs. This has encouraged several innovator companies to support the current shift towards more 
transparency in the pharmaceutical sector. In addition to regulatory responses and initiatives from 
authorities89, the drug industry has initiated their own transparency projects. These include biobank-
initiatives with a various level of transparency.90 However, due to the immense risks and costs 
associated with pharmaceutical R&D and clinical trials, the industry and investors would – at least at 
some stage – presumably require a certain type of exclusivity. This could e.g. be achieved through 
IPRS and licenses, regulatory exclusivities or trade secrets. Therefore, determining the right balance 
between openness and exclusivity is particularly decisive but also difficult here.  
So far only a limited number of studies have delivered in-depth insights in strategies and policy 
choices with regard to IPRs in biobanking. The inherent complexity involving many areas of expertise 
and stakeholders, probably explains why. Previous studies focused on the potential negative impacts 
and risks of IPRs in the context of biobanking(131). Only a few projects highlighted the opportunities 
and potential benefits of user-generated solutions and proper governance of IPRs in 
                                                       
89 This shift has not only resulted in data disclosure provisions in the new European regulations on clinical trials 
but also to – arguably rather cautious - transparency initiatives by the FDA and the EMA. 
90See e.g. Astra Zeneca’s transparency program at: http://www.astrazeneca-us.com/responsibility/corporate-
transparency  (last visit 10 May 2014). 
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biobanking(112,132). Moreover, there seems to be a far too narrow understanding of the concept of 
IPRs in the academic debates on biobanking. After all, IPRs are not only about the protection of 
private interests. The underlying rationales of intellectual property intend in fact to stimulate innovation 
and to promote technology transfer under fair conditions. The debate on IPRs and biobanking is 
furthermore often narrowed down to patent rights, while several other types of IPRs could be relevant 
for biobanking. Another misconception is that “IP might not be so relevant for biobanks” and would 
only constitute a hurdle for access to biobanks.  
Against this background, the paper aims to provide an overview and analysis of the most relevant 
IPRs in biobanking. It further discusses the risks and opportunities associated with the identified IPRs 
for an effective use of biobanks in translational research and innovation. In pursuing this goal it will 
often be necessary to distinguish between different types of biobanks. Different types of biobanks 
exist, depending on their design and purpose, as well as on the perspectives of multiple stakeholders. 
We decided to focus on biobanks collecting human samples.91 We therefore define for the purpose of 
this paper “a biobank” as “an organized collection of human biological materials and associated 
information stored for one or more research purposes”(26).92 
To achieve our objectives, we first identify the types of IPRs that we consider as most relevant in 
relation to ‘access to biobanks’. We also briefly describe the basic requirements and rationales for 
receiving IP protection. We then define potential right holders and ownership options, and explain the 
legal effects of the protection granted.  
Section 2 specifies potential challenges in finding a balance between an open and a close 
collaboration model. We elaborate on possible tensions between the exclusive nature of IPRs and 
obligations posed by funding agencies and “open innovation” partnerships to share the results from 
research on and with biobank material and data. Moreover, we discuss how rights of donors or 
patients may influence the possibility to obtain IPRs on technologies developed with biobank material 
and data. 
Taken into account the above, section 3 will analyse and discuss potential strategies and options to 
stimulate the exchange of HBM, data and research results. It will also look into the question of how to 
address, govern and manage IPRs directed to biobank material and data. We investigate in more 
detail if, and under which conditions, a biobank could/should become co-owner of upstream and 
downstream IPRs. 
This will ultimately allow us to draw conclusions in section 4.  
                                                       
91 These can be distinguished by various categories depending on purpose and design. They include i.a. 
population-based biobanks, disease-oriented biobanks, case control biobanks, tissue biobanks and biobanks for 
clinical trials. These basic categories can be divided into specific sub-groups, such as stem cell biobanks, tumour 
biobanks or cord-blood banks.   
92 Note that collections of non-human material, such as plant, animal, microbe, environmental, may also be 
described as biobanks but this is less relevant for the purposes of this paper. For a more detailed and generally 
applicable definition of biobanks cf. (6). 
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2 Different IPRs relevant for access to biobank 
2.1 Definition, nature and different forms of intellectual property rights 
Previous debates on IPR and biobanking often started from a narrow focus of the concept of IPRs. 
Some authors limited their analysis to patent rights, while several other types of IPRs could be 
relevant for biobanking. After all, the term ‘intellectual property rights’ (‘IPRs’) is used to describe 
several distinct (exclusive) rights that are granted to creators of intellectual creations, i.e. creations of 
the mind, such as a scientific article or an invention(110). Other IPRs that can be relevant in the 
biobank context are copyright, sui generis databases protection (in Europe), trade secrets, trademarks 
and data exclusivity.  
Previous publications almost exclusively focused on the potential negative impacts and risks of IPRs 
for biobanking. They do not take into consideration that IPRs can be used/exercised in many different 
ways. An IPR can be described as a negative right to prohibit others from using a protected creation 
without the authorization of the IPR holder. However, IPRs can also be used to protect and balance 
the interests of the different parties involved. Several studies confirmed that IPRs are often not 
exercised in a manner that prevents others from using IPR-protected creations to develop new 
technology or knowledge(132). In some cases (see hereunder) IPRs holders grant third parties the 
right to use their creations under reasonable (market) access fees and conditions. 
Several authors focus on the distinction between the ‘closed/exclusive’ IP world and ‘open/shared’ 
biobank world(131). However IPRs are not only about the protection of private or commercial 
interests. In fact, IPRs are granted as incentives and rewards to authors and inventors that develop 
new products or intellectual works that may benefit the society as a whole(110). It allows them to 
recover their development costs(133).  
Finally some feel that negotiations on IPRs form an additional hurdle(16,134). Although negotiating 
about IPRs can take some time, it can still be worthwhile to have clear contractual arrangements on 
how to manage IPRs that could arise from the use of HBM and data in research projects. This could 
avert situations where biobanks, funders or researchers are no longer allowed to use research results 
or analyses carried out using HBM and/or data that are stored in publicly funded biobanks. 
Furthermore clear contractual arrangements on IPRs could avert further discussions or litigation 
between different actors that provided a significant contribution to creations that can be protected by 
IPRs(134). 
The relevance of particular IPRs depends on the particular phase in the ‘lifetime’ of a biobank(134). 
During the creation phase, the biobank sets up the necessary infrastructure, such as technical 
equipment and software, and databases to store HBM and data. The biobank develops policy 
documents and templates, operational procedures and often uses a particular name or logo for its 
identification. Websites may be created as well as online tools for applicants or managers to 
communicate with the biobank. During the collection phase human biospecimen and data from 
different resources are collected and arranged – according to certain (selection) criteria – in a biobank 
and/or database. Often HBM are further processed (e.g. DNA extraction from blood samples) 
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according to certain protocols. Software may be developed to conduct and analyse interviews with 
participants and to process the collected data(16). Researchers that are interested in some of the 
collected HBM and data can apply for access to the collection (access phase). Once the application 
for access has been approved, the applicant/researcher can use the HBM and data in a research 
project (research phase). Finally the use of the HBM and data in the research project may lead to 
products or services, such as new diagnostic tests, therapies or medicine (valorisation phase) (16). 
This chapter focuses on the so-called ‘access phase’. 
2.2 Copyright protection 
Copyright protection is offered to literary and artistic creations (art. 2 of the Berne Convention93), such 
as scientific and technical texts, reports, images, software, the "look and feel" (appearance/design) of 
a database or the content and form of a website. Creations are only protected by copyright if one can 
demonstrate that the creation is original, i.e. it bears the personal stamp of the author and draws from 
the intellectual effort of the author(135–137). This implies for instance that the design of the database 
should not be merely determined by functional features, such as the organization per type of HBM or 
data. It should not merely contain a list of factual information without a special manner of organizing or 
representing the information(137). Copyright furthermore does not offer protection to an idea in itself, 
but only to the concrete expression/form of the idea. If an idea can take shape in various ways, it is 
only the concrete expression of the idea that is protected under copyright(136,137). 
During the access, research and valorisation phase, copyright could be held in relation to the 
appearance or design of the database of HBM and data(137) or the website94 that provides virtual 
access to the collection of HBM and/or data. One can furthermore hold copyright in relation to data 
and publications that result from the use of HBM and/or data used in the framework of a research 
project. Copyright protection allows the custodian of the biobank to decide who has access to the 
collection of HBM and/or data and to which extent a third party could use a similar structure to 
represent its collection. 
If a biobank or elements within the biobank are protected by copyright, the ‘custodian’ of the biobank 
could prohibit third parties from copying those elements that are protected by copyright(137). In case 
the biobank would allow a third party to use those elements, it has the right to require the third party to 
make reference to the original creator of those elements. The copyright holder cannot however 
prevent a third party from reproducing or communicating (part of) the creation for the sole purpose of 
illustration for teaching or scientific research. 
 
 
                                                       
93 Berne Convention for the Protection of Literary and Artistic Works of September 9, 1886 
94 A sui generis data base right, as explained hereunder, could protect the investment in the content of the 
database. 
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Copyright protection is obtained from the moment the creation is disclosed and does not require the 
fulfilment of any formalities or any registration. The protection in principle continues for 70 years after 
the natural person (/author) is deceased (art 2 of the EU Directive on the term of protection of 
copyright and certain related rights95)(136,137).  
2.3 Sui generis data base protection 
In the European Union the investment in the content of a database (in other words the data in the 
database) may be protected by a special "database right"(136,137). Some argue that collections of 
HBM that are organized in a systematic or methodical way, could be considered as a database as 
defined in article 1, § 2 of the Database Directive (131,137).  
One should furthermore demonstrate that a substantial investment - in money, time, effort or energy - 
has been made to obtain, verify or present the content of the database (art. 7 of the Database 
Directive). This investment must relate specifically to the creation of the database and cannot take into 
account the investments made in order to create the data. It is important to remember that database 
rights do not provide any protection for the creation of the elements included in the database. The 
protection only relates to the investment made in the acquisition and collection of the data(136,137).  
During the access phase, the biobank can invoke its sui generis database rights to determine the 
conditions applicable to access and use of the collection of HBM and data. It can use its right to only 
allow access to applicants that successfully submitted an application for access to the collection. The 
biobank can ensure that applicants initially only obtain access to evaluate the usefulness of the 
collection for the research project and subsequently to use the HBM and data within the scope of the 
access applications. Applicants can be prohibited from extracting substantial parts of the biobank to 
create their own collections of HBM and data (136,137).  
Different parties that invested or contributed to the establishment and development of the database 
could claim simultaneously sui generis rights on the whole or parts of the biobank(137). These parties 
could be the funders, the persons and institutions that establish and operate the database, but also 
individual researchers or clinicians that made a substantial contribution to the collection of HBM and 
the collection and/or generation of data stored in the database(129). That is why it may be important to 
have clear arrangements on whether and under which conditions different concerned parties could 
hold sui generis database rights and how the different stakeholders will be able to use the collection of 
HBM and data(119,137).  
The protection of the sui generis database right starts from the date when the database is completed 
or made publicly available and does not require the fulfilment of any formalities or any registration. The 
protection continues for a period of 15 years (art. 10 of the Database Directive). Whenever the 
database is modified in a substantial way and this modification requires a substantial investment, a 
new term of 15 years starts for the new form of the database. Biobanks could theoretically enjoy an 
                                                       
95 DIRECTIVE 2006/116/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 12 December 2006 
on the term of protection of copyright and certain related rights 
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eternal protection, since the collections of HBM and data periodically undergo substantial updates 
(136,137). 
2.4 Trademarks 
Trademark protection could be obtained for the following signs: (a) a word or combination of words 
(slogans, domain names or the name of a company, a product or a service, etc.); (b) drawing, figures, 
shapes, smells and even sounds (art. 2 of the EU Trademark Directive96). 
The biobank could register the name, the logo or the slogan of the biobank or its products or services 
as a trademark(131). The biobank could also register a trademark in relation to the name or the logo 
of the database or software it developed. The UK Biobank is an example of this. It registered the name 
“UK Biobank” and the logo of the biobank as trademark for amongst others scientific, technological 
and medical services, research in the fields of medicine and the design and development of computer 
hardware and software97.  
Trademark protection can only be obtained for signs that fulfil a number of conditions (art. 3 of the EU 
Trademark Directive). First it has to be demonstrated that the sign can be represented graphically. 
Since it is difficult to provide a graphical representation of a smell, few trademarks are obtained in 
relation to such ‘sign’. Furthermore, the sign must have a sufficient distinctive character. This implies 
that the sign must be appropriate to distinguish the goods or services of a particular undertaking 
compared to those of other undertakings. The sign should not merely describe the goods or services 
for which the trademark is requested. Thus, one can obtain a trademark registration for the word 
"apple" in relation to computers, but not for the fruit apple. 
Trademark protection requires a successful application to a national or regional trademark office (such 
the (European) Office for Harmonization in the Internal Market ("OHIM") or the International Bureau of 
the WIPO. Such trademark office will evaluate whether the concerned sign fulfils the requirements to 
be registered as a trademark. The applicant has to indicate in the trademark application the goods or 
services for which he/she wishes to obtain trademark protection(136) (138). 
During the access, research and valorisation phase, the biobank could invoke its trademark rights to 
oblige the researcher to explicitly mention the name, logo or slogan whenever the goods or services of 
a biobank are used. It could also oppose the use of its trademark for goods or services that are not 
provided by the biobank (art. 5 of the EU Trademark Directive). 
The biobank cannot in principle oppose the use of an identical or similar trademark, if such use is 
necessary to indicate the intended purpose of the goods or services (art. 6 of the EU Trademark 
Directive). For example, it is unlikely that the UK Biobank could oppose the fact that another biobank 
in the United Kingdom would describe its biobanks using the terms ‘UK’ and ‘Biobank’ in combination 
with another sign, such as the UK DNA Biobank.  
                                                       
96  DIRECTIVE 2008/95/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 22 October 2008 to 
approximate the laws of the Member States relating to trade marks 
97 See: http://www.trademarkia.com/uk-biobank-77806660.html and http://www.trademarkia.com/biobank-uk-
77806839.html (last consulted on 10 December 2014) 
IPRs and biobanking 
Page | 122  
 
The registration of a sign as trademark offers a protection of 10 years starting from the moment of the 
application or registration of the concerned sign (art. 46 of the Community Trademark Regulation). 
However, the trademark registration may be renewed for unlimited periods of 10 years and thus the 
trademark protection could in principle be obtained for an indefinite period of time. 
2.5 Trade secrets 
The protection of trade secrets can be considered an important and complementary tool to protect 
information, ideas and knowledge that required substantial investments.  
The way of establishment or operation of a biobank could have an important impact on the quality of 
the HBM, associated data and the services provided by the biobank. It could therefore be considered 
a valuable trade secret, Trade secrets could for instance relate to the (systematic) approach chosen to 
collect, store, label, process and track HBM and data or to the algorithm used to analyse data 
collected in the framework of the biobank. The biobank could also hold trade secrets in relation to 
standard operating procedures and protocols, digital templates, working models and construction of 
databases.  
Biobanks may have invested considerable amounts of time and funds in such trade secrets and may 
want to avoid that a third party could simply copy and apply them. Researchers that access collections 
of HBM and data could be requested to commit themselves to respect the confidentiality of the trade 
secrets developed by the biobank. A third party would not only have to copy the database content or 
structure or software, but would also need access to certain confidential knowhow or information to 
establish and operate the database or software in an optimal manner. In this respect, trade secrets 
could offer an additional protection of databases or software developed by the biobank. 
Currently no harmonized definition of a ‘trade secret’ exists. Nor does the European Union have a 
harmonized protection system for trade secrets. The member states of the European Union offer 
different levels of protection via different legal instruments, such as unfair competition, contract and 
criminal laws.  
In November 2013 the European Commission published a proposal of EU “Directive on the protection 
of undisclosed know-how and business information (i.e. trade secrets) against their unlawful 
acquisition, use and disclosure”(139) (hereafter Proposal Directive). On 26 May 2014, the Council of 
the European Union published a modified text of the Proposal Directive (140). The Proposal of 
Directive suggests a harmonized definition of trade secrets information, in particular information that 
meets 3 requirements: (a) is secret in the sense that it is not, as a body or in the precise configuration 
and assembly of its components, generally known among or readily accessible to persons within the 
circles that normally deal with the kind of information in question; (b) has commercial value because it 
is secret; (c) has been subject to reasonable steps under the circumstances, by the person lawfully in 
control of the information, to keep it secret (art. 2, §1 (1)).  
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The future directive would also protect compilations of publicly available information that is combined 
in such a manner that it becomes commercially valuable and is not yet known within the concerned 
sector (art 2, § 1 (1) (a)). One could for instance think of combining characteristics of different known 
manufacturing process to optimize the production of a certain product. 
Trade secrets are only protected as long as they remain secret. Once the underlying information is 
publicly available, anybody can use the knowhow or information (110). 
Protection is only offered to trade secrets that have a certain commercial value (art 2, § 1 (1) (b)) and 
not to information that is trivial, vague or publicly available(133). The trade secret holder does not, 
however, have to demonstrate that the trade secret constitutes an innovative step or is novel or 
original.  
The person or organization that claims protection of its trade secrets has to demonstrate that it has 
taken reasonable steps to protect the confidentiality of the trade secret (art 2, § 1 (1) (c)). Such 
reasonable steps could consist of ICT protection of confidential information or confidentiality 
agreements (i.e. non-disclosure agreements) with third parties that need to have access to the trade 
secrets.  
Trade secrets offer protection for knowhow and business information that cannot be protected by 
IPRs. This could, for instance, be an invention that does not fulfil the requirements to obtain patent 
protection, in particular novelty, inventive step or industrial application (110)(133). The application of 
an existing technology in a new sector could constitute a trade secret, even when such application 
seems obvious.  
Trade secrets also protect knowhow or information that is not described in a patent application but that 
remains secret and is crucial to optimize the use of an invention. Patent holders often decide not to 
disclose such knowhow or information in the patent application because this would enable other 
parties to use the knowhow or information after the expiration of the patent. The patent application 
needs to contain sufficient information to be able to ‘enable’ the invention (Art. 84 of the EPC), but it 
does not need to contain all information necessary to apply the invention in an optimal manner.  
One of the advantages of trade secrets is that the protection can in principle last in perpetuity, while 
other conventional types of IPRs – except for trademark rights – offer protection for a limited period or 
time. However, the protection stops as soon as the information, protected by the trade secret, 
becomes publicly available or looses its commercial value (110,141). 
Trade secrets provide protection without the fulfilment of any formalities or registration at an official 
authority. The costs to register, maintain and defend other types of IPRs – such as patents – can be 
quite substantial. Trade secret protection however, does not require any additional investment(141). 
One could consider the possibility of depositing a text describing the trade secret at a notary or for 
instance in an i-DEPOT at the Benelux Office for Intellectual Property98 (110). This would enable the 
                                                       
98 www.boip.int 
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trade secret holder to prove in a future conflict the existence of the trade secret and the date when the 
trade secret was developed and described. However, depositing a trade secret does not grant the 
trade secret holder any exclusive rights. 
Article 3 of the Proposal Directive defines the unlawful acquisition, use and disclosure of trade secrets. 
The acquisition of trade secrets is considered unlawful when carried out without the consent of the 
trade secret holder. This could happen by: (a) unauthorised access to, copying or appropriation of any 
documents, objects, materials, substances or electronic files containing the trade secret or from which 
the trade secret can be deduced; or (b) any other conduct which, under the circumstances, is 
considered contrary to honest commercial practices (art. 3, § 2).  
The use or disclosure of a trade secret shall be considered unlawful whenever carried out, without the 
consent of the trade secret holder, by a person who (a) acquired the trade secret unlawfully; or (b) is in 
breach of (i) a confidentiality agreement or any other duty to maintain the secrecy of the trade secret; 
or (ii) a contractual or any other duty to limit the use of the trade secret (art. 3, § 3). The acquisition, 
use or disclosure of a trade secret shall also be considered unlawful whenever a person, at the time of 
acquisition, use or disclosure, knew or should have known that the trade secret was obtained directly 
or indirectly from another person who was using or disclosing the trade secret unlawfully (art. 3, § 4). 
Finally the production, offering or placing on the market and the import, export or storage of infringing 
goods is considered unlawful, when a person carrying out such activities, knew or should have know 
that a trade secret was used unlawfully. 
Article 4 (1) of the Proposal Directive provides a number of exceptions. The acquisition of trade 
secrets shall be considered lawful when the trade secret is obtained by: (a) independent discovery or 
creation; (b) observation, study, disassembly or test of a product or object that is publicly available or 
that it is lawfully in the possession of the acquirer of the information (i.e. reverse engineering); (c) any 
other practice which, under the circumstances, is in conformity with honest commercial practices. The 
independent discovery or creation of product that contains the trade secret is thus not unlawful. One, 
however, has to demonstrate the independent and lawful nature of the discovery or creation.  
Article 4 (2) of the Proposal Directive contains another exception. The alleged acquisition, use or 
disclosure of the trade secret will not be punishable, if such activity is carried out in any of the 
following cases: (a) for making legitimate use of the right to freedom of expression and information; (b) 
for the purpose of revealing an applicant’s misconduct, wrongdoing or illegal activity; (c) the trade 
secret was disclosed by workers to their representatives as part of the legitimate exercise of their 
representative functions; (d) for the purpose of protecting a legitimate interest. The possibility to 
acquire, use or disclose trade secrets in the framework of the right to information could lead to some 
conflicts. Think of someone using the right to freedom of expression to acquire access to data 
submitted to regulatory authorities in the framework of the registration of medicinal products. 
Trade secret protection relates to the content of the protected information, knowhow or idea. It does 
not relate to the way the trade secret is expressed. The trade secret holder, therefore, cannot only 
object to the use of identical drawings or designs, but also to drawings or designs that represent the 
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same information or knowledge(141). The trade secret holder cannot, however, object to the fact that 
a third party would develop independently identical production process or algorithms(141). 
2.6 Patents  
In Europe, the four essential pre-conditions governing the patentability of inventions under the 
European Patent Convention (EPC) are laid down in Article 52(1) EPC. It reads: ‘European patents 
shall be granted for any inventions, in all fields of technology, provided that they are new, involve an 
inventive step and are susceptible of industrial application’. Thus, in a first step, in order to be 
patentable, there needs to be an invention. Thereafter, that invention has to fulfil the patentability 
requirements of novelty, inventive step and industrial applicability. Article 53 EPC stipulates that “no 
European patent shall be granted in respected of inventions (in case) the commercial exploitation of 
(such invention would be contrary to "ordre public" or morality”99. 
The concept of ‘invention’ as such is not defined in the EPC. The Implementing Regulations to the 
EPC however, do specify that the invention must have a technical character (Rule 29(1)), that is 
related to a technical field (Rule 27(1)(a)) and concerned with a technical problem (Rule 27(1)(c)). It is 
clear from these rules that ‘technicality’ is a key precondition for qualification as a patentable invention 
in Europe(110).  
Article 52(2) EPC lists exclusions which should not be regarded as inventions, if claimed ‘as such’ 
(Article 52(3) EPC), because they are abstract in nature (discoveries) or non-technical in nature 
(scientific theories or methods for performing mental acts). In Europe, whether products or processes 
identified in the context of biobanking are to be regarded as inventions eligible for patent protection, or 
whether they are discoveries or principles of nature and thus excluded from patentability, depends on 
the technical character related to the claimed subject matter. There must be something more than 
mere disclosure of a natural phenomenon(110).  
Statutory, any “biological material isolated from its natural environment or produced by means of a 
technical process, may be the subject of an invention even if it previously occurred in nature” (Art. 3 
Biotechnology Directive 98/44/EC). For human genes, the industrial applicability of the invention, 
meaning its function, needs to be disclosed in the patent application (Art. 5 Biotechnology Directive 
98/44/EC). Thus, in principle, a cell or gene could become patentable as soon as some human 
intervention is needed to isolate such cell or gene from its natural environment by any technical means 
and as soon as the cell or gene (accompanied by its function) can be properly characterized by either 
the process by which it is obtained (product-by-process), by its structure or other means (110). 
Furthermore, processes of manipulating HBM (such as isolation, characterisation or storing) may be 
patentable inventions. Under European law, only a very thin line separates inventions from 
discoveries.  
                                                       
99 We will not go deeper into this exception, since this chapter is focused on access to biobanks and not on the 
commercial exploitation of inventions. The thesis of Sarah Panis (110) studied this issue in detail in relation to the 
patentability of stem cells. 
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Therefore, it is useful to investigate the second and third very important patentability requirements, 
namely novelty and inventive step. These are of high relevance for cells and genes of human origin. 
An invention can be patented only if it is new and involves an inventive step. An invention is 
considered to be new if it does not form part of the state of the art (art. 54 EPC). In other words, if the 
cells or gene as claimed in the patent have never been isolated or produced before. An invention is 
considered as involving an inventive step if, having regard to the state of the art, it is not obvious to a 
person skilled in the art (art. 56 EPC). The literature with respect to cells and genes is enormous and 
this makes it more and more difficult to demonstrate that a particular cell or gene is new or involves an 
inventive step.  
HBM – as such – could be considered natural products isolated from the human body. Hence, most 
HBM – such as blood or sperm that has not been the object of a technical process (110) – stored in 
the biobank would probably not be the object of patent rights. Patent rights have been granted both in 
Europe and the US in relation to (isolated) DNA, stem cells and – most importantly – methods and 
particular applications useful in diagnostics and personalized medicine(110). Nonetheless, the 
granting of such patent rights remains much debated(142,143). A biobank could acquire patent rights 
in relation to innovative technology or equipment developed for the improved collection, labelling, 
processing, storage, tracking and retrieval of HBM and data(16), as well as for data analysis and 
presentations(144). The use of HBM and data from the biobank in the framework of a research project 
could result in patentable inventions further downstream(129). Patent rights will in principle not be 
granted in relation to the data resulting from the research project, as such. They will only be granted 
for an application of such data such as a genetic tests or a new biomarker. Patents may be applied 
for, for modified HBM such as differentiated stem cells, or isolated genetic sequences or methods to 
generate modified HBM. Granting a patent in relation to modified HBM could limit the possibilities to 
commercialize data, products or services that are developed on the basis of such patented HBM(145). 
A biobank will only be able to claim patent rights, if it demonstrates that it made an essential 
contribution to the invention. The mere provision, selection and/or processing of HBM and data will 
probably not be enough to demonstrate such inventive contribution.  
One can only obtain patent protection after a patent application has been submitted to a competent 
patent office that evaluates whether the conditions are fulfilled to obtain patent protection. 
A supplementary protection period for the product covered by the basic patent may be requested for 
medicinal products with a marketing authorization and a patent for the active medicinal substance100. 
The supplementary protection will last maximal five extra years.  
  
                                                       
100 REGULATION (EEC) NO 1768/92 OF THE COUNCIL of 18 June 1992 concerning the creation of a 
supplementary protection certificate for medicinal products 
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2.7 Regulatory data exclusivity  
Many of the costly steps involved in biomedical research or pharmaceutical R&D are either not 
patentable by their nature or very likely to be invalidated in patent challenges. When the conduct of 
clinical trials has taken a considerable amount of time, the remaining patent protection period is 
sometimes also rather limited. Therefore, the European system provides for various forms of 
additional protection. Some of these types of protections are linked to the previous existence of 
patents, such as supplementary protection certificates (SPCs). Other forms of protection are 
completely independent from patents. These are, for instance, the protection of clinical test data 
through regulatory data exclusivity, regulatory market exclusivity or trade secrets. A detailed 
comparative analysis of the available types of regulatory exclusivities in Europe falls outside the scope 
of this paper. Instead we will briefly describe their most basic general features. This will allow us to 
ultimately discuss their relevance for biobanking. 
2.7.1 Basic characteristics of regulatory data exclusivities in Europe and in the US 
The EU rules governing regulatory exclusivity changed in 2005. The (new) Directive 2001/83/EC101 
and Regulation (EC) No 726/2004102 adopted the so-called "8 + 2 + 1" year rule. According to this 
approach, data exclusivity applies during the first 8 years from the grant of the innovator company's 
marketing authorization. Following the expiration of the first 8 years period, a generic company may 
start to cross-refer to the pre-clinical and clinical trial data of the originator in their regulatory 
applications. The data exclusivity period is followed by a 2-year market exclusivity period. Therefore, 
generic competitors still cannot market their product for another 2 years. Following the period of 10 
years (8+2) from the grant of the innovator company's marketing authorisation, the generic company 
may also market their product. This is, provided that the innovator product does not qualify for a 
further one year of market exclusivity. This additional 1-year protection could be granted in a number 
of circumstances. There exists for instance a 1-year additional market exclusivity for a new therapeutic 
indication for the relevant medical product that brings significant benefit in comparison with existing 
therapies (Art. 14(11) Reg. (EC) No 726/2004).103 An additional 1-year data or market exclusivity may 
be available for a new therapeutic indication of a well-established substance, provided that significant 
pre-clinical or clinical studies were carried out in relation to the new indication (Art. 10(5) Dir. 
2001/83/EC). An additional 1-year of data or market exclusivity may be available for a change in 
classification of a medicinal product on the basis of significant pre-clinical tests or clinical trials (Art. 
74(a) Dir. 2001/83/EC). 
                                                       
101 DIRECTIVE 2001/83/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 November 2001 
on the community code relating to medicinal products for human use, Official Journal L – 311, 28/11/2004, p. 67 – 
128. 
102 REGULATION (EC) NO 726/2004 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 31 March 
2004 laying down Community procedures for the authorisation and supervision of medicinal products for human 
and veterinary use and establishing a European Medicines Agency (Text with EEA relevance) (OJ L 136, 
30.4.2004, p. 1). 
103 For initial MA applications submitted after 20 November 2005 and authorisation of new indication within 8 
years. 
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In addition to the 8+2+1 regime, the European system recognizes specific sui generis forms of 
protection. These aim specifically at fostering the development of specific inventions and applications 
that are useful for the treatment of children (paediatric extensions) or very rare diseases (orphan 
drugs). These may encompass dosage regimes useful for paediatric applications under Regulation 
(EC) No 1901/2006104 (e.g. 6 months SPC extensions) and strong marketing exclusivities (10-12 
years) for orphan drugs and paediatric orphan drugs under Regulation (EC) No 141/2000105. 
2.7.2 The relevance of regulatory exclusivities in biobanking scenarios 
An increasing importance is given to regulatory exclusivities for innovation policy debates. It appears 
important that biobank operators are aware of the significance of these special “late stage” IP rights 
and that they address them accordingly in their guidelines and set-up. Public biobanks may not be 
directly involved in clinical trials and MA procedures. They should however carefully consider potential 
conflicts with guidelines requiring commercial users to return to the biobank research data that is 
derived from downstream research or clinical trials conducted with the biobank samples. It could be 
the intention of the relevant biobank to make the returned (clinical trials-) data publicly available to any 
subsequent users of the relevant biobank samples. If this subsequent user then intends to also apply 
for MA approval of a generic drug or wants to cross-reference to existing pre-clinical or clinical data, 
the medicine authorities may not accept such references due to data exclusivity. Or in other words, 
data exclusivity rules could undermine the primary goals of a given biobank and its internal guidelines. 
Biobanks and biobank organization should therefore carefully monitor new developments with regard 
to regulatory (data) exclusivity. 
3 Challenges in finding a balance between an open and a closed collaboration model 
3.1 General  
Large biomedical research projects depend on access to large amounts of HBM and data. That is why 
it is crucial to stimulate the exchange of HBM and data among the different members of the scientific 
community and biobanks. A number of challenges today still hinder access to large amount of HBM 
and data.  
Although collections of HBM and data are considered fundamental research tools, we would argue 
that biobanks receive insufficient recognition for their investments and efforts. Little recognition is 
granted to purely technical contributions to research projects, such as the collection and provision of 
HBM and associated data. Guidelines of the International Committee of Medical Journal Editors and 
the Committee on Publications Ethics only grant authorship to research that participated in “drafting 
the article or revising it critically for important intellectual content” and “the final approval of the version 
                                                       
104 REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 12 
December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 
2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance), OJ L 378/1, 
27.12.2006. 
105 REGULATION (EC) No 141/2000 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 
December 1999 on orphan medicinal products, OJ L 18/1, 22. 1. 2000. 
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to be published” (ICMJE, 2009). The provision of HBM or data for a research project is not considered 
a sufficient ground to grant authorship. In some cases however, biobanks made important 
contributions to research projects via the collection, processing and organization of unique collections 
of HBM and data. We would argue that the biobank should be recognized for such 
contribution(106,112).  
Biobanks could have an interest in becoming more than merely providers of HBM and data. When 
biobanks only supply HBM and data, they receive a one-time payment fee that most likely does not 
cover all costs invested by the biobank in the collection of HBM and data. If biobanks would participate 
in research projects, they could use the results of the research project to enrich their collections. They 
could contribute to the analysis and interpretation of research results. They could provide know how 
and expertise in relation to, for instance, the specific type of HBM and data that is required for a 
particular research project. Their expertise could be used to evaluate the statistical relevance of a 
certain amount of HBM and data to demonstrate a research hypothesis. Biobanks can create 
selections of HBM with specific characteristics for a research project and can collect additional HBM or 
data during the research project.  
Biobanks, funding agencies, ”open innovation” partnerships and journals increasingly require 
researchers to share the data and results of their research with other researchers. They are 
increasingly required to deposit them into publicly accessible repositories(115,146,147), such as 
dbSNP106 in the US and the European Genome-phenome Archive (‘EGA’)107. This makes it possible to 
maximize the use of results of publicly funded research and to learn from and build on previous 
research. It reduces occurrences in which HBM and resources are spent on research projects that 
repeat existing research. Sufficient funding needs to be provided to guarantee the optimal storage and 
the security of the research results. Funding is also needed to be able to make the research results 
publicly available or share them with other researchers. Furthermore, biobanks, funding agencies and 
“open innovation” partnerships need to recognize the possibility to postpone the sharing of data during 
a reasonable period of time. They need to allow the initial researcher to publish the data or research 
results or to claim intellectual property rights in relation to such data or research results. The fact that 
one would claim intellectual property rights on research results does not preclude that the right holder 
could make the research results available under reasonable access conditions and fees.  
Today biobanks often still depend on individual researchers or principal investigators for the collection 
of HBM and/or associated data. Empirical studies suggest that researchers are reluctant to share the 
HBM and data, which they collected(112,132). Some perhaps fear loosing control, once they transfer 
the HBM and data to the biobank. They made important investments – both in financial and human 
resources – in the collection, storage and processing of HBM and data and they perhaps feel that the 
collection of HBM and data might not exist without their contribution. The individual researchers may 
                                                       
106 dbSNP collects discovered simple genetic polymorphisms and is maintained at the National Center for 
Biotechnology Information (NCBI), a division of the United States National Institutes of Health. 
107 The European Genome-phenome Archive (EGA) is a service for permanent archiving and sharing of all types 
of personally identifiable genetic and phenotypic data resulting from biomedical research projects. 
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have concerns regarding the possibility to continue their own research projects or to maintain the 
priority to publish research results(112) if they no longer can decide on the use of the HBM and data. 
That is why they could desire to be involved or consulted in the decision which future research 
projects can use “their” HBM and data(112). Funding agencies could require researchers to 
demonstrate that they will have access to the necessary HBM and data to be able to conduct the 
research project. This shows that access to HBM and data could also have an influence on the 
funding possibilities. Some have also argued that researcher acquire a certain academic reputation or 
prestige from the HBM and data which they collected(148). Finally collectors may worry about the 
confidentiality and security of the personal data of the donors(112). Some authors suggest developing 
additional and improved mechanism to share HBM and data between researchers and biobanks(132). 
Individual researchers would perhaps be more willing to share HBM and data, if they receive 
recognition for their contribution – for instance in the form of co-authorship – and a compensation of 
their investments.  
3.2 Challenges specifically related to intellectual property rights on HBM 
The comparative analysis of access arrangements – reported in Chapter 1 – revealed that the large 
majority of biobank initiatives do not have any policy in relation to upstream and downstream IPRs 
(83,149). Biobanks could hold upstream IPRs, such as sui generis database rights and/or copyrights 
in relation to their collection of HBM and data. Additionally, they could receive trade secret protection 
on their know how in relation to the collection, storage and processing of their HBM and data. Such 
IPRs could be a tool for the biobank to receive recognition for the important investments it made in the 
collection of HBM and data. It may be a way for them to recover some of its investments. 
Some authors argued that biobanks should not be involved in downstream IPRs, i.e. IPRs on 
creations that accrue from the use of HBM and data in research projects. They argue that biobanks 
could only hold or participate in downstream IPRs, if the biobank made an intellectual or scientific 
contribution to the results of the research project. Today, this very often would not be the case(16). 
However, it has been argued above that biobanks could be entitled to a proper recognition for their 
“non-intellectual contributions” to research projects. Others argue that the participation of biobanks in 
downstream IPRs could hinder access to HBM and data because the biobank and the researchers 
would have to negotiate about the participation of both parties in downstream IPRs(134). 
Even when a biobank decides not to be involved in downstream IPRs, this does not imply that it 
should not have any policy on such IPRs. Biobanks could make access to publicly funded collections 
of HBM and data conditional. They could include the obligation to allow the biobank or other 
researchers to use the downstream IPRs under reasonable access conditions and fees. Some authors 
have argued that such obligations could have a negative impact on the willingness to invest in 
research and the development of new applications(150). Researchers who use HBM and data to 
develop new health care applications made considerable investments to create such applications. 
They could be reluctant to make these applications available. They perhaps feel that the provision of 
HBM and data by the biobank does not justify a right to use such applications(134). Furthermore, 
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researchers use HBM, data and research tools from many different resources. Granting everyone the 
right to use the application would make its exploitation unnecessary complicate(150). 
Biomedical researchers, clinicians and legal scholars debated many years on whether intellectual 
property rights should be granted on HBM or data derived from such HBM, such as stem cells, human 
genes, biomarkers or genetic diagnostics test (110,151,152). The discussion included the question 
under which conditions such IPRs should be allowed. Some argue that HBM, as such, is a product of 
nature that should be freely accessible to everybody and should not be the object of exclusive rights. 
The mere discovery of, for instance, a certain DNA sequence with interesting features does not 
constitute an intellectual contribution. Others argue that IPRs on HBM, such as patents, are essential 
for the survival of the biopharmaceutical industry. They defend that such IPRs would stimulate the 
development of products, therapies and tests based on HBM and derived data, such as diagnostic 
methods and therapeutics (110) (150,153,154). However, if the scope of protection offered by IPRs is 
too broad, IPRs could prevent or make it more difficult for others to develop new products, services or 
technologies, such as diagnostics test or research tools, cell lines or stem cells, …(112,148,150) 
(110). There also exists controversy about the excessive nature of IPR monopolies and/or restrictive 
licensing policies(155). A right holder could exercise its IPRs in such a way that it does not only claim 
exclusive rights in relation to the product, services or methods protected by its IPRs. The same right 
holder could extend his claims to other products, services or methods of which it may be doubtful if 
they are effectively protected under the concerned IPRs. Such use of IPRs creates a legal uncertainty 
as to whether certain products, services or test can be developed, produced or used without the 
permission of the right holder. A right holder can also require the fulfilment of unreasonable conditions 
or the payment of very high fees to allow the use of products or services protected by IPRs. A famous 
example in this respect is the Myriad Genetics case. Myriad Genetics developed a genetic diagnostic 
test to identify mutations associated with a significant risk of breast cancer and/or ovarian cancer in 
the BRCA1 (breast cancer 1, early onset) and BRCA2 (breast cancer 2, early onset) genes. Myriad 
obtained patent rights on two isolated human genes associated with breast and ovarian cancer 
(BRCA1 and BRCA2) and the genetic diagnostic testing methods. Those patents allowed Myriad to 
prevent other biopharmaceutical companies from developing similar diagnostic tests. It furthermore 
attempted to prevent European and US laboratories from developing and offering diagnostics tests 
that make use of the patented genetic sequences or methods, without Myriad’s consent. Due to the 
exploitation policy of Myriad, the patents have been the object of a very strong debate(152,156,157) 
and have been attacked in legal proceedings. The US Supreme Court decided on 13 June 2013 that 
Myriad could not claim patent rights in relation to – merely – isolated fragments of BRCA-encoding 
genomic DNA. However, the Court did upheld Myriad’s patents claims in relation to cDNA molecules 
encoding BRCA proteins(158). The mere isolation of DNA from the human body is thus not sufficient 
to obtain patent protection in the US(110), while in the European Union such isolation might lead – 
under certain conditions – to valid patent claims on DNA sequences(157). 
Similar controversies arose around patents owned by universities, such as “the University of 
Wisconsin’s human embryonic stem cell patents, the Harvard and MIT’s NF-kB pathway patent, the 
University of Rochester’s patent on inhibition of the COX-2 pathway, and the Johns Hopkins 
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University’s purified stem cell patent” (155). The different cases resulted in a climate where both IPR 
agencies, funding organizations and right holders have become more aware of the possible negative 
consequence of claiming IPRs in relation to HBM and exercising those IPRs in excessive 
ways(132,155).  
However, a number of empirical studies have shown that IPRs on HBM and data may not be the main 
factor inhibiting the sharing of HBM and data (112,132). Other important factors are competition 
between researchers, concerns about the commercialization of HBM and a lack of willingness among 
researchers to share HBM (see above).  
Recital 26 of the EU Biotechnology Directive108 stipulates: ‘when a patent application is filed for an 
invention that is based on HBM or uses such HBM, the person whose body HBM was taken from, 
must have had the opportunity of expressing a free and informed consent thereto’. The lack of an 
informed consent does not, however, have a negative effect on the possibility to obtain a patent or on 
the validity of a patent(110). It is nevertheless advisable to take into account whether the consent of 
the donors or patients provides for the possibility to obtain IPRs on innovations or technologies 
developed with biobank material and data. The initial consent could specify that no IPRs can be 
obtained on the results of the use of HBM or data in a research project. If the consent does not 
stipulate anything in relation to IPRs, the question arises whether this automatically implies that one 
can obtain IPRs on the results of using such HBM and data. This question received quite a bit of 
attention when the direct-to-consumer genetic testing company 23andMe applied for a patent on a 
genetic test developed with data from users of the test. The consent form provided the possibility that 
23andME could obtain intellectual property rights in relation to data collected in the framework of the 
genetic tests. Because 23andME only informed the users only after it had obtained the patent, many 
users of the test felt that their trust had been breached. Many authors have stressed how important it 
is that donors maintain trust in how their HBM and data is used in research. A loss of trust could 
results in fewer persons donating their HBM for research purposes, while biomedical research 
depends on such donations. It seems not enough for the informed consent to provide for the possibility 
to obtain IPRs on research results that accrue from HBM and/or associated data. It seems important 
to inform and consult donors in relation to the commercial use of HBM and data and the possibility of 
obtaining IPRs(155,159). The donors should be informed as to which policy would be applied to allow 
third parties to use the research results and IPRs(144). Such information and consultation should not 
only happen when the donor provides his HBM and data. It should also be applied in later stages, 
since one can often not predict from the start to which extent the use of HBM and/or data in research 
projects could lead to IPRs(129). Sarah Panis furthermore suggests that one could provide the 
possibility for the donor to claim a compensation of his damages, when IPRs were obtained in 
violation of the informed consent(110). 
  
                                                       
108 DIRECTIVE 98/44/EC of the EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 July 1998 on the legal 
protection of biotechnological inventions, Official Journal L 213, 30/07/1998 P. 0013 - 0021 
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4 Potential strategies and options to stimulate the sharing of HBM, data and research results 
This chapter will discuss potential strategies and options to create a right balance between several 
facets that are essential for the creation of research tools and medicinal products and therapies. 
These include facilitating access to HBM and data, promoting scientific openness and incentivizing 
sufficient investments in life sciences (150,160).  
It is important to recognize and protect the interest of the different stakeholders that contributed to the 
collection of HBM and data, such as donors, funders and institutions that establish and manage 
biobanks. However, one should stimulate researchers to use HBM and data and share the results of 
their research as much possible. It is important to take into account their legitimate interests in 
valorising their research results.  
We will discuss a number of possible strategies and options, such as (1) the development of a biobank 
policy on the involvement in downstream and upstream IPRs; (2) the development of biobank policies 
on upstream IPRs held by researchers on research results accruing from use of HBM and data from 
publicly funded biobank; (3) stimulating the sharing of research results; (4) increasing funding for 
maintaining operating collections of HBM; (5) review mechanism to recognize contribution of biobanks 
and collectors to research projects and (6) involve all stakeholders in policies on commercialization, 
IPRs and sharing of non-financial benefits. 
4.1 Possible solutions related to IPRs  
4.1.1 Policy on involvement of biobanks in downstream and upstream IPRs 
There have been a number of examples where IPRs were used in an excessive way that inhibited the 
development of new biomedical products, therapies or tests. This lead to controversy on IPRs on HBM 
and data. However, the mere fact of obtaining IPRs does not automatically imply that such rights will 
be exercised in an excessive way(129).  
Literature contains several examples in which publicly funded institutions exercised IPRs in such a 
manner that stimulated biomedical research and did not hinder access to the scientific advancements 
of such research. Stanford University met with potential users to discuss how it could under 
reasonable conditions provide access to production methods for recombinant DNA protected by patent 
rights. It also decided not to attempt to obtain an extension of those patents right. Stanford University 
filed a terminal disclaimer, which meant that all subsequent divisional applications claiming 
recombinant DNA would expire on the same data as the original patent(161).  
The Association of American Medical Colleges and a number of top universities in the US released 
policy recommendations to promote access to genetic diagnostic technologies(162). The 
Massachusetts General Hospital determined its patenting and licensing strategy in relation to research 
into Huntington’s disease in consultation with the Huntington Disease Consortium(155).  
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A number of reasons could justify the fact that biobanks would become involved in IPR policies. An 
IPR policy could constitute a tool to enhance the acknowledgement and protection of the interests of 
the biobank. It could stimulate the development of biobanks as essential research tools or 
infrastructures(150). It could also provide an additional tool to recover some of the investments of the 
biobank. Furthermore, it may strengthen the bargaining power of biobanks to request applicants to 
feed some of the scientific advancements and benefits back into the biobank and the health care 
system and to share their research results with the scientific community. 
In order to ensure that biobanks maintain public trust and support, it is advisable that a number of 
elements are taken into account in the development of IPR policies. First, biobanks should consult and 
inform stakeholders about their approach and policies in relation to IPRs.  
Second, biobanks should be careful not to exercise their IPRs in an excessive manner.  
IPRs in relation to the database and the software developed in the framework of the biobank should 
not be used to limit access to the collection of HBM and data. It could however allow biobanks to 
control that only those applicants that comply with reasonable and non-discriminatory license 
conditions use their databases and software. It could be used to prevent others from copying their 
databases, technology, and software. Biobanks could also, under reasonable conditions, request 
applicants to allow access to data generated with creations protected by IPRs of the biobank 
(150,155).  
Trademarks could allow biobanks to protect their name and logo. This would allow biobanks to prevent 
others from using the same or similar names for ‘products’ or ‘services’ that are not provided by the 
biobank and that could damage the reputation of the biobank and its ‘products’ and ‘services’. 
The main aim of an IPR policy should not be to generate profit(155). One could, however, charge 
reasonable user fees for the use of the database and/or technology within a biobank. Different users 
fees could be applied depending on whether the database and/or technology are used for commercial 
and non-commercial purposes.  
The policy should contain clear information on which IPRs the biobank could claim in relation to the 
collection of HBM and data and which rights the potential users can hold in relation to his research 
results.  
Unless the biobanks made an important (intellectual or scientific) contribution to the results of a 
research project, biobanks could decide to focus on the protection of their upstream IPRs and not on 
so-called downstream IPRs. Researchers could be hesitant to use HBM and data from a biobank that 
would claim downstream IPRs in an excessive manner.  
Discussions about the desirability of exclusive rights on HBM, as such, could be avoided if biobanks 
would commit themselves to not claim IPRs in relation to basic HBM and basic data and data directly 
derived from such HBM. They could limit their IPRs to their real contributions or added value to 
collections of HBM and data(160). Such added value could consist of the investment made in creating 
high quality databases and software and the knowhow and trade secrets in relation to the optimal 
manner of collecting, storing and processing HBM and data.  
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4.1.2 Policy on downstream IPRs held by researchers on research results accruing from use of 
HBM and data from publicly funded biobank 
A proper policy on downstream IPRs should encourage applicants not to obtain excessive IPRs, but 
should at the same time contain sufficient incentives to innovate(145,150,163).  
The desirability to obtain IPRs is considered in a different way depending on whether the IPRs would 
relate to (a) basic upstream data directly derived from the biobank, (b) basic research tools or enabling 
technologies and (c) downstream clinical applications with potential commercial value at the other end.  
The biobank policy should prohibit users from strategically obtaining IPRs on primary HBM and data or 
upstream data (directly) derived from the collection of HBM and data. For such IPRs could limit the 
possibilities of other applicants to use such HBM and data for commercial purposes(163). 
The scientific community should be able to access and use basic research tools and enabling 
technologies under reasonable and non-discriminatory access conditions. That is why some authors 
suggests that applicants should be encouraged to grant a non-exclusive license to use such research 
tools or enabling technologies to the users of the biobank. In the same line of thinking, the applicants 
could grant the biobank a non-exclusive right to sublicense the tools or technologies to its users. The 
scope of such license could be limited to (a) use in research projects; (b) use by academic institutions; 
or (c) use for internal purpose only. It could explicitly exclude the possibility that a third party would 
valorise or commercialize the concerned research tools. Some suggest that such “so-called grant back 
arrangement” works best for research results that are sufficient upstream, such as genetic sequence 
databases, cell lines and assays(146,150).  
In order to stimulate biomedical innovation, applicant should be given the freedom to obtain exclusive 
IPRs. They should be allowed to commercialize downstream clinical applications or products, such as 
diagnostic tests, therapies and medicines that arise from using the biobank(146,150,163). 
The biobank could however maintain the right to request a non-exclusive license on the IPRs that 
cover the basic materials. This could avert that applicant would use the IPRs in such a manner that 
would limit access to and use of the collection of HBM and data.  
Literature contains a number of examples that could inspire biobank policies on downstream IPRs. 
Researchers that wanted to use data from the International Hap Map Consortium had to comply with a 
click- and wrap-license that aimed to ensure that the data generated by the Project would remain 
available to all users. Under the Hap Map license, applicants were free to use the data for any type of 
analysis and to publish the results of those analyses. Applicants were, however, not allowed to include 
details of individual genotypes that the HapMap Project had not yet released in publications. They 
furthermore had to commit themselves not to file any patent application that contained claims to any 
composition of matter or any use of SNP, genotype or haplotype data (directly or indirectly) obtained 
from the Genotype Database. Exception was made under condition that such claims did not restrict 
the ability of others to use at no cost the Genotype Database or the data it contains for other 
purposes(164). Licensees were entitled to obtain patents on new or inventive associations between 
SNP or haplotype and a particular disease risk or drug response, if such patents would not limit 
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access to the underlying HapMap Data(145). The license also provided that applicants could only 
transfer HapMap Data to third parties that were bound by the license. Unfortunately it appeared that 
researchers had problems to convince scientific journals to publish research data under the conditions 
stipulated in the HapMap License(150). 
Navigenics, a consumer genomics company, commits itself to grant non-exclusive, non-discriminatory 
licenses on its patents in relation to the association between a SNP and the susceptibility for a 
particular disease(145). The Malaria Genomic Epidemiology Network allows participants to obtain IPR 
protection for clinical applications if 3 conditions are met: (a) the discovery must be directly relevant to 
a medical application; (b) it must be licensed for development immediately; (c) the discovery must 
have been shown to require IPR as a stimulus for further development.” If possible such IPRs should 
be licensed to non-profit organizations(165).  
The UK Biobank Access Procedures(166) contain specific IPRs provisions that ‘aim to make the 
collection of HBM and data available to all approved researchers, but at the same time facilitate 
development of clinical advancements’. The IPR provisions contain a division of rights between the UK 
biobank and applicants in relation to (1) the database of HBM and data; (2) researcher’s generated 
datasets and (3) inventions and associated IPRs. First, the IPR provisions provide that the UK 
Biobank is the owner of the database and the HBM and holds database rights and copyright in relation 
to data stored in biobank. The applicant is granted a limited non-exclusive license to use the data and 
HBM in the framework of an approved research project and for limited period of time. Second, 
applicants or their institutions hold IPRs on researcher-generated datasets. The UK Biobank is 
granted a non-exclusive, royalty free license to use the datasets and make them available to other 
approved researchers, i.e. researchers that are granted access to the UK Biobank. Finally the IPRs 
provisions stipulate that the UK Biobank makes no claims on inventions and associated IPRs 
developed in the framework of the research project. In the occurrence that IPRs are used to 
unreasonably restrict biomedical research or health care, the UK Biobank would be granted a non-
exclusive and royalty free license. This license would give them the right to use and allow other 
approved researchers to use the concerned inventions and IPRs in their research projects. Finally, the 
IPR provisions clarify that it would not expect an applicant to obtain IPRs on naturally occurring 
genetic sequences, biomarkers, proteins and biochemical processes.  
The P3G generic access agreement for population genomic studies (2011) stipulates that applicants 
should not claim IPRs on HBM and data derived directly from a population genomic study. Applicants 
are allowed to obtain patents on downstream inventions, if they agree to implement licensing policies 
that will not obstruct further research. Finally the Applicants own all results, data and inventions which 
arise from their research project, but they are expected to grant “a perpetual, non-cancellable, royalty-
free, worldwide license, with right to sublicense, to use study results for all purposes” to the population 
genomic study(77). 
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4.2 General solutions 
4.2.1 Stimulating the sharing of research results 
Biomedical research could benefit in different ways if biobanks would require applicants to share the 
upstream results and data that accrue from research projects with them. Sharing both positive and 
negative results of research projects would allow other researchers to learn from previous projects and 
build on existing knowledge. When making research results publicly available, one would have to 
demonstrate that the invention is novel and/or inventive compared to the publicly available data. So 
this would also limit the danger of obtaining IPRs on HBM and data directly derived from the collection 
of HBM and data and upstream research results. Returning data about the biological characteristics of 
the HBM to the biobank could also enrich the collection of HBM and data. Additional information on 
the collection of HBM and data could be useful for future research projects that use the collection. The 
information could be used to improve the quality of the collection of HBM and data. 
Researchers would only accept to share their research results if a number of conditions are fulfilled. 
The necessary infrastructure needs to be available to store and allow access to the research results. 
Appropriate mechanism should be created to ensure that research results are only used for research 
projects that obtained the necessary ethical and/or scientific approval(146). The researchers that 
generated the data, need to be given sufficient time to analyse and publish their research results and 
to obtain IPRs in relation to the research results(145,146,163). It would be advisable that data 
generators would be informed and possibly also consulted, when a new researcher applies for access 
to research results. Finally, upfront rules should be stipulated on the conditions that apply to determine 
whether the data generator is entitled to receive a recognition and/or compensation for his contribution 
to the new research project. Depending on how important the contribution of the initial researcher is 
the conditions could provide for an acknowledgement, co-authorship or even participation in IPRs that 
accrue from the new project(167). 
4.2.2 Review mechanism to recognize the contribution of biobanks and collectors to research 
projects 
Organizations and persons that provide HBM and data for research projects are often only mentioned 
in the acknowledgement. Such acknowledgement could increase the visibility of the biobank, but only 
has a limited impact. 
Guidelines on authorship provided by ICMJE and other organizations focus on intellectual 
contributions to publications. They value other types of contributions to research projects to a lesser 
extend. Unless they demonstrate that they participated in the drafting or the revision of the publication, 
persons or institutions that contributed to the collection, processing and analysis of HBM and data are 
in principle not eligible for co-authorship.  
This is unfortunate, since co-authorship of publications could constitute an important incentive to 
participate and contribute in research projects. An empirical study from FM Colledge, BS Elger and 
DM Shaw revealed that biomedical researchers in Switzerland unanimously agreed “that authorship is 
a motivation to make samples available to other researchers, or collaborate with individuals external to 
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their own department in some way (168).” It is therefore not surprising that research project 
sometimes ignore formal guidelines on co-authorship to acknowledge persons that made important 
contributions that would not fulfil the general applicable criteria on co-authorship(168).    
Considering the above, we suggest revising international guidelines on co-authorship. It should be 
clarified which type of contributions could result in co-authorship. It would raise awareness and 
appreciation with regard to the more essential technical or scientific contributions, such as the 
development of unique databases of HBM and data. This could prevent that international guidelines 
are increasingly ignored and that uncertainty would arise on the rules that would be applied to grant 
co-authorship to participants in biomedical research projects(168).  
An alternative could be that biobank policies would clarify how contributions to research projects would 
be recognized and rewarded(16). One could for instance distinguish the following types of 
contributions: (1) the mere collection, storage and provision of HBM and data; (2) the systematic 
collection, storage and provision of HBM and data according to certain (selection) criteria; (3) 
hypothesis-generated data and collected HBM (possibly in the framework of a previous research 
project); and (4) the analysis and interpretation of data. A similar approach is suggested in the 
International Charter of principles for sharing bio-specimens and data(106).  
Another mechanism that is currently developed to acknowledge the contribution of HBM and data to 
research projects and to increase the visibility of biobanks is the Bio-Resource Impact Factor (BRIF). 
BRIF aims to calculate the impact of collections of HBM and data on biomedical research. It is 
modelled in analogy to existing impact factors systems for publications in journals. BRIF would provide 
objective data on the “1. the quantitative use of a collection of HBM and data, 2. the quality and 
importance of research results involving it, and 3. the scientific and management efforts of those who 
set up and made available a valid bioresource and their institution” 109. 
4.2.3 Involve all stakeholders in policy on IPRs  
IPR policies will receive more support when biobanks carefully consider and address the concerns of 
the different stakeholders in relation to the possibility of obtaining IPRs on HBM and data(155). 
Biobanks need to be transparent to donors about the decision to claim IPRs on collections of HBM 
and data. They should explain that such IPRs will not relate to the HBM and data as such, but only to 
the added value created via operations conducted on the HBM and data. Donors need to be clearly 
informed about the fact that their HBM and data could be used for research projects that could result 
in commercial applications.  
A clear, upfront policy should be developed and communicated to the different stakeholders about the 
conditions that apply to determine whether applicants can obtain IPRs on the results of their research 
project. 
                                                       
109 http://www.p3g.org/brif-bioshare-pilot-study 
Chapter 4 
Page | 139  
 
It would be advisable that biobanks create a continuous dialogue with the donors, the applicants and 
funders on how they implement and update their IPR policy. Omitting to consult stakeholders on the 
IPRs policy could lead to a lack of support. Researchers may be more motivated to collaborate and 
share research results with the biobank, when a clear IPR policy has been developed.  
Finally biobanks could consider developing a policy on the sharing of non-financial benefits that arise 
from using HBM and data in research projects between the biobank, the applicants and the donors. 
Such policy could provide that part of the benefits should be fed back in to the collection of HBM and 
data or other research or health care infrastructure. Applicants could commit themselves to make the 
results of the research project publicly available. Simultaneously or alternatively they could allow – 
under reasonable conditions and fees – access to applications developed in the framework of the 
research project, such as genetic test or therapeutics. 
5 Conclusions  
This chapter provide more in-depth information on the possibility and desirability of obtaining IPRs in 
the context of publicly funded collections of HBM and data.  
An IPR policy may be used as a tool to enhance the acknowledgement and protection of the interests 
of the biobank and to stimulate the development of biobanks as essential research tools or 
infrastructures(150). One should however avoid ending up in a situation in which IPRs would 
constitute an obstacle to the use of HBM and data in research projects. 
IPR policies should contain clear information on which IPRs the biobank might claim in relation to the 
collection of HBM and data. It should also be clear which IPRs the potential users can hold in relation 
to his research results. Unless the biobank made an important (intellectual or scientific) contribution to 
the results of a research project, it could be useful for them to focus on the protection of their upstream 
IPRs and not on downstream IPRs. A proper policy on downstream IPRs should encourage 
applicants/researchers not to obtain excessive IPRs. The policy should however contain sufficient 
incentives to innovate. Substantial and risky investments are made to develop downstream clinical 
applications or products, such as biomedical treatments or diagnostics. Applicants have a legitimate 
interest to obtain IPRs on downstream clinical applications or products (134). Basic upstream data, 
research tools and enabling technologies should, however, remain available to the scientific 
community(145,150,163). Finally we suggest revising international guidelines on co-authorship to 
clarify which type of contributions could result in co-authorship. Such new guidelines could focus their 
recognition on the more essential technical or scientific contributions to research projects and less on 
the participation in drafting the final manuscript (168). Alternatively biobank policies could clarify how 
contributions to research projects would be recognized and rewarded(16,106,119). 
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The PhD project studied the legal framework that determines the relationship between a biobank and 
a researcher who applies for access to HBM and data stored in a biobank. The legal framework is 
regulated by the applicable legislation. It is also to a large extent determined by access arrangements. 
Such access arrangements consist of guidelines, best practices and opinions from biobank 
organizations. They furthermore consist of policies and agreements adopted by biobank networks and 
biobanks that define the rules on access to and use of collections of HBM and data. 
1 General discussion of the research findings 
A specific discussion of the results concludes each chapter. Therefore we will present a general 
overview of the findings in this part. 
1.1 Harmonization across biobank initiatives 
The comparative analysis of access arrangements revealed a lack of harmonization on how access 
conditions are defined and implemented (see conclusion of Chapter 1). This lack of harmonization can 
be explained by the fact that the concepts of ‘biobanks’ and ‘biobank networks’ represent a 
heterogeneous group of infrastructures that collect various types of HBM and data (as explained in the 
General Introduction). Some discrepancies could also be explained by the various approaches on 
ethical and legal issues in biobanking in the different countries (23). This heterogeneity in access 
conditions makes it questionably whether one should provide ‘one size fits all’ conditions on access to 
biobanks(1). Attempts to harmonise access conditions could focus on particular types of biobanks, 
such as tumour or stem cell banks or population-based biobanks. In another approach they could 
focus on rather technical issues, such as quality standards or minimum data sets. Harmonization 
could also focus on specific access conditions, such as IPRs, the sharing of research results(169) and 
non-financial benefit sharing. The interviews (Chapter 2) and the legal study (Chapter 3) confirmed 
that also such specific conditions are not yet harmonized. Finally, attention could be given to some 
other biobank initiatives (such as OECD and P3G), which did not attempt to harmonize access rules, 
but rather to develop best practices or guidelines. Such best practices (3,36,77,163,170) or guidelines 
do not suggest a uniform set of rules. They aim to provide a general (legal) framework that can be 
used as inspiration for the creation of access rules within other biobank initiatives. In this way they 
may indirectly stimulate harmonisation. 
A considerable number of access arrangements – studied in Chapter 1 – did not contain clear 
information on how the biobank initiatives (should) implement several of the studied access conditions. 
The lack of clear information on access conditions could hinder access to biobanks and biobank 
networks(14,16,63,69,77,81,82,84,91). Applicants need to be informed on the rules that need to be 
respected to obtain access to collections of HBM and data.  
Historically many clinicians and researchers created their own collections of HBM and data. The 
analysis in Chapter 1 revealed a trend to grant custodianship to biobanks or biobank networks and no 
longer to individual collectors or principal investigators (see section 4.3 of Chapter 1). The interviews 
in Chapter 2 confirmed this trend. Since the last decennium many institutions centralize the HBM and 
data collections from different departments in one single biobank infrastructure. This can be explained 
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by the fact that biomedical research requires access to large amounts of HBM and data of high 
quality(23,65,81,91).  
The majority of access arrangements provides custodianship of HBM at the level of a biobank and not 
at the level of a biobank network (see section 4.4 of Chapter 1). This is probably due to the fact that 
biobanks want to maintain control over the HBM that they collected.  
Finally the comparative analysis in Chapter 1 confirmed that the majority of the biobank initiatives 
establishes an access committee to evaluate requests for access to HBM and data (see section 4.6 of 
Chapter 1). The mandate of such access committees is not always clearly defined. Chapter 2 dug 
deeper into the question how biobanks define such mandate. 
1.2 Custodianship on HBM and data stored in biobanks 
The interviews (Chapter 2) aimed to gain a more in-depth understanding on how access arrangements 
(as explored in Chapter 1) are applied in the daily practice of biobank initiatives. The first part of the 
interview focused on the evaluation of access requests by access committees (see section 3.1 and 4.1 
of Chapter 2). REC (Research Ethics Committee), access committees and possibly also funding 
bodies evaluate research projects from applicants that request access to collections of HBM and data. 
The interviews raised the importance of clarifying the interaction between those different entities (105). 
There was no consensus among the interviewees on whether and to which extent access committees 
of biobanks should evaluate the quality, the scientific and medical usefulness and the ethical value of 
research projects. The legal study in Chapter 3 revealed that the existing legislation does not contain 
any guidance in this respect. The interviewees did agree that access committees should only evaluate 
access requests on the condition that they dispose of sufficient expertise, experience and 
independence(11,23,105,106). Two interviewees with a legal background posed the question whether 
some or all of the evaluation criteria should be determined by binding legislation. They furthermore 
highlighted that the criteria should be equitable and proportionate. The legal study in Chapter 3 
revealed that the Best Practice 7.4 of the OECD Guidelines for Human Biobanks and Genetic 
Research Databases stipulates in this respect that custodians “need ensure that any stratified access 
or fees policies are fair, transparent and do no inhibit research”(36). There was a consensus among 
the interviewees that equal access conditions should apply to internal and external academic 
applicants and non-academic applicants (see section 3.3 of Chapter 2).  
The informants in Chapter 2 seem to agree that the custodian of the biobank has the right to take the 
final decision on whether leftover HBM should be returned or destroyed. However, the interviews 
demonstrated the difficulty to determine generally applicable criteria on whether the biobank should 
request the return or destruction of leftover HBM (see section 3.2 and 4.2 of Chapter 2). An important 
criterion (according to the interviewees) is whether one can guarantee the quality of the leftover HBM 
for future research purposes. The comparative analysis (Chapter 1) and other previous studies 
confirmed that biobanks apply different policies on leftover HBM (17,67). Following the interviews, 
there is however no doubt that applicants need to obtain an approval of the (access committee of a) 
biobank – and a research ethics committee – to use leftover HBM in another project. There was 
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furthermore a consensus that applicant should not transfer leftover HBM to third parties without the 
prior authorization of the custodian of the biobank. 
The access fees charged by biobanks are often insufficient to compensate all costs in relation to the 
collection, storage and distribution of HBM and data for research purposes. New mechanisms need to 
be developed to feed some of the benefits of biomedical research back into the biobank infrastructure 
and the health care system(23,111). The interviewees were rather sceptical about the idea that 
providers of HBM and associated data should be able to participate in downstream IPRs or royalties 
on such IPRs (see section 3.3 and 4.3 of Chapter 2). Chapter 4 on IPRs and biobanking confirmed 
that biobanks should only be involved in downstream IPRs if they made a (intellectual or 
scientific/technical) contribution to the results of a research project. The interviews in Chapter 2 
(section 3.3 and 4.3) suggest that public biobanks might charge a higher access fee to industrial 
applicants – compared to academic applicants – for the access to a publicly funded collection of HBM 
and data(16,25). This could be justified by the fact that those collections have been created with public 
funding. The comparative analysis in Chapter 1 had already shown that several biobank initiatives 
apply different access fees depending on the type of applicant. However, the best practice 7.4 of the 
OECD Guidelines stipulates that the custodian of a biobank has to ensure that any stratified access 
conditions and fees are fair, transparent and do not inhibit research (see section 3.1.3 of Chapter 3).  
There was consensus among the interviewees that an applicant could be required to share his 
research results with the biobank and/or other researchers (section 3.4. and 3.5 of Chapter 2). This is 
no surprise, since the majority of the access arrangements studied in Chapter 1 provided that a 
biobank could require the return and/or the sharing of research results. One should however protect 
the legitimate interests of the researcher that generated the research results. The OECD Guidelines 
for Human Biobanks and Genetic Research Databases (studied in Chapter 3) suggest in this respect 
that a biobank should develop a policy on whether and how the results of research and analyses 
carried out using HBM and data stored in biobanks should be returned to the biobank. Chapter 4 
studies more in depth how biobanks could develop policies on the return and sharing of research 
results.  
None of the interviewees was in favour of the idea of granting applicants the exclusive right to access 
and use a specific collection of HBM and data. Such exclusivity is looked upon as an unjustified 
limitation to the accessibility of HBM and data for other research projects (see section 3.6). This 
explains why only a small minority of access arrangements (studied in Chapter 1) stipulates some kind 
of exclusivity.  
Today, quite some collections of HBM and data are established at the initiative of the principal 
investigators of specific research projects. Furthermore biobanks still rely on individual clinicians or 
researchers for the collection of specific HBM and data. Biobank initiatives could recognize such 
contribution by granting a temporary priority right to conduct research with the collected HBM and data 
and to allow publication of the results(16,106). 
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1.3 Legal framework governing access and use of HBM and data for research purposes 
The legal study in Chapter 3 showed that the Belgian legislation applicable to biobanks mainly focuses 
on the rights and obligations of the donor and the custodian. Fewer provisions relate to the rights and 
obligations of the applicants. The legal framework contains, for instance, quite detailed rules on the 
obligation to respect the informed consent of the donor and the protection of the personal data of the 
donor. The study of legal documents (Chapter 3) also revealed a considerable list of rights and 
obligations held by the custodian of a biobank. Finally several legal documents stipulate that a REC or 
another competent authority should review the aims and activities of a biobank. 
The Belgian and Danish legislation applicable to biobanks contain specific rules on the review of 
access requests by ethics committees (see Chapter 3). It does not provide anything in relation to the 
mandate of an access committee. Some international normative instruments do provide additional 
guidance on the role of an access committee and the development of access policies, procedures and 
mechanisms (see section 3.1.3 of Chapter 3). The OECD Guidelines for Human Biobanks and 
Genetic Research Databases (36) formulate a general principle on the development of biobanks 
policies. They express the principle that biobanks should develop policies on the commercialization of 
HBM and data, IPRs, the sharing in scientific advancements and its benefits and the sharing of 
research results. They do not contain concrete guidance on how to develop such policies. The 
interviews in Chapter 2 (sections 3.3 and 4.3) revealed that no consensus exists among biobank 
initiatives on how to develop a policy on IPRs and benefit sharing. Chapter 4 studied how biobanks 
could develop policies on IPRs, the sharing in scientific advancements and its benefits and the sharing 
of research results.  
1.4 IPRS in biobanking: challenges and opportunities for translational research 
Chapter 4 of this PhD studied the possibility and desirability of obtaining IPRs in the context of publicly 
funded collections of HBM and data. Both the comparative analysis of access arrangements (Chapter 
1) and the interviews (Chapter 2) confirm that the majority of the biobank initiatives did not develop 
any policy in relation to IPRs. This might be explained by the fact that the existence and especially the 
exercise of IPRs in relation to HBM and data have been found controversial in the past. The exclusive 
nature of IPRs could also be considered incompatible with the need to facilitate access to 
biobanks(131). An IPR policy may just as well be used as a tool to enhance the acknowledgement and 
protection of the interests of the biobank and to stimulate the development of biobanks as essential 
research tools or infrastructures(150). One should however avoid ending up in a situation in which 
IPRs would constitute an obstacle to the use of HBM and data in research projects. Chapter 4 
highlights the main challenges and suggests possible strategies and options with regard to this topic. It 
tackles the question of how to address and manage IPRs directed to HBM, the associated data stored 
in the biobank and the results of research using the HBM and associated data. We looked amongst 
others into the question whether biobanks should be involved in upstream and downstream IPRs. 
Finally the chapter highlights how biobanks could be involved in the development of policies on the 
sharing of research results. We also suggest developing policies to ensure an increased recognition of 
the contributions of biobanks and collectors to research projects. 
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1.5 Does the existing legal framework regulate the key access conditions? 
The PhD project studied to which extent the existing legal framework regulates the different key 
access conditions identified in the empirical studies (Chapter 1 and 2) and the legal study (Chapter 3). 
This allows us to determine to which extent certain access conditions need to be addressed via 
additional legislation or soft law or access arrangements. 
Chapter 1 revealed that several “key access conditions” are regulated by the majority of the studied 
access arrangements, such as (1) the level of custodianship; (2) the establishment of access 
committees; and (3) the mandate of such access committees.  
We concluded from Chapter 2 that a number of “key access conditions” would preferably be regulated 
via access arrangements, such as (1) the access conditions and fees that apply to industrial and 
external applicants; (2) priority setting; (3) priority access for collectors of HBM and data; and (4) the 
return and destruction of leftover HBM.  
Chapter 3 revealed that other “key access conditions” are mainly regulated via legislation or soft law, 
in particular: (1) the review of the aims, activities and policies of biobanks by RECs; (2) the rights and 
obligations of custodians; (3) the review of access requests by REC; (4) the principle that one should 
not generate profit on HBM (as such); (5) data protection; (6) consent. 
A limited number of ‘key access conditions” seem to be insufficiently regulated via the existing legal 
framework, in particular: (1) the sharing or returning of research results; (2) benefit sharing; and (3) 
intellectual property.  
2 Recommendations to facilitate access to biobanks 
2.1 An optimal legal framework combines legislation, soft law and access arrangements  
The PhD project studied the question whether the existing legal framework is adapted to the needs of 
the different stakeholders concerned by access to biobanks. It engages in the question as to which 
extent legislation or soft law is required for the creation of a transparent, feasible and encouraging 
legal framework for access to biobanks. Many different players and instruments determine the legal 
conditions for access to biobanks. National legislation, international normative instruments and access 
arrangements each play a distinct role in the regulation of access to biobanks. Access arrangements 
do not need to contain specific rules on legal issues that are already sufficiently regulated by national 
legislation or international normative instruments (or soft law). The protection of personal data is a 
good example of an issue that access arrangements do not have to deal with in detail given the well-
developed international, European and national legislation in this regard. Another issue that is 
regulated in detail by legislation and soft law is the requirement to obtain the informed consent of the 
donor for the removal, the storage and/or the use of HBM and data for research purposes. On the 
other hand, the existing legislation and soft law does not provide any guidance on how to calculate 
financial and material compensations for operations conducted with HBM and data. Here, guidance in 
access arrangements could provide an additional tool to avoid the commercialization of HBM.  
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Taking into account the international embedment and heterogeneous nature of biobanks, legislation 
should not over-regulate access to biobanks. That is why we doubt, for instance, whether national 
legislation or international normative documents should regulate the requirement to return or destroy 
leftover HBM. The interviews (Chapter 2) demonstrated that no general rules could be formulated in 
this respect. One could also doubt whether the evaluation of access requests by access committees 
should be regulated in detail by national legislation or international normative instruments.   
Some aspects of access to biobanks could be regulated via codes of conduct, guidelines and best 
practices. Those instruments could, for instance, be used to develop policies on (1) priority access of 
collectors of HBM and data; (2) the sharing or returning of research results; (3) benefit sharing; and (4) 
intellectual property. The advantage of such instruments is that they are created after consultation with 
the different stakeholders involved in biobanking. Such instruments may also be more easily 
adaptable in order to take new evolutions into account. Although they are not enforceable as national 
legislation, they do have an important influence. An example of this is the Code of Conduct developed 
in the Netherlands by FEDERA – the Dutch Federation of Medical Scientific Societies – and COREON 
– the Commission on Regulation in Research –. It was realized in close collaboration with the Dutch 
Patient Consumer Federation, the Federation of Parent and Patient Organisations and BBMRI-NL. 
This Code of Conduct contains relatively detailed rules and principles on how to deal in a responsible 
manner with HBM (and data) in the context of health research(171). The Code of Conduct created a 
certain extent of harmonization, since many biobanks, biobank networks and organizations in the 
Netherlands committed to respect this common set of rules and principles. Other important access 
arrangements have been developed by the National Cancer Institute in the US(3), ISBER(85), the 
OECD(36,170) and P3G(77,163).  
2.2 Biobanks should develop clear policies on the evaluation of access requests  
Biobanks should provide publicly available information about their access arrangements and 
procedures(36,172). Access arrangements should clarify the mandate of access committees. They 
should in particular specify which criteria and procedures will be applied in the evaluation of access 
requests (11,16,36,105). The procedure for the evaluation of access requests should protect the 
interests of the donor and the biobank. It should, for instance, avoid that HBM and data is wasted on 
research projects of insufficient quality. It should not, however, become unnecessarily burdensome. 
For instance, an access committee should not evaluate the same criteria as a REC and/or a data 
protection authority. Access arrangements could clarify how access committees will supplement the 
mandatory evaluations by REC or other competent authorities(6).  
When an access committee evaluates access requests and the scientific merits of applicants, it needs 
to make sure that it disposes of the necessary competence to make such evaluation. That is why it 
may be advisable to consult external reviewers in the evaluation of certain access requests.  
Access arrangements should contain clear instructions on which information an applicant needs to 
provide in his research protocol(36). One could refer in this respect to the Good Clinical Practices that 
are applied in clinical trials. They could constitute a source of inspiration.  
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Access arrangements should stipulate to which extent certain types of research will be given 
priority(36). One could for instance imagine that diseases-oriented biobanks would prioritize research 
that corresponds with their own core field of interest.  
Access arrangements should clearly specify the rights and obligations of the custodian, the applicant 
and the donor in relation to the collection of HBM and data.  
Finally one should avoid ‘restrictive’ access arrangements that would limit access to collections of 
HBM and data and as consequence would unnecessarily hamper the development of biomedical 
research.  
2.3 Define the conditions for access by industrial companies 
The majority of the biobank initiatives agree that industrial companies – such as pharmaceutical and 
biotechnological companies – can access and use HBM and data from publicly funded biobanks. 
Industrial companies play an important role in the transformation of research into a drug candidate and 
eventually into a medical product. However, access by industrial companies should not have a 
negative impact on the donors’ trust and willingness to provide HBM and data to biobanks(129). That 
is why biobank initiatives should clearly communicate about their relationships with industrial 
companies. It would be desirable to clearly define the conditions under which industrial companies can 
access publicly funded collections of HBM and data. Those conditions could be developed in 
consultation with the different stakeholders, such as the funders of the biobanks, the donors and the 
applicants.  
2.4 Recognize the contribution of individual collectors 
The comparative analysis of access arrangements and the interviews confirmed that custodianship 
over HBM and data has shifted over time from individual collectors to biobanks. However, individual 
collectors still make important contributions to the collections of HBM and associated data. Individual 
collectors could also provide important know how on the HBM and associated data. Proper incentives 
should be given to the individual collectors and their contributions (6). It could be envisioned to grant 
certain collectors a temporary priority right to conduct research with the collected HBM and data and 
to publish the results(16,106). It is considered good practice to inform the collectors of HBM and data, 
when such HBM and data is used in research projects. One should however investigate the practical 
implications of such practice. It may be a good idea to also consult individual collectors in the decision 
to make HBM and data available for a specific research project. This does not imply a veto right for the 
individual collector. The final decision to distribute HBM and associated data remains with the 
custodian of the biobank. 
2.5 Develop policy on sharing of research results 
Previous studies confirmed that an increasing number of biobanks(67) and funding bodies(115) 
require researchers to make their research results publicly available. Such requirement is motivated 
by the desire to maximize the use of results of publicly funded research(113,116). Some authors also 
invoke the principle of reciprocity. Researchers could be expected to share their results with 
stakeholders that contributed to the collection of HBM and data, such as biobanks and 
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donors(106,108). However, the sharing of research results will only be useful and acceptable for 
researchers if the following three conditions are fulfilled. First, the proper infrastructure needs to be 
available to store and allow other researchers access to the research results (116). Second, the 
conditions under which other researchers can access the results should be clearly defined. Finally, it 
should be taken into account that researchers could have a legitimate interest to request that some 
research results remain confidential. This is necessary to allow the researchers to publish their results 
and possible obtain IPRs on clinical applications based on those results(105,106,108,116,119). 
2.6 Develop policy on intellectual property rights 
IPR policies could constitute an important tool to protect the considerable investments made in the 
creation of collections of HBM and data. Such policies will only be successful if the interest and 
concerns of the different stakeholders are taken into account(155). Transparency towards the donors 
is important. The donors should be aware of the possibility of obtaining and exercising IPRs in relation 
to the collection of HBM and data. The policy should contain clear information on which IPRs the 
biobank (or the collecting researchers) might claim in relation to the collection of HBM and data. It 
should also be clear which IPRs the potential users can hold in relation to research results obtained 
from using HBM and data. Unless the biobank made an important (intellectual or scientific) 
contribution to the results of a research project, it could be useful for them to focus on the protection of 
their upstream IPRs and not on downstream IPRs. A proper policy on downstream IPRs should 
encourage applicants/researchers but also biobanks not to obtain excessive IPRs. The policy should 
however contain sufficient incentives to innovate. Applicants have a legitimate interest to obtain IPRs 
on downstream clinical applications or products (134). Basic upstream data, research tools and 
enabling technologies should, however, remain available to the scientific community(145,150,163). 
Finally we suggest revising international guidelines on co-authorship to clarify which type of 
contributions could result in co-authorship. Such new guidelines could recognize more essential 
technical or scientific contributions to research projects (168). Alternatively biobank policies could 
clarify how contributions to research projects would be recognized and rewarded(16,106,119). 
2.7 Involve donors and patients in the biobank policy 
The future evolution of biobanks depends to a large extent on the willingness of donors to provide 
HBM and data for biomedical research. That is why biobanks need to make sure that they maintain 
the trust of those donors. The interests and concerns of donors and patients should be taken into 
account in every aspect of a biobank policy(129). Biobanks should maintain an open dialogue with the 
donors about the activities and the policies of the biobank. Finally it is important to create more public 
awareness of the important contributions of biobanks to biomedical research and innovation (6). 
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3 Methodological considerations 
This PhD project focused on access to biobanks. It focused, more precisely on the relationship 
between the custodian of a biobank and the applicant/researcher who requests access to HBM and 
data stored in the biobank. We paid less attention to both the – no doubt important – relationship 
between the custodian and the donor and to the relationship between the donor and the applicant. We 
made this choice in order for our study to complete existing studies which focused on public 
perception and participation in biobanks, governance, consent, and return of incidental findings 
(23,56–59,61–68). However, some studies of this PhD project did touch upon the mentioned 
relationships. In the framework of the qualitative study reported in Chapter 2, we interviewed, for 
instance, four patient representatives. In addition, the comparative analysis in Chapter 3 provides a 
more in-depth study of the legal relationship between the custodian of a biobank and the donor as well 
as their respective rights and obligations.   
This PhD project looked at many different types of biobanks and biobank networks (as described in 
the introduction). It furthermore studied the legal framework applicable to various uses of HBM and 
data in the framework of scientific research. This allowed us to gain a broad insight into the topic of 
access to biobanks. It did not allow considering all details applicable to particular types of biobanks. It 
could be useful to focus future studies on a particular type of biobank. Separate studies could 
concentrate on, for instance, disease-oriented or population based biobanks. Another possibility could 
be to focus on the use of HBM and data for a particular type of research, such as research on cancer 
or particular genetic disorders. This could allow a more in-depth understanding of a particular type of 
biobank or use of HBM and data. 
3.1 Harmonization across biobank initiatives 
Chapter 1 of this PhD project lists our findings on a comparative document analysis of publicly 
available access arrangements. We analysed the access arrangements of 26 organizations, 36 
biobank networks and 20 biobanks worldwide. The results of the comparative analysis are not 
generalizable, since we only compared a selection of access arrangements. A literature review 
allowed us to identify 21 key conditions in relation to access to HBMs and data. Our analysis focused 
on these 21 key conditions. We cannot exclude that other conditions might become equally relevant 
for access to biobanks. Information on the 21 key conditions was summarized and compared using 
predefined templates. Access arrangements did not always explicitly refer to one or more of the 21 
access conditions under study (as explained in this study by the lack of clarity of the terminology). 
Whenever this was the case, we interpreted the text of the arrangement to discover implicit 
information on the access conditions. It was however not possible to enquire for each biobank initiative 
whether our interpretations fully correspond with the real (unexpressed) intentions of the concerned 
biobank initiative. The comparative analysis allowed us to study a considerable amount of access 
arrangements. It did not allow us to make an in-depth study of all policies of the concerned biobank 
initiatives. We are furthermore aware of the fact that access arrangements only represent the publicly 
available policy information of a biobank initiative. They do not present information on the actual (often 
not public) access practices of biobank initiatives. That is why interviews were conducted with 
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stakeholders and experts in the second empirical study. In the course of the study we realized that 
quite a lot of access arrangements do not contain any information on several key access conditions. 
This made it more difficult to compare the access arrangements. It also made it more difficult to come 
to generalizable conclusions on the extent of harmonization. 
3.2 Custodianship on HBM and data stored in biobanks 
Another limitation is related to the sample of interviewees included in the second chapter of the PhD, 
namely the empirical study of access practices. We conducted interviews with 28 stakeholders and 
experts in the Benelux, Denmark, Norway and Sweden. The main purpose of the sampling of 
interviewees was to capture perspectives of different types of stakeholders and experts. That is why 
we interviewed both legal and ethical experts, custodians of biobanks, representatives of biobank 
networks, academic, clinical and industrial (research) applicants and patient representatives. The 
majority of the informants were interviewed in Belgium. A more limited number of informants were 
interviewed in Denmark (2), Luxemburg (1), the Netherlands (2), Sweden (2) and Norway (2). We 
noticed that some informants fulfilled a double role, such as applicant and representative of 
stakeholders within an access committee. The interviewers took those double roles into account in the 
analysis, but focused on the main role of the informant. During the analysis of the interviews we 
discovered fewer variations in opinion than we would have expected. We were also not able to 
contribute variations of opinions to specific types of stakeholders or experts. The fact that we 
discovered fewer variations might be due to the fact that we were only able to interview 28 informants. 
It might also be due to the fact that some topics discussed during the interviews were relatively new to 
some of the informants.   
3.3 Legal framework governing access and use of HBM and data for research purposes 
Chapter 3 of the PhD aimed to compare the national legal framework applicable to access to biobanks 
in Belgium and normative documents at the international level and at the level of the Council of 
Europe. It also compared the applicable legal framework in Belgium and Denmark. Comparing those 
different legal documents cannot provide a complete answer to the question which rights and 
obligations are held by the custodian, the applicant and the donor. First, we could only study the main 
international normative instruments that are relevant to “access to biobanks”, due to the abundance of 
instruments that might be relevant to biobanks. Second, the scope and the binding force of the legal 
documents are different. Only the studied national legislations create legal enforceable rights and 
obligations. The international normative documents rather provide general principles and guidance on 
access to biobanks. Finally we studied two legal documents that did not enter into force yet. The legal 
provisions on biobanks in the Belgian Act on HBM have been modified several times and have still not 
entered into force. The new Minister of Health furthermore indicated in her policy note that the legal 
provisions on biobanks will be further modified and improved. One or more Royal Decrees executing 
the future provisions on biobanks are still pending. It is therefore no surprise that the literature on the 
future legal provisions on biobanks in Belgium is rather limited. We also studied the most important 
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modifications suggested to the Recommendation (2006)4110 in the Working document on research on 
biological materials of human origin (hereafter the “Working Document’”). The final text of the 
modifications to Recommendation (2006)4 has not been published yet. We nevertheless decided to 
include the Working Document in the legal analysis, since a lot of the new provisions suggested in the 
Working Document relate specifically to access to biobanks. 
3.4 IPRS in biobanking: challenges and opportunities for translational research 
Chapter 4 of the PhD reports on a literature review on intellectual property rights in biobanking and to 
a lesser extent on the sharing of benefits and the sharing and return of research results. We 
concentrated on the question how to address and manage IPRs and the sharing of benefits and 
research results in the access arrangements of biobanks. This chapter provides input for a discussion 
on strategies and options for publicly funded biobanks with regard to this question. The strategies and 
options exposed in this chapter are, however, not supported by empirical data. 
4 Future perspectives  
This PhD project studied in an interdisciplinary manner whether the existing legal framework 
corresponds to the needs of biobanks and other stakeholders. 
We quickly came to realize that the concepts of ‘biobanks’ and ‘biobank networks’ represent a 
heterogeneous group of infrastructures. It is therefore not so straightforward to formulate uniform rules 
on access to biobanks in general.  
We also noticed that the discipline of biobanking is still relatively young(25). Many countries are still 
developing new biobank infrastructures. This might explain why several access arrangements of 
biobank initiatives (studied in Chapter 1) did not contain information on several key access conditions. 
Many biobanks initiatives will presumably develop further their access arrangements. One can refer in 
this respect to recent initiatives of, for instance, P3G(77,163). Some biobank initiatives increasingly 
exchange experiences on practical matters related to biobanking but also on legal knowledge. We 
hope this PhD can contribute to these efforts. 
In November 2014 BBMRI-ERIC announced the creation of a European Centre for Ethical, Legal and 
Social Issues (ELSI) on biobanking. Such European Centre will provide common services on Ethical, 
Legal and Social Issues to the members of BBMRI-ERIC. One can expect that this will generate new 
opportunities to develop code of conducts, guidelines or best practices on access to biobanks. Those 
opportunities might even lead to an increased harmonisation of the European legal framework 
applicable to biobanks. In addition, BBMRI-ERIC is about to start a Stakeholder forum to align 
interests of different stakeholders in the context of biobanking. 
  
                                                       
110 The Recommendation Rec (2006) 4 of the Committee of Ministers to Member States on Research on 
Biological Materials of Human Origin 
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The legal study (Chapter 3) showed that the legal framework on biobanks is still evolving. One can 
refer in this respect to the fact that the future provisions on biobanks in the Belgian Act on HBM have 
not entered into force yet. The Minister of Health Furthermore, furthermore, announced in her policy 
note that the provisions on biobanks will further be developed and improved in consultation with the 
stakeholders.  
Recommendation (2006)4111 of the Council of Europe is furthermore under revision. The final text of 
the modifications to Recommendation (2006)4 have not been published yet. We nevertheless noticed 
that the Working Document112 published by the Committee of Bioethics suggests a lot of new 
provisions that specifically relate to access to biobanks. 
Taken into account the evolving nature of biobanks, we hope that this PhD project can be inspiring to 
these recent legal developments and may contribute to the creation of a clear and smooth legal 
framework on access to biobanks.  
                                                       
111 The Recommendation Rec (2006) 4 of the Committee of Ministers to Member States on Research on 
Biological Materials of Human Origin 
112 The Working document on ‘research on biological materials of human origin’ was published by the Committee 
on Bioethics – an intergovernmental body within the Council of Europe – on 18 March 2014 
 Page | 155  
 
Summary
Summary 
Page | 156  
 
The European Strategy Forum on Research Infrastructures (ESFRI) identified biobanks as one of the 
main priority research infrastructures for the European Research Area (ERA) for the next 10 to 20 
years(8). Millions of human biological material (HBM) and associated data are collected each year for 
a variety of purposes. These purposes may include basic research studies, clinical trials and 
epidemiological studies(11,12). 
The legal framework that determines access to biobanks remains unclear. The absence of a defined 
set of applicable rules creates legal uncertainty for biobanks and applicants. The PhD project studied 
the legal framework that determines the relationship between a biobank and a researcher that applies 
for access to HBM and data stored in a biobank. In an interdisciplinary context, the PhD project aims 
to contribute to the creation of a clear and smooth legal framework – i.e. legislation, non-binding 
normative instruments and access arrangements – applicable to biobanks.  
The general introduction provides a deeper insight into the use of HBM and associated data for 
research purposes. First, it highlighted the importance of biobanks for biomedical research. Second, it 
looked at different types of HBM and data collected for research purposes. Third, it described the 
different research purposes to collect and use HBM and data. Finally, it dug deeper into the definition 
of the terms ‘biobanks’ and ‘biobank networks’. 
The first chapter of the PhD reports on a comparative analysis of access arrangements of 
organizations, biobank networks and biobanks. The comparative analysis revealed a lack of 
harmonization on how access conditions are defined and implemented. A considerable number of 
access arrangements did not contain clear information on how the biobank initiatives (should) 
implement several of the studied access conditions. The lack of clear information on access conditions 
could hinder access to biobanks and biobank networks(14,16,63,69,77,81,82,84,91). The analysis did 
reveal a trend to grant custodianship to biobanks or biobank networks and no longer to individual 
collectors or principal investigators. This can be explained by the fact that biomedical research 
requires access to large amounts of HBM and data of high quality(23,65,81,91). Finally the 
comparative analysis confirmed that the majority of the biobank initiatives establishes an access 
committee to evaluate requests for access to HBM and data. The mandate of such access committees 
is not always clearly defined.  
The second chapter of the PhD reports on an empirical study of access practices in the context of 
biobanking. Interviews were conducted with stakeholders and experts to gather qualitative data on the 
different perspectives held by stakeholders in relation to the rights and obligations of custodians and 
applicants with respect to access to HBM and data stored in biobanks. The first part of the semi-
structured interviews focused on the evaluation of access requests by access committees. The 
interviews raised the importance of clarifying the interaction between research ethics committees and 
access committees of biobanks (105).  
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There was no consensus among the interviewees on whether and to which extent access committees 
of biobanks should evaluate the quality, the scientific and medical usefulness and the ethical value of 
research projects. The interviewees did agree that access committees should only evaluate access 
requests on the condition that they dispose of sufficient expertise, experience and 
independence(11,23,105,106). The interviewees felt that similar evaluation criteria should apply to 
academic and non-academic applicants. Following the interviews, there is no doubt that applicants 
need to obtain the approval from the access committee of a biobank – and a research ethics 
committee – to use leftover HBM in a new project.  
The access fees charged by biobanks are often insufficient to compensate all costs in relation to the 
collection, storage and distribution of HBM and data for research purposes. Two interviewees raised 
the need to develop new mechanism to feed some of the benefits of biomedical research back into the 
biobank infrastructure and the health care system(23,111). Public biobanks could charge a higher 
access fee to industrial or external applicants – compared to internal applicants – for the access to a 
publicly funded collection of HBM and data(16,25).  
There was consensus among the interviewees that an applicant could be required to share his 
research results with the biobank and/or other researchers. One should however protect the legitimate 
interests of the researcher that generated the research results.  
Today, quite some collections of HBM and data are established at the initiative of the principal 
investigators of specific research projects. Furthermore biobanks still rely on individual clinicians or 
researchers for the collection of specific HBM and data. Biobank initiatives could recognize such 
contribution by granting a temporary priority right to conduct research with the collected HBM and 
data(16,106). 
The third chapter of the PhD reports on a comparative study of the legal framework applicable to 
access to biobanks. The comparative study started with description and analysis of the legal 
framework applicable to access to biobanks in Belgium and Denmark, at the international level and at 
the level of the Council of Europe. Subsequently it compared the different legal frameworks applicable 
to access to biobanks. The conclusion summarized to which extent the rights and obligations of the 
custodian and the applicant are regulated via the existing legal framework. 
The legal study in Chapter 3 shows that the Belgian legislation applicable to biobanks mainly focuses 
on the rights and obligations of the donor and the custodian. Fewer provisions relate to the rights and 
obligations of the applicants. The Belgian and Danish legislation applicable to biobanks do not contain 
any provisions on the mandate of an access committee. Some international normative instruments 
provide additional guidance on the role of an access committee and the development of access 
policies, procedures and mechanisms. The OECD Guidelines for Human Biobanks and Genetic 
Research Databases (36) formulate the general principle that biobanks should develop policies on the 
commercialization of HBM and data, intellectual property rights (IPRs), the sharing in scientific 
advancements and its benefits and the sharing of research results.  
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The fourth chapter of the PhD reports on a legal study on IPRs in biobanking and on the return and 
sharing of research results. This study discusses the risks and opportunities associated with the 
identified IPRs for an effective protection and use of biobanks in translational research and innovation. 
The study concluded that an IPR policy may be used as a tool to enhance the acknowledgement and 
protection of the interests of the biobank. Such policy may also be used to stimulate the development 
of biobanks as essential research tools or infrastructures(150). However, one should avoid that IPRs 
would become an obstacle to the use of HBM and data in research projects. Chapter 4 tackled the 
question of how to address and manage IPRs directed to HBM and data stored in the biobank and the 
results of research using the HBM and associated data. We looked amongst others into the question 
whether biobanks should be involved in upstream and downstream IPRs. Finally the chapter highlights 
how biobanks could be involved in the development of policies on the sharing of research results.  
The fifth chapter of the PhD formulates concluding findings and recommendations on the legal 
framework applicable to biobanks. First, we conclude that an optimal legal framework combines 
legislation, soft law and access arrangements. Second, we recommend that biobanks should develop 
clear policies on the evaluation of access requests. Third, we suggest that biobanks clearly define the 
conditions under which industrial companies can access publicly funded collections of HBM and data. 
Fourth, we draw the attention to the importance of recognizing the contributions of individual collectors 
to the collections of HBM and associated data. Fifth, we recommend that biobank initiatives would 
develop a policy on the sharing of research results. Sixth, biobanks are invited to develop a policy on 
IPRs. Finally, we highlight the importance of involving donors and patients in the access policies of 
biobanks. 
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Het Europees Strategisch Forum inzake de onderzoeksinfrastructuur heeft biobanken geïdentificeerd 
als een van de belangrijkste prioritaire onderzoeksinfrastructuren voor de Europese Onderzoeksruimte 
in de komende 10 tot 20 jaar (8). Elk jaar worden miljoenen stalen menselijk lichaamsmateriaal (MLM) 
en daarmee samenhangende gegevens verzameld voor verschillende doeleinden. Deze doeleinden 
hebben onder meer betrekking op fundamenteel onderzoek, klinische proeven en epidemiologische 
studies (11,12). 
Het juridisch kader dat de regels inzake toegang tot biobanken bepaalt, blijft onduidelijk. Het 
ontbreken van een duidelijk gedefinieerd kader leidt tot rechtsonzekerheid. Het doctoraatsonderzoek 
bestudeerde het juridische kader dat van toepassing is op de relatie tussen een biobank en een 
onderzoeker die een aanvraag indient om toegang te krijgen tot MLM en gegevens die zijn 
opgeslagen in een biobank. Het doctoraatsproject heeft als doel een bijdrage te leveren aan de 
totstandkoming van een helder en toegankelijk juridisch kader voor biobanken. Dit juridisch kader kan 
bestaat uit wetgeving, juridisch niet-bindend normatieve instrumenten en toegangsregelingen.  
De algemene inleiding biedt een nader inzicht in het gebruik van MLM en daarmee samenhangende 
gegevens voor onderzoeksdoeleinden. In de eerste plaats wordt het belang van biobanken voor 
biomedisch onderzoek nader toegelicht. Vervolgens worden de verschillende types van MLM en 
gegevens die worden verzameld voor onderzoek beschreven. Ten derde behandelt de inleiding de 
verschillende onderzoeksdoeleinden waarvoor MLM en data worden verzameld en gebruikt. Tot slot, 
gaan we dieper in op verschillende definities van de begrippen 'biobanken' en 'biobank netwerken'. 
Het eerste hoofdstuk van het doctoraat brengt verslag uit van een vergelijkende analyse van 
toegangsregelingen van organisaties, biobank netwerken en biobanken. De vergelijkende analyse 
duidt op een gebrek aan harmonisatie in de wijze waarop toegangsvoorwaarden worden gedefinieerd 
en geïmplementeerd. Een aanzienlijk aantal van de toegangsregelingen bevatten bovendien geen 
duidelijke informatie over hoe biobank initiatieven een aantal van de onderzochte 
toegangsvoorwaarden implementeren. Het gebrek aan duidelijke informatie over de 
toegangsvoorwaarden kan de toegang tot biobanken en biobank netwerken belemmeren 
(14,16,63,69,77,81,82,84,91). De analyse bracht een trend aan het licht om het beheer van 
verzameling van MLM en data toe te vertrouwen aan biobanken of biobank netwerken en niet langer 
aan individuele verzamelaars of hoofdonderzoekers. Dit kan worden verklaard door het feit dat 
biomedisch onderzoek toegang vereist tot grote hoeveelheden MLM en gegevens van hoge kwaliteit 
(23,65,81,91). Tenslotte bevestigde de vergelijkende analyse dat de meerderheid van de biobank 
initiatieven een toegangscomité in het leven roepen om toegang tot MLM en gegevens te beoordelen. 
Het mandaat van een dergelijk toegangscomité is echter niet altijd duidelijk omschreven. 
Het tweede hoofdstuk van het doctoraat bestaat uit een empirische studie inzake de 
toegangspraktijken toegepast door biobanken. Interviews werd uitgevoerd met belanghebbenden en 
deskundigen om kwalitatieve gegevens te verzamelen over de verschillende perspectieven met 
betrekking tot de rechten en verplichtingen van beheerders en aanvragers inzake toegang tot MLM en 
de gegevens die in biobanken zijn opgeslagen. 
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Het eerste deel van deze semigestructureerde interviews was gericht op de beoordeling van 
toegangsaanvragen door toegangscomités. De interviews wezen uit dat het belangrijk is om de 
interactie tussen ethische comités en toegangscomités (105) duidelijk te regelen. Er bestond geen 
consensus onder de geïnterviewden over de vraag of en in welke mate een toegangscomité de 
kwaliteit, het wetenschappelijk en medisch nut en de ethische waarde van onderzoeksprojecten moet 
evalueren. De geïnterviewden waren het er wel over eens dat de toegangscomités enkel 
toegangsaanvragen kunnen beoordelen, indien zij over voldoende deskundigheid, ervaring en 
onafhankelijkheid beschikken (11,23,105,106). De geïnterviewden waren van mening dat soortgelijke 
evaluatiecriteria moeten gelden voor academische en niet-academische aanvragers. De interviews 
bevestigden dat aanvragers in ieder geval goedkeuring dienen te verkrijgen van het toegangscomité 
van de biobank – en een ethisch comité – om residuair MLM te gebruiken in een nieuw project.  
De toegangsvergoedingen die biobanken aanrekenen zijn vaak onvoldoende om alle kosten te 
compenseren met betrekking tot het verzamelen, opslaan en ter beschikking stellen van MLM en 
gegevens voor onderzoeksdoeleinden. Een aantal geïnterviewden identificeerden de nood om nieuwe 
mechanismen te ontwikkelen zodat een aantal van de voordelen van het biomedisch onderzoek terug 
zouden vloeien naar de biobank infrastructuur en de gezondheidszorg (23,111). Publieke biobanken 
zouden een hogere toegangsvergoeding kunnen aanrekenen aan externe en industriële aanvragers – 
in vergelijking met interne aanvragers – voor het verlenen van toegang tot publiek gefinancierde 
collecties van MLM en data (14,36). 
Er bestond consensus onder de geïnterviewden dat een aanvrager kan worden gevraagd om zijn 
onderzoeksresultaten te delen met de biobank en/of andere onderzoekers. Men dient evenwel de 
rechtmatige belangen van de onderzoeker met betrekking tot deze onderzoeksresultaten te 
beschermen.  
Vandaag de dag, worden heel wat collecties van MLM en data opgericht op initiatief van 
hoofdonderzoekers van specifieke onderzoeksprojecten. Verder rekenen biobanken nog vaak op 
individuele clinici en onderzoekers voor het verzamelen van specifieke MLM en data. Biobank 
initiatieven kunnen een dergelijke bijdrage erkennen door hen een tijdelijk prioritair recht te verlenen 
om het verzamelde MLM en data te gebruiken voor onderzoek (16,106). 
Het derde hoofdstuk van het doctoraat gaat nader in op een vergelijkende studie van het juridisch 
kader dat van toepassing is op toegang tot biobanken. De vergelijkende studie begon met een 
algemeen overzicht van de toepasselijk nationale wetgeving in België en Denemarken, en niet-
bindende normatieve normen op internationaal niveau en op het niveau van de Raad van Europa. Het 
hoofdstuk bestaat vervolgens uit een vergelijking tussen de verschillende juridische kaders.  
De juridische studie in hoofdstuk 3 toont aan dat de Belgische wetgeving die van toepassing is op 
biobanken, vooral gericht is op de rechten en verplichtingen van de donor en de beheerder. De 
wetgeving bevat minder bepalingen met betrekking tot de rechten en verplichtingen van de 
aanvragers. De wetgeving in België en Denemarken bevat evenmin bepalingen over het mandaat van 
een toegangscomité.  
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Sommige internationale normatieve instrumenten bevatten wel richtlijnen inzake de rol van een 
toegangscomité en de ontwikkeling van een beleid, procedures en mechanismen inzake toegang tot 
biobanken. De OESO-richtlijnen voor ‘Human Biobanks and Genetic Research Databases’ (36) 
formuleert het algemene beginsel dat biobanken een beleid moeten ontwikkelen inzake de 
commercialisering van MLM en data, intellectuele eigendomsrechten (IER), het delen van 
wetenschappelijke vooruitgang en de vruchten daarvan, en het delen van onderzoeksresultaten. 
Het vierde hoofdstuk van het doctoraat bestaat uit een juridische studie inzake het belang van IER 
voor biobanken en het delen van onderzoeksresultaten door onderzoekers. De studie bespreekt de 
risico's en opportuniteiten van de geïdentificeerde IER voor een effectieve bescherming en gebruik 
van biobanken in translationeel onderzoek en innovatie. Een IER beleid kan worden gebruikt als een 
instrument om de erkenning en bescherming van de belangen van de biobank te versterken. Ze kan 
ook de ontwikkeling van biobanken als essentieel onderzoeksinstrumenten of -infrastructuren (150) 
stimuleren. Men moet evenwel vermijden dat IER een belemmering vormen voor het gebruik van MLM 
en gegevens in onderzoeksprojecten. Hoofdstuk 4 gaat dieper in op de vraag hoe IER te beheren, 
wanneer deze betrekking hebben op MLM en gegevens die zijn opgeslagen in de biobank of met de 
resultaten van onderzoek met behulp van de MLM en bijbehorende gegevens. We bestudeerden 
onder meer de vraag of biobanken moeten worden betrokken bij ‘upstream’ en ‘downstream’ IER. 
Tenslotte belicht het hoofdstuk hoe biobanken betrokken kunnen worden bij de ontwikkeling van een 
beleid inzake het delen van onderzoeksresultaten. 
Het vijfde hoofdstuk van het doctoraat formuleert een aantal conclusies en bevat een aantal 
aanbevelingen inzake het juridisch kader van toepassing op biobanken. Vooreerst, kunnen we 
concluderen dat een optimaal juridisch kader bestaat uit een combinatie van wetgeving, niet-bindende 
normatieve normen en toegangsregelingen. Ten tweede, raden wij biobanken aan een duidelijk beleid 
te ontwikkelen inzake de evaluatie van toegangsaanvragen. Ten derde, raden we biobanken aan de 
voorwaarden duidelijk te definiëren waaronder industriële bedrijven toegang kunnen hebben tot 
publiek gefinancierde collecties van MLM en data. Ten vierde, vestigen wij de aandacht op het belang 
om de bijdragen van de individuele verzamelaars tot de collecties van MLM en bijbehorende 
gegevens te erkennen. Ten vijfde, raden wij aan dat biobank initiatieven een beleid zouden 
ontwikkelen inzake het delen van onderzoeksresultaten. Ten zesde, moedigen we biobanken aan om 
een beleid inzake IER te ontwikkelen. Tenslotte benadrukken we het belang om donoren en patiënten 
te betrekken in het toegangsbeleid van biobanken. 
 
  
Page | 163 
 
References
References 
 
Page | 164  
 
 
  
References 
 
Page | 165  
 
1.  Morente MM, Cereceda L, Luna-Crespo F, et al. Managing a Biobank Network. Biopreserv 
Biobank. 2011 Jun;9(2):187–90.  
2.  Yassin R, Lockhart N, González del Riego M, et al. Custodianship as an ethical framework for 
biospecimen-based research. Cancer Epidemiol Biomarkers Prev. 2010 Apr [cited 2014 Mar 
4];19(4):1012–5.  
3.  NCI Best Practices for Biospecimen Resources [Internet]. 2011 p. 85. Available from: 
http://biospecimens.cancer.gov/bestpractices/2011-NCIBestPractices.pdf 
4.  P3G Sample and data Access Policy: Core Elements [Internet]. P3G; 2008. Available from: 
http://www.p3gobservatory.org/download/P3G Sample and Data Access_SEW.doc 
5.  Parks A. 10 Ideas Changing the World Right Now- Biobanks. Time Magazine. 2009;  
6.  Biobanks for Europe: A challenge for governance. Luxembourg; 2012 p. 62. Available from 
7.  Biological and Medical Sciences: Roadmap Working Group: Report 2008. Brussels; 2008 p. 1–
139. Available from 
8.  Report of the Expert Group on Research Infrastructures: A vision for strengthening world class 
research infrastructures on the ERA. 2010. Available from 
9.  Asslaber M, Zatloukal K. Biobanks: transnational, European and global networks. Brief Funct 
Genomic Proteomic. Zatloukal, K., Institute of Pathology, Medical University of Graz, A-8036 
Graz, Austria; 2007 Sep [cited 2014 Mar 4];6(3):193–201.  
10.  Yuille M, van Ommen G-J, Brechot C, et al. Biobanking for Europe. Brief Bioinform. Yuille, M., 
The University of Manchester, School of Translational Medicine, CIGMR, Manchester M13 
9PT, United Kingdom; 2008;9(1):14–24.  
11.  Vaught J, Lockhart NC. The evolution of biobanking best practices. Clin Chim Acta. Elsevier 
B.V.; 2012 Oct 9 [cited 2014 Mar 4];413(19-20):1569–75.  
12.  Czerepak E a., Ryser S. Drug approvals and failures: implications for alliances. Nat Rev Drug 
Discov. 2008 Mar [cited 2013 Feb 1];7(3):197–8.  
13.  Vaught JB, Henderson MK, Compton CC. Biospecimens and biorepositories: from afterthought 
to science. Cancer Epidemiol Biomarkers Prev. 2012 Feb [cited 2014 Dec 2];21(2):253–5.  
14.  Cadigan RJ, Easter MM, Dobson AW, et al. “That’s a good question”: university researchers’ 
views on ownership and retention of human genetic specimens. Genet Med. 530 WALNUT ST, 
PHILADELPHIA, PA 19106-3621 USA: LIPPINCOTT WILLIAMS & WILKINS; 2011 
Jun;13(6):569–75.  
15.  Meir K, Gaffney EF, Simeon-Dubach D, et al. . Biopreserv Biobank. 2011;9(3):279.  
16.  Fortin S, Pathmasiri S, Grintuch R, et al. “Access arrangements” for biobanks: a fine line 
between facilitating and hindering collaboration. Public Health Genomics. Deschenes, M., P3G 
Consortium, Montreal, QC H3V 1A2, Canada; 2011 Jan [cited 2014 Mar 4];14(2):104–14.  
17.  Edwards T, Cadigan RJ, Evans JP, et al. Biobanks containing clinical specimens: defining 
characteristics, policies, and practices. Clin Biochem. Elsevier B.V.; 2014 Mar 15 [cited 2014 
Jun 15];47(4-5):245–51.  
18.  Gottweis H, Zatloukal K. Biobank governance: trends and perspectives. Pathobiology. 2007 
Jan [cited 2011 May 31];74(4):206–11.  
References 
 
Page | 166  
 
19.  Advice no. 45 of 19 January 2009 concerning banks of human bodily material for research 
purposes. 2009 p. 1–33. Available from 
20.  Bell WC, Sexton KC, Grizzle WE. Organizational issues in providing high-quality human tissues 
and clinical information for the support of biomedical research. Methods Mol Biol. 2010 Jan 
[cited 2011 May 31];576:1–30.  
21.  Hasan S. The Increasing Role of Biobanks in Personalized Medicine [Internet].  
22.  Donato J. Biobanking for Rare Diseases - Impact on Personalised Medicine. In: Özgüç M, 
editor. Rare Diseases: Integrative PPPM Approach as the Medicine of the Future. Dordrecht: 
Springer Netherlands; 2015 [cited 2014 Dec 20]. p. 23–31.  
23.  Cambon-Thomsen A, Rial-Sebbag E, Knoppers BM. Trends in ethical and legal frameworks for 
the use of human biobanks. Eur Respir J. 2007 Aug [cited 2014 Mar 4];30(2):373–82.  
24.  Godard B, Schmidtke J, Cassiman J, et al. Data Storage and DNA Banking for Biomedical 
Research: informed consent, confidentiality, quality issues, ownership, return of benefits. A 
professional perspective”. Eur J Hum Genet. 2003;11(Suppl 2):S88–122.  
25.  Riegman PHJ, Morente MM, Betsou F, et al. Biobanking for better healthcare. Mol Oncol. 
Riegman, P.H.J., Department of Pathology, Josephine Nefkens Institute, Erasmus Medical 
Center, 3015 GE Rotterdam, Netherlands; 2008 Oct [cited 2014 Mar 4];2(3):213–22.  
26.  Hewitt RE. Biobanking: The foundation of personalized medicine. Curr Opin Oncol. Hewitt, R. 
E., 13100 Aix-en-Provence, France; 2011;23(1):112–9.  
27.  Riegman PHJ, van Veen E-B. Biobanking residual tissues. Hum Genet. 2011 Sep [cited 2013 
Nov 29];130(3):357–68.  
28.  Linsen L, Hensen K, Rummens J-L (Virga J. Biobanken: Bouwstenen voor translationeel 
onderzoek. Virghaal Wet. 2009;2.  
29.  Brisson AR, Matsui D, Rieder MJ, et al. Translational research in pediatrics: tissue sampling 
and biobanking. Pediatrics. 2012 Jan [cited 2014 Dec 2];129(1):153–62.  
30.  Andersson K, Bray F, Arbyn M, et al. The interface of population-based cancer registries and 
biobanks in etiological and clinical research - current and future perspectives. Acta Oncol. 2010 
Nov [cited 2010 Oct 27];49(8):1227–34.  
31.  Zielhuis G a. Biobanking for epidemiology. Public Health. Elsevier Ltd; 2012 Mar 9 [cited 2014 
Dec 20];126(3):214–6.  
32.  Almqvist C, Adami H-O, Franks PW, et al. LifeGene - A large prospective population-based 
study of global relevance. Eur J Epidemiol. Almqvist, C., Department of Medical Epidemiology 
and Biostatistics, Karolinska Institutet, Box 281, Stockholm SE-171 77, Sweden; 
2011;26(1):67–77.  
33.  Elger BS, Caplan AL. Consent and anonymization in research involving biobanks: differing 
terms and norms present serious barriers to an international framework. EMBO Rep. 2006 Jul 
[cited 2011 May 31];7(7):661–6.  
34.  Hewitt R, Watson P. Defining Biobank. Biopreserv Biobank. 2013 Oct;11(5):309–15.  
35.  Nys H. Bloed, zweet en tranen. Kritische ontleding van de wet van 19 december 2008 inzake 
het verkrijgen en het gebruik van menselijk lichaamsmateriaal. Rechtskundig Weekbl. 
2009;(5):178–89.  
References 
 
Page | 167  
 
36.  OECD Guidelines on Human Biobanks and Genetic Research Databases. 2009.  
37.  Commission Implementing Decision of 22 November 2013 on setting up the Biobanks and 
Biomolecular Resources Research Infrastructure Consortium (BBMRI-ERIC) as a European 
Research Infrastructure Consortium. 2013 p. 63–80.  
38.  Legislation on biotechnology in the Nordic countries. 2014 p. 51. Available from 
39.  Petersen J. Biobanks and the Law in Denmark. Eur Intellect Prop Rev. 2004;383–9.  
40.  Recommendation 2006(4) of the Committee of Ministers to member states on research on 
biological materials of human origin. Council of Europe; 2006. p. 6.  
41.  Tutton R. Banking expectations: the promises and problems of biobanks. Per Med. Tutton, R., 
Lancaster University, Centre for the Economic and Social Aspects of Genomics (CESAGen), 
Institute for Advanced Studies, Lancaster LA1 4YD, United Kingdom; 2007 Nov [cited 2014 Apr 
16];4(4):463–9.  
42.  Sak J, Pawlikowski J, Goniewicz M, et al. Population biobanking in selected European 
countries and proposed model for a Polish national DNA bank. J Appl Genet. 2012 Jan 27 
[cited 2012 Mar 11];  
43.  Ollier W, Sprosen T, Peakman T. UK Biobank: from concept to reality. Pharmacogenomics. 
2005 Sep [cited 2014 Dec 3];6(6):639–46.  
44.  Barbareschi M, Fasanella S, Cantaloni C, et al. Scientific and Managerial Premises and 
Unresolved Issues in Tumour Biobanking Activities. In: Pascuzzi G, Izzo U, Macilotti M, editors. 
Comparative Issues in the Governance of Research Biobanks: Property, Privacy and 
Intellectual Property, and the Role of Technology. Trento: Springer; 2013. p. 301–10.  
45.  Shickle D, Griffin M, El-Arifi K. Inter- and intra-biobank networks: classification of biobanks. 
Pathobiology. Shickle, D., Academic Unit of Public Health, Institute of Health Sciences, 
University of Leeds, Leeds LS2 9LJ, United Kingdom; 2010 Jan;77(4):181–90.  
46.  Bergmann MM. The EPIC study – data, samples and ethical challenges. Leuven; 2012.  
47.  Tybring G. Managing and Using a Biobank in Sweden [Internet]. 2013. p. 24.  
48.  Van den Eynden J, Degaillier C, Van Eycken L, et al. the Belgian Virtual Tumourbank a tool for 
translational cancer research. Biopreserv Biobank. 2011;9(3):292.  
49.  Bekaert S, Ectors N, in’t Veld P, et al. Multidisciplinary working groups around the Flemish 
Biobank stimulates the Translational Biomedical Research, Poster at ESBB Conference 2014. 
Leipzig; 2014. p. 1.  
50.  Welcome to the European Cancer Sample Exchange Platform [Internet].  
51.  Riegman PHJ, de Jong BWD, Llombart-Bosch A. The Organization of European Cancer 
Institute Pathobiology Working Group and its support of European biobanking infrastructures 
for translational cancer research. Cancer Epidemiol Biomarkers Prev. 2010 May [cited 2011 
May 31];19(4):923–6.  
52.  Groen licht vier nieuwe parels [Internet].  
53.  Talmon JL, Ros MG, Legemate DA. PSI: The Dutch Academic Infrastructure for shared 
biobanks for translational research. Transl Bionforma. 2008 Jun;110–4.  
References 
 
Page | 168  
 
54.  Ectors N. International and national initiatives in biobanking. Verh K Acad Geneeskd Belg. 
2011 Jan [cited 2012 Feb 8];73(1-2):5–40.  
55.  Thirlway H. The Sources of International Law. Oxford: Oxford University Press; 2014.  
56.  Platt J, Bollinger J, Dvoskin R, et al. Public preferences regarding informed consent models for 
participation in population-based genomic research. Genet Med. 2014 Jan [cited 2014 Mar 
4];16(1):11–8.  
57.  Kerath SM, Klein G, Kern M, et al. Beliefs and attitudes towards participating in genetic 
research - a population based cross-sectional study. BMC Public Health. 2013;13:114.  
58.  Cervo S, Rovina J, Talamini R, et al. An effective multisource informed consent procedure for 
research and clinical practice: an observational study of patient understanding and awareness 
of their roles as research stakeholders in a cancer biobank. BMC Med Ethics. BMC Medical 
Ethics; 2013 Jan [cited 2014 Jan 10];14(1):30.  
59.  Chen H, Gottweis H, Starkbaum J. Public Perceptions of Biobanks in China: A Focus Group 
Study. Biopreserv Biobank. 2013 Oct [cited 2013 Nov 29];11(5):267–71.  
60.  Gottweis H, Gaskell G, Starkbaum J. Connecting the public with biobank research: reciprocity 
matters. Nat Rev Genet. Nature Publishing Group; 2011 Jan [cited 2011 Oct 21];12(11):738–9.  
61.  Gaskell G, Gottweis H, Starkbaum J, et al. Publics and biobanks: Pan-European diversity and 
the challenge of responsible innovation. Eur J Hum Genet. 2013 Jan [cited 2013 May 
22];21(1):14–20.  
62.  Schildmann J, D’Abramo F, Vollmann J. Information and consent in biobanking research. A 
review of socio-empirical research on the views and preferences of research participants and 
the public. Onkologie. 2013;36(Supplement 7):200–1.  
63.  Vaught J, Kelly A, Hewitt R. A review of international biobanks and networks: Success factors 
and key benchmarks. Biopreserv Biobank. Vaught, J., Office of Biorepositories and 
Biospecimen Research (OBBR), National Cancer Institute, National Institutes of Health, 
Bethesda, MD 20892, United States; 2009;7(3):143–50.  
64.  Hens K, Nys H, Cassiman J-J, et al. Biological sample collections from minors for genetic 
research: a systematic review of guidelines and position papers. Eur J Hum Genet. 2009 Aug 
[cited 2014 Mar 4];17(8):979–90.  
65.  Bauer K, Taub S, Parsi K. Ethical issues in tissue banking for research: a brief review of 
existing organizational policies. Theor Med Bioeth. 2004 Jan [cited 2014 Mar 4];25(2):113–42.  
66.  Master Z, Nelson E, Murdoch B, et al. Biobanks, consent and claims of consensus. Nat 
Methods. Nature Publishing Group; 2012 Sep 30 [cited 2014 Mar 4];9(9):885–8.  
67.  Henderson GE, Edwards TP, Cadigan RJ, et al. Stewardship Practice of U.S. Biobanks. Sci 
Transl Med. 2013;5(215):1–6.  
68.  Crawford G, Foulds N, Fenwick A, et al. Genetic medicine and incidental findings: it is more 
complicated than deciding whether to disclose or not. Genet Med. 2013 Nov [cited 2014 Mar 
4];15(11):896–9.  
69.  Access to collections of data and materials for health research: A report to the Medical 
Research Council and the Wellcome Trust [Internet]. Medical Research Council and the 
Wellcome Trust; 2006. Available from: http://www.wellcome.ac.uk/About-
us/Publications/Reports/Biomedical-ethics/WTX030843.htm 
References 
 
Page | 169  
 
70.  Scott CT, Caulfield T, Borgelt E, et al. Personal medicine--the new banking crisis. Nat 
Biotechnol. Nature Publishing Group; 2012 Feb 8 [cited 2014 Mar 4];30(2):141–7.  
71.  Fleiner T. Common Law and Continental Law  : Two Legal Systems. 2005. p. 1–35.  
72.  Dyèvre A. Realism About Legal Integration  : Outline of a Nuanced Legal Realist Approach. 
2013 p. 1–25. Available from 
73.  Pukkala E, Andersen A, Berglund G, et al. Nordic biological specimen banks as basis for 
studies of cancer causes and control - More than 2 million sample donors, 25 million person 
years and 100 000 prospective cancers. Acta Oncol (Madr). Pukkala, E., Finnish Cancer 
Registry, Institute for Statistical and Epidemiological Cancer Research, FI-00170 Helsinki, 
Finland; 2007;46(3):286–307.  
74.  Frank L. The Epidemiologist ’s Dream  : Denmark. Science (80- ). 2003;301:70.  
75.  Kaye J. Do we need a uniform regulatory system for biobanks across Europe? Eur J Hum 
Genet. 2006 Mar [cited 2011 May 31];14(2):245–8.  
76.  Material and Data Access Agreement- Core Elements and Generic Clauses [Internet]. P3G; 
2008 p. 6. Available from: http://www.p3gobservatory.org/repository/ethics.htm 
77.  Knoppers BM, Chisholm RL, Kaye J, et al. A P3G generic access agreement for population 
genomic studies. Nat Biotechnol. Nature Publishing Group; 2013 May [cited 2014 Mar 
4];31(5):384–5.  
78.  Zatloukal K, Vaught J. What Are the Next Steps to Overcoming Roadblocks to Transnational 
Biobank Collaboration? Biopreserv Biobank. 2012 Feb [cited 2012 Feb 27];10(1):2–3.  
79.  Watson PH, Ravid R, Eng CB, et al. What Are the Main Roadblocks to Transnational Biobank 
Collaboration, and How Can We Overcome Them? Biopreserv Biobank. 2011 Sep [cited 2011 
Dec 2];9(3):213–6.  
80.  Lopez-Guerrero JA, Riegman PHJ, Oosterhuis JW, et al. TuBaFrost 4: access rules and 
incentives for a European tumour bank. Eur J Cancer. 2006 Nov [cited 2014 Mar 
4];42(17):2924–9.  
81.  Lemrow SM, Colditz GA, Vaught JB, et al. Key elements of access policies for biorepositories 
associated with population science research. Cancer Epidemiol Biomarkers Prev. 2007 Aug 
[cited 2014 Mar 4];16(8):1533–5.  
82.  Joly Y, Zeps N, Knoppers BM. Genomic databases access agreements: legal validity and 
possible sanctions. Hum Genet. 2011 Jun 25;130(3):441–9.  
83.  Creation and Governance of Human Genetic Research Databases [Internet]. OECD; 2006. 
Available from: 
http://www.oecd.org/science/biotech/creationandgovernanceofhumangeneticresearchdatabase
s.htm 
84.  Colledge F, Elger B, Howard HC. A Review of the Barriers to Sharing in Biobanking. 
Biopreserv Biobank. 2013 Dec [cited 2014 Jan 17];11(6):339–46.  
85.  Campbell LD, Betsou F, Garcia DL, et al. Development of the ISBER Best Practices for 
Repositories: Collection, Storage, Retrieval and Distribution of Biological Materials for 
Research. Biopreserv Biobank. 2012 Apr [cited 2012 May 7];10(2):232–3.  
References 
 
Page | 170  
 
86.  Principles and Guidelines for Access to Research Data from Public Funding [Internet]. OECD; 
2007. Available from: http://www.oecd.org/science/sci-tech/38500813.pdf 
87.  Wichmann H-E, Kuhn K a, Waldenberger M, et al. Comprehensive catalog of European 
biobanks. Nat Biotechnol. 2011 Sep [cited 2014 Jan 22];29(9):795–7.  
88.  Human biobanks for research: Opinion [Internet]. Berlin: Deutscher Ethikrat; 2010. Available 
from: http://www.ethikrat.org/dateien/pdf/stellungnahme-humanbiobanken-fuer-die-
forschung.pdf 
89.  Zika E, Paci D, Schulte in den Bäumen T, et al. Biobanks in Europe: Prospects for 
Harmonisation and Networking. 2010 p. 170. Available from 
90.  Watson RWG, Kay EW, Smith D. Integrating biobanks: addressing the practical and ethical 
issues to deliver a valuable tool for cancer research. Nat Rev Cancer. 2010 Sep 12 [cited 2014 
Mar 4];10(9):646–51.  
91.  O’Brien SJ. Stewardship of human biospecimens, DNA, genotype, and clinical data in the 
GWAS era. Annu Rev Genomics Hum Genet. 2009 Jan [cited 2014 Mar 4];10(May):193–209.  
92.  Hakimian R, Korn D. Ownership and use of tissue specimens for research. JAMA. 2004 Nov 24 
[cited 2014 Mar 4];292(20):2500–5.  
93.  All for one and one for all. Nat Methods. 2009 Feb [cited 2014 Dec 2];6(2):111–111.  
94.  Quigley M. Property and the body: applying Honore. J Med Ethics. 2007 Nov [cited 2014 Mar 
4];33(11):631–4.  
95.  Björkman B. Different types--different rights. Distinguishing between different perspectives on 
ownership of biological material. Sci Eng Ethics. 2007 Jun [cited 2014 Mar 4];13(2):221–33.  
96.  Samples and data for research: Template for access policy development [Internet]. National 
Cancer Research Institute, the National Cancer Intelligence Network and onCorde UK; 2009 p. 
45. Available from: http://www.oncoreuk.org/pages/researchers_data.html 
97.  Milanovic F, Pontille D, Cambon-Thomsen A. Biobanking and Data Sharing: A Plurality of 
Exchange Regimes. Genomics, Soc Policy. 2007;3:17–30.  
98.  Fullerton SM, Anderson NR, Guzauskas G, et al. Meeting the governance challenges of next-
generation biorepository research. Sci Transl Med. 2010 Jan 20;2(15):1–8.  
99.  Winickoff DE, Winickoff RN. The charitable trust as a model for genomic biobanks. N Engl J 
Med. 2003 Oct 18 [cited 2011 May 31];349(12):1180–4.  
100.  Conley JM, Mitchell R, Cadigan RJ, et al. A Trade Secret Model for Genomic Biobanking. J 
Law Med Ethics. 2012 Sep [cited 2012 Dec 6];40(3):612–29.  
101.  Haddow G, Laurie G, Cunningham-Burley S, et al. Tackling community concerns about 
commercialisation and genetic research: A modest interdisciplinary proposal. Soc Sci Med. 
2007 Jan [cited 2013 May 16];64(2):272–82.  
102.  Lincoln YS, Guba EG. Naturalistic Inquiry. Beverly Hills: Sage; 1985.  
103.  Patton MQ. Qualitative evaluation and research methods. 2nd ed. Newbury Park: SAGE 
Publications, Inc; 1990.  
References 
 
Page | 171  
 
104.  Dierckx de Casterlé B, Gastmans C, Bryon E, et al. QUAGOL: a guide for qualitative data 
analysis. Int J Nurs Stud. 2012 Mar [cited 2014 Mar 24];49(3):360–71.  
105.  Shabani M, Borry P. From the Principles of Genomic Data Sharing to the Practices of Data 
Access Committees. 2014. Available from 
106.  Mascalzoni D, Dove ES, Rubinstein Y, et al. International Charter of principles for sharing bio-
specimens and data. Eur J Hum Genet. 1] Center for Research Ethics and Bioethics Uppsala 
University, Uppsala, Sweden [2] Center for Biomedicine, EURAC Research, Bolzano, Italy 
Centre of Genomics and Policy, Mc Gill University, Montreal, Quebec, Canada Office for Rare 
Diseases Research, Natio; 2014 Sep 24 [cited 2014 Dec 11];(1476-5438 (Electronic)).  
107.  Cook. Pharmaceuticals, biotechnology and the law. Second. London: LexisNexis; 2009.  
108.  Boggio A. Transfer of samples and sharing of results: requirements imposed on researchers. 
In: Elger BS, Biller-Andorno N, Mauron A, et al., editors. Ethical and regulatory aspects of 
human genetic databases. Ashgate; 2008. p. 1–11.  
109.  Peeters M. De rol van het EU-recht op vermarkting in de (gezondheids)zorg. Vermarkting van 
de zorg: meer dan commercialisering alleen? Die Keure / La Charte; 2011. p. 111–62.  
110.  Panis S. Stamcellen en recht: een juridische analyse van wegneming tot gebruik. 2014. p. 
1050.  
111.  Bovenberg JA. Whose tissue is it anyway? Nat Biotechnol. 2005 Aug;23(8):929–33.  
112.  Smith E. The Limits of Sharing: An Ethical Analysis of the Arguments For and Against the 
Sharing of Databases and Material Banks. Account Res. Taylor & Francis Group; 
2011;18(6):357–81.  
113.  Ness RB. Biospecimen “ownership”: point. Cancer Epidemiol Biomarkers Prev. 2007 Feb [cited 
2013 Mar 15];16(2):188–9.  
114.  Cambon-Thomsen A, Thorisson G a, Andrieu S, et al. The role of a bioresource research 
impact factor as an incentive to share human bioresources. Nat Genet. Nature Publishing 
Group; 2011 Jun [cited 2011 Jun 14];43(6):503–4.  
115.  Kosseim P, Dove ES, Baggaley C, et al. Building a data sharing model for global genomic 
research. Genome Biol. 2014 Aug 11 [cited 2014 Oct 16];15(8):430.  
116.  Knoppers BM, Harris JR, Tassé AM, et al. Towards a data sharing Code of Conduct for 
international genomic research. Genome Med. 2011;3(7):46.  
117.  Sharing Data from Large-scale Biological Research Projects: A System of Tripartite 
Responsibility. 2003 p. 6. Available from 
118.  Creating a Global Alliance to Enable Responsible Sharing of Genomic and Clinical Data. 2013 
p. 34. Available from 
119.  Framework for Responsible Sharing of Genomic and Health-Related Data [Internet]. Global 
Alliance for Genomics and Health; 2013. Available from: 
http://genomicsandhealth.org/framework 
120.  Panis S, Van Gelder N. De Wet Menselijk Lichaamsmateriaal van 19 december 2008  : een 
grondige analyse. Tijdschr voor Gezondheidsr. 2008;(4):217–53.  
References 
 
Page | 172  
 
121.  Coëffé M, Callens S. Le matériel corporel humain. Waterloo: Wolters Kluwer Belgium SA; 
2012.  
122.  De Bot D. Art. 21 Wet Persoonsgegevens. Personen- en familierecht Artikelsgewijze 
commentaar met overzicht van rechtspraak en rechtsleer. 2001. p. 5.  
123.  DE BOT D. Art. 22 Wet Persoonsgegevens. Personen- en familierecht Artikelsgewijze 
commentaar met overzicht van rechtspraak en rechtsleer. 2001. p. 5.  
124.  Biobanks and the public: Governing biomedical research resources in Europe. 2013 p. 77. 
Available from 
125.  Hoeyer KL. Person, patent and property: a critique of the commodification hypothesis. 
Biosocieties. 2007;2(3):327–48.  
126.  Ravid R. Standard Operating Procedures, ethical and legal regulations in BTB 
(Brain/Tissue/Bio) banking: what is still missing? Cell Tissue Bank. 2008 Jun [cited 2010 Oct 
21];9(2):121–37.  
127.  Kyvik KO. Danish biobank legislation, a simple approach  ? Nor Epidemiol. 2012;21(2):161–2.  
128.  Hartlev M. Collecting samples for future uses Case  : Opt-out in Danish Biobanking Samples for 
future use Stakeholders and interests. Society. Uppsala; 2011. p. 19.  
129.  Minssen T, Schovsbo J. Legal aspects of biobanking as key issues for personalized medicine 
and translational exploitation. Per Med. 2014 Jul [cited 2014 Oct 9];11(5):497–508.  
130.  Nicol D, Gold ER. Standards for Biobank Access and Intellectual Property. In: Rimmer M, 
McLennan A, editors. Intellectual Property and Emerging Technologies: The New Biology. 
Queen Mary. Cheltenham UK: Edward Elgar; 2012. p. 133–16.  
131.  Dove ES, Joly Y. The contested futures of biobanks and intellectual property. Teoría y derecho. 
2012;11:132–47.  
132.  Caulfield T, Cook-Deegan RM, Kieff FS, et al. Evidence and anecdotes: an analysis of human 
gene patenting controversies. Nat Biotechnol. 2006 Sep [cited 2014 May 26];24(9):1091–4.  
133.  Roy AG. Protection of Intellectual Property in the Form of Trade Secrets. J Intellect Prop 
Rights. 2006;11(May):192–200.  
134.  Pathmasiri S, Deschênes M, Joly Y, et al. Intellectual property rights in publicly funded 
biobanks: much ado about nothing? Nat Biotechnol. Nature Publishing Group; 2011 Apr [cited 
2011 Apr 14];29(4):319–23.  
135.  De Visscher F, Michaux B. Précis du droit d’auteur et des droits voisins. Brussels: Bruylant; 
2000.  
136.  Vandewynckel S, Verlinden M, Meyer G. Overzicht van procesregels inzake intellectuele 
eigendomsrechten. Kortrijk: UGA; 2014.  
137.  Hellstadius A, Wolk S, Wessman R. Intellectual property and biobanks. In: Hansson MG, Levin 
M, editors. Biobanks as resources for health. Uppsala: Universitetstryckeriet; 2003. p. 207–25.  
138.  Evrard J-J, Péters P. La défense de la marque dans le Benelux - marque Benelux et marque 
communautaire. 2000.  
References 
 
Page | 173  
 
139.  Proposal for a Directive of the European Parliament and of the Council on the protection of 
undisclosed know-how and business information (trade secrets) against their unlawful 
acquisition, use and disclosure [Internet]. Brussels; 2013 p. 26.  
140.  Proposal for a Directive of the European Parliament and of the Council on the protection of 
undisclosed know-how and business information (trade secrets) against their unlawful 
acquisition, use and disclosure [Internet]. Brussels: Council of the European Union; 2014 p. 1–
50.  
141.  Keshri H, Keshri S. Trade Secrets: A Secret Still to Unveil. J Intellect Prop Rights. 
2008;13:208–17.  
142.  Minssen T, Schwartz H. Standing on shaky ground - US patent-eligibility of isolated DNA and 
genetic diagnostics after AMP v. USPTO - Part IV. Queen Mary J Intellect Prop. 
2013;3(2):118–44.  
143.  Minssen T, Nilsson D. The US Supreme Court in Mayo v Prometheus – taking the fire from or 
to biotechnology and personalized medicine? Queen Mary J Intellect Prop. 2012 Dec 
1;2(4):376–88.  
144.  Sterckx S, Cockbain J, Howard H, et al. “Trust is not something you can reclaim easily”: 
patenting in the field of direct-to-consumer genetic testing. Genet Med. 2013 May [cited 2014 
Sep 16];15(5):382–7.  
145.  Simon BM, Law S, Barton J, et al. How to get a fair share: IP policies for publicly supported 
biobanks. Stanf J Law Sci Policy. 2008 Sep [cited 2011 Oct 17];452(2003):65–79.  
146.  Gitter DM. The Challenges of Achieving Open-Source Sharing of Biobank Data. Biotechnol 
Law Rep. 2010 Dec [cited 2014 Apr 16];29(6):623–35.  
147.  Henderson GE, Edwards TP, Cadigan RJ, et al. Stewardship practices of U.S. biobanks. Sci 
Transl Med. 2013 Dec 11 [cited 2014 Aug 25];5(215):215cm7.  
148.  Ducato R. “Adiós Sui Géneris”: a study of the legal feasibility of the sui generis right in the 
context of research biobanks [Internet]. Revista de derecho y genoma humano = Law and the 
human genome review / Cátedra de Derecho y Genoma Humano/Fundación BBV-Diputación 
Foral de Bizkaia. 2013 p. 125–46. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/24340829 
149.  Verlinden M, Nys H, Ectors N, et al. Access to biobanks: harmonization across biobank 
initiatives. Biopreserv Biobank. 2014 Dec [cited 2014 Dec 17];12(6):415–22.  
150.  Pénin J, Wack J-P. Research tool patents and free-libre biotechnology: A suggested unified 
framework. Res Policy. 2008 Dec [cited 2014 May 26];37(10):1909–21.  
151.  Huys I, Matthijs G, Van Overwalle G Van. The fate and future of patents on human genes and 
genetic diagnostic methods. Nat Rev. Nature Publishing Group; 2012;  
152.  Caulfield T. Reflections on the Gene Patent War: The Myriad Battle, Sputnik and Beyond. Clin 
Chem. 2011;57(7):977–9.  
153.  Holman CM. Preliminary Thoughts on Mayo v. Prometheus: The implications for 
Biotechnology”. Biotechnol Law Rep. 2012;111–3.  
154.  Reiter TA, R. S. McQuade. Commentary: The Federal Circuit Court of Appeals decided that 
isolated DNA claims are patentable. Ind Biotechnol. 2011;272–5.  
References 
 
Page | 174  
 
155.  Heaney C, Carbone J, Gold R, et al. The Perils of Taking Property Too Far. Stanf J Law Sci 
Policy. 2009 May [cited 2014 Apr 15];1:46–64.  
156.  Conley JM, Vorhaus D, Cook-Deegan R. How Will Myriad Respond to the Next Generation of 
BRCA Testing? Genomics Law Report. 2011;4.  
157.  Huys I, Matthijs G, Van Overwalle G, et al. Gene and genetic diagnostic method patent claims: 
a comparison under current European and US patent law. EJHG. Nature Publishing Group; 
2011 Jun 8 [cited 2011 Jun 28];(September 2010):1–4.  
158.  Holman BCM. Editorial: In Myriad the Supreme Court Has, Once Again, Increased the 
Uncertainty of U.S. Patent Law. Biotechnol Law Rep. 2013;32(5):289–93.  
159.  Andrews LB. Harnessing the Benefits of Biobanks. J Law, Med Ethics. 2005;33(1):22–30.  
160.  Winickoff DE. Partnership in U.K. Biobank: a third way for genomic property? J Law Med 
Ethics. 2007 Jan [cited 2011 May 31];35(3):440–56.  
161.  Feldman MP, Colaianni A, Liu CK. Lessons from the Commercialization of the Cohen-Boyer 
Patents: The Stanford University Licensing Program. In: Krattiger A, Mahoney RT, editors. 
Intellectual property management in health and agricultural innovation: A handbook of Best 
Practices. 2007. p. 1797 – .  
162.  In the Public Interest: Nine Points to Consider in Licensing University Technology [Internet]. 
2007 p. 17. Report No.: 1. Available from: http://news-
service.stanford.edu/news/2007/march7/gifs/whitepaper.pdf 
163.  Mallete A, Tassé AM, Knoppers BM. P3G Model Framework for Biobank Governance 
[Internet]. Montreal; 2013 p. 1–21. Available from: http://www.p3g.org/biobank-toolkit/p3g-
model-framework-biobank-governance 
164.  Data Access Policy for the International HapMap Project [Internet].  
165.  A global network for investigating the genomic epidemiology of malaria. Nature. 2008 Dec 11 
[cited 2015 Jan 7];456(7223):732–7.  
166.  ACCESS PROCEDURES: Application and review procedures for access to the UK Biobank 
Resource [Internet]. 2011. p. 35.  
167.  O’Rourke PP, Abelman M, Heffernan KG. Centralized banks for human embryonic stem cells: 
a worthwhile challenge. Cell Stem Cell. 2008 Apr 10 [cited 2011 May 31];2(4):307–12.  
168.  Colledge FM a, Elger BS, Shaw DM. “Conferring authorship”: biobank stakeholders’ 
experiences with publication credit in collaborative research. PLoS One. 2013 Jan [cited 2015 
Jan 7];8(9):e76686.  
169.  International Code of Conduct for Genomic and Health-Related Data Sharing. 2014 p. 8. 
Available from 
170.  OECD Best Practices Guidelines for Biological Resource Centres. 2007 p. 1–115. Available 
from 
171.  Human Tissue and Medical Research: Code of conduct for responsible use. 2011. Available 
from 
172.  Working document on research on biological materials of human origin. Strasbourg: Committee 
on Bioethics; 2014 p. 10.  
 Page | 175  
 
 
Annexes
Annexes 
Page | 176  
 
  
Annexes 
Page | 177  
 
Annex 1: Supplementary Table to Chapter 1: Access arrangements of selected organizations, 
biobank networks and biobanks 
Table 8: Overview of access arrangements of organizations, biobank networks and biobanks  
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Annex 2: Supplementary Table to Chapter 1: Overview of qualitative results of comparative 
analysis  
Table 9: Results of comparative analysis of access arrangements 
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Condition 14: Priority setting Organizations Networks Biobanks       
Yes (total) 6 8 8 
  
  
Precedence 1 0 2 
  
  
Collector 2 2 0 
  
  
Scientific merit 4 3 3 
  
  
Funding 1 0 0 
  
  
Working in particular institution 2 1 0 
  
  
Internal/affiliated project 2 5 2 
  
  
Lottery 1 0 0 
  
  
Linking of other sources with BB 0 1 0 
  
  
Increasing quality of sources of BB 0 1 0 
  
  
Closeness to purpose of BB 0 3 4 
  
  
Required number of HBM 0 1 3 
  
  
Technical requirements 0 0 1 
  
  
Geographical closeness 0 3 0 
  
  
Peer review funded 0 1 0 
  
  
Not specified 20 28 12 
  
  
              
Condition 15: Intellectual property Organizations Networks Biobanks       
IP on primary HBM 2 1 4 
  
  
No IP on primary HBM 7 3 3 
  
  
No reach-through IP for biobank 7 7 5 
  
  
Reach-through IP for biobank 0 0 3 
  
  
Research use license 1 2 3 
  
  
Not specified 14 25 9       
       Condition 16: Exclusive (access) right of 
applicant 
Organizations Networks Biobanks 
      
Yes 3 4 5 
  
  
No 1 4 3 
  
  
Only to derived data 1 0 0 
  
  
Not specified 21 28 12 
  
  
Condition 17: Preferential (access) right 
of collector Organizations Networks Biobanks 
  
  
Yes 7 4 4 
  
  
No 1 1 2 
  
  
Not specified 18 31 14       
       Condition 18: Benefit sharing Organizations Networks Biobanks       
Yes 16 2 0 
  
  
Recognition/feedback to donors 2 0 0 
  
  
Contribution to BB 1 1 0 
  
  
Contribution to public fund 0 1 0 
  
  
Preferential access to healthcare 
developments 3 0 0 
  
  
No 0 0 0 
  
  
Not specified 10 34 20       
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Annex 3: Interview guide for semi-structured interviews 
1. Factual biography 
1.1. Interview date 
1.2. Name of informant 
1.3. Position of informant 
1.4. Short description of the relationship of the informant with biobanking 
2. Short description of purpose and nature of the interview 
• The current research would like to study practical experience and personal opinion on 
hopes and concerns regarding the relationship between custodians and researchers/PI 
3. Guidelines 
• The informant’s identity remains anonymous in the written report of the study and responses 
are treated in confidence. There will only be references to the concerned biobank or function, 
but not the combination of both, since this would allow identification of the informant 
• Request permission to tape record interview 
4. Checklist of topics 
4.1. Aim of research project:  
i. Collect data on practical experience and personal opinion on hopes and concerns in 
collaboration between custodian and researcher 
4.2. Questions in relation to access to biobanks:  
1. Professional experience with biobanking? 
a. How is your institute involved in biobanking? 
2. How to handle requests for access?  
a. Policy at your institute? Rules in your country? 
b. Your experience? Your own opinion?  
c. Is access policy/arrangement publicly available? 
3. Distinction between access to HBM and access to data? 
a. Different policy? 
4. Leftover HBM?  
a. Policy at your institute? Rules in your country? 
b. Your experience? Your own opinion?  
5. Which benefits?  
• Prompts: Participation in such benefits? When? 
o Policy at your institute? Rules in your country? 
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o Your experience? Your own opinion?  
 
6. What is understood by returning ‘research results’  
• Is ‘Returning research results’ a category of benefits? 
o Policy at your institute? Rules in your country? 
o Your experience? Your own opinion?  
o Decision of researcher on use of returned results? 
§ What if HBM was prospectively collected at the request of the applicant? 
7. Publicly available information on access to HBM and/or associated data? 
• Prompts: How to increase transparency? 
o Policy at your institute? Rules in your country? 
o Your experience? Your own opinion?  
• Registration obligation? 
8. Access by industry: Allow access to biobanks? Different policy? 
 
4.3. Open question: Any other hopes or concerns in relation to access to biobanks? 
 
5. Closing comments 
5.1. Debriefing 
5.2. Copy of final report will be sent 
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Annex 4: Common list of concepts 
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Annex 5: Web of rights and obligations of custodian and applicant  
1. Rights and obligations in relation to decision on access to HBM and data  
A. Rights of custodian 
§ Evaluate access request and decide on access to HBM 
§ Consensus:  
§ Evaluate availability and suitability of HBM and data for project 
§ Evaluate impact on existing collection of HBM and data 
§ Determine priorities between different research projects  
§ No consensus:  
o Evaluate quality and scientific and medical useful of project 
o Evaluate research merits of applicant 
o Evaluate ethical value 
B. Obligations of custodians 
§ Consensus:  
§ Access committee should dispose of sufficient expertise/experience  
§ Access committee should act independently 
§ No consensus: Should access committee 
§ follow advice of ethics committee? 
§ consult external experts? 
§ motivate its decisions? 
§ have discretionary power or apply criteria determined by national legislator? 
 
C. Rights of applicant 
§ Access collection of HBM and data 
§ Use HBM and data in research project 
§ Keep certain information confidential 
§ Priority access in case applicant collected HBM and data 
 
D. Obligations of applicant 
§ Consensus: 
§ Use for specific project and certain time period 
§ Provide synopsis of project 
§ No consensus: 
§ Provide elaborated description of project 
§ Specify type of research 
§ Provide technical motivation of requested HBM and data 
 
2. Rights and obligations in relation to leftover HBM  
A. Rights of custodian 
Ø Decide on return or destruction 
Ø Decide on use in new or follow-up project 
Ø Verify leftover HBM 
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Ø Provide minimum amount of HBM 
 
B. Obligations of applicant 
Ø Inform biobank about leftover HBM 
Ø Return or destroy 
Ø Submit new request for new use of HBM 
Ø Prohibition to transfer to third party 
 
3. Right to participate in benefits of research project 
A. Rights of custodian 
Ø Charge access fee 
§ Right to distinguish between internal applicant and external and industrial applicants 
Ø Request that some of the benefits are fed back into biobank infrastructure 
Ø Share in benefits of research project 
§ Condition: Scientific contribution to project 
 
B. Right of applicant 
Ø Enjoy benefits of research project 
 
C. Obligations of applicant 
§ Pay access fee 
§ Feed some of the benefits back into biobank infrastructure 
 
4. Right to request the return of research results 
A. Rights of custodian 
Ø Request return and sharing of research results 
Ø Conditions 
§ Consensus:  
• Proper infrastructure to store and share research results 
• Clear rules on access to research results 
• Sufficient recognition of researcher that generates results 
• Respect legitimate interest of researcher that generates results 
• No consensus 
o Obligatory requirement to access collection of HBM and data 
 
B. Rights of applicant 
Ø Be informed and/or consulted on access to research results 
Ø Sufficient recognition for returning research results 
Ø Respect his legitimate interests 
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1 Professional career 
§ September 2012 until June 2013 and January until July 2014: Visiting Researcher at 
Copenhagen University 
§ September 2010 until March 2015: PhD Candidate at KU Leuven 
§ October 2005 until March 2011: Attorney at Law at Stibbe Brussels 
§ February 2005 until October 2005: Scientific Researcher at VUB 
 
2 List of original peer-reviewed publications 
1. Articles (IT or AT) indexed in VABB  
§ Verlinden Michiel, Nys Herman, Ectors Nadine and Huys Isabelle, Access to biobanks: 
harmonization across biobank initiatives. Biopreserv Biobank. 2014; 12(6): 415–22. 
§ Stevens Hilde, Verbeken Gilbert, Verlinden Michiel, Huys Isabelle (2011). Kijken naar cel- 
en gentherapie als „geneesmiddel” – Technische en juridische uitdagingen in ATMP-
ontwikkeling. Tijdschrift voor Geneeskunde, 67 (22), 1105-1111 (VABB-1).  
§ Verlinden Michiel, Stevens Hilde, Huys Isabelle (2011). Geen octrooibescherming van 
genetische informatie bij functieverandering via verwerking in een biotechnologisch 
proces. Intellectuele Rechten - Droits Intellectuels, 3, 213-216 (VABB-1).  
2. Articles IT not indexed in WoS or VABB  
§ Pirnay, Jean-Paul; Baudoux, Etienne; Cornu, Olivier; Delforge, Alain; Delloye, Christian; 
Guns, Johan; Heinen, Ernst; Van den Abbeel, Etienne; Vanderkelen, Alain; Van Geyt, 
Caroline; van Riet, Ivan; Verbeken, Gilbert; De Sutter, Petra; Verlinden, Michiel; Huys, 
Isabelle; Cockbain, Julian; Chabannon, Christian; Dierickx, Kris; Schotsmans, Paul; De 
Vos, Daniel; Rose, Thomas; Jennes, Serge and Sterckx, Sigrid, “Access to human tissues 
for research and product development: From EU regulation to alarming legal 
developments in Belgium”, EMBO reports 2015 (accepted for publication) 
§ Callewaert Koen *, Clerix Andre*, D'Halleweyn Nele*, Dauwe Brigitte*, De Gryse Erik*, 
Dekoninck Christian *, Ronse Christoph*, Theunis Patrick*, Verlinden Michiel* (2010). 
[AIPII - Question Q204P] Liability for contributory infringement of IPRs [Intellectual 
property rights] - certain aspects of patent infringement. Revue de Droit Intellectuel: 
l'Ingénieur-Conseil, 3, 317-325.  
§ Dupont Renaud*, Kaesmacher Dominique*, Santantonio Olivia*, Sorreaux Gregory*, Van 
den Bulck Paul*, Verlinden Michiel*, Vernimme Ignace* (2009). AIPPI Report on Q210: 
The Protection of Major Sports Events and associated Commercial activities through 
Trademarks and other IPR. Revue de Droit Intellectuel: l'Ingénieur-Conseil, 258.  
§ Wright David, Friedewald Michael, Schreurs Wim, Verlinden Michiel, Gutwirth Serge, 
Punie Yves, Maghiros I, Vildjiounaite E, Alahuhta P (2008). The Illusion of Security: A 
fiction scenario of daily life. Communications of the ACM, 51 (3), 57-63 (IF publication 
year: 2.65) (IF most recent: 2.86).  
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§ Cornu Emmanuel *, De Gryse Ludovic*, Kaesmacher Dominique*, Leherte George*, 
Meyer Gunther*, Missoten Stephanie*, Mottet Annick*, Santantonio Olivia*, Van Bunnen 
Louis*, Verlinden Michiel* (2008). L'épuisement des droits de propriété intellectuelle dans 
les cas de recyclage et de réparation des produits. Revue de Droit Intellectuel: l'Ingénieur-
Conseil, 3, 365-385.  
§ Verlinden Michiel, Vernimme Ignace (2008). IP-aandachtspunten in het kader van een 
due diligence. Intellectuele Rechten - Droits Intellectuels, 4, 331-338.  
3. Book IBa not indexed in VABB  
§ Ahonen, P., Alahuhti, P., Daskala, B., Delaitre, S., De Hert, P., Friedewald, M., Gutwirth, 
S., Lindner, R., Maghiros, I., Moscibroda, Punie, Y., Schreurs, W., Verlinden, M., 
Vildjionaite, E., Wright, D. (2008). Safeguards in a World of Ambient Intelligence 
(SWAMI), Spring Science + Business Media B.V. 2008, 290 p. (Friedewald, Michaël, Ed. 
Gutwirth, Serge, Ed. Wright, David, Ed. Vildjiounaite, Elena, Ed. Punie, Yves, Ed.). The 
International Library of Ethics, Law and Technology, 1. Spring Science + Business Media 
B.V. 
4. Book ABa-p (other: no VABB type)  
§ Meyer, G., Verlinden, M., Vandewynckel, S. (2013). Overzicht van procesregels inzake 
Intellectuele Eigendomsrechten. Brussels: UGA.  
 
3 Presentations at conferences and published abstracts 
1. Presentation at conferences 
§ Poster Presentation ‘Access rules stimulating the exchange of human biological material 
within biobank networks’ at 3rd European Conference on Health Law on 6-7 October 2011 
in Leuven 
§ Poster and Oral Presentation ‘Access rules within biobank networks’ at ESBB Inaugural 
Conference on 16-19 November 2011 in Marseille 
§ Oral Presentation ‘Comparative analysis of access instruments’ at Biobanking Network 
Meeting on 24 August 2011 in Leuven 
§ Poster Presentation ‘Comparative analysis of access instruments’ at HandsOn: Biobanks 
2012 on 20-21 September 2012 in Uppsala 
§ Poster presentation ‘Comparative analysis of access instruments’ at Joint Congress of 
ESBB & the Spanish National Biobank Network on 7-9 November 2012 in Granada 
§ Oral Presentation ‘Access to human biological material and data stored in (research) 
biobanks’ at Colloque ‘Les Biobanques’ on 17 April 2013 in Brussels 
§ Poster Presentation ‘Balancing the rights and obligations of stakeholders in relation to 
access to biobanks’ at ESBB Conference 2013 on 8-11 November 2013 in Verona 
§ Poster Presentation ‘Lack of clear and harmonized information on key access principles’ 
at HandsOn 2013 on 21-22 November 2013 in Den Hague 
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§ Poster and Oral Presentation ‘Access to biobanks: relationship between custodian and 
applicant’ at ESBB Conference 2014 on 22-24 October 2014 in Leipzig 
§ Oral Presentation ‘Access to biobanks: relationship between custodian and 
applicant’ at Workshop "Driving Regenerative Medicine to the Market and Clinic: An 
Exploration of Enablers, Impediments, and Ethical-Legal Challenges" on 4-6 November 
2014 in Toronto 
 
2. Conference Abstracts 
§ Verlinden, M., Ectors, N., Nys, H., Huys, I. (2012). Legal Nature of Custodianship of 
Human Biological Material Stored in Biobanks. Biopreservation and Biobanking: Vol. 10 
(5). ESBB & Spanish National Biobank Network Joint Conference. Granada, 7-9 
November 2012 (pp. A39-A39).  
§ Verlinden, M., Ectors, N., Nys, H., Huys, I. (2011). Access Rules within Biobank Networks. 
Biopreservation and Biobanking: Vol. 9 (3). ESBB's Inaugural Conference. Marseille, 16-
19 November 2011 (pp. 304-304).  
